Rna-guided endonuclease fusion polypeptides and methods of use thereof

ABSTRACT

The present disclosure provides a fusion polypeptide comprising: a) an enzymatically active RNA-guided endonuclease that introduces a single-stranded break in a target DNA; and b) an error-prone DNA polymerase. The present disclosure provides a system comprising: a) a fusion polypeptide of the present disclosure; and b) a guide RNA. The present disclosure provides a cell comprising a fusion polypeptide of the present disclosure, or a system of the present disclosure. The present disclosure provides a method of mutagenizing a target polynucleotide.

CROSS-REFERENCE

This application is a division of U.S. patent application Ser. No.17/340,822, now U.S. Pat. No. 11,649,443, filed Jun. 7, 2021, which is acontinuation of U.S. patent application Ser. No. 16/641,950, now U.S.Pat. No. 11,649,442, filed Feb. 25, 2020, which is a U.S. National PhaseApplication of PCT Application No. PCT/US2018/049766, filed Sep. 6,2018, which claims the benefit of U.S. Provisional Patent ApplicationNo. 62/556,127, filed Sep. 8, 2017, and U.S. Provisional PatentApplication No. 62/662,043, filed Apr. 24, 2018, which applications areincorporated herein by reference in their entirety.

INCORPORATION BY REFERENCE OF SEQUENCE LISTING PROVIDED AS A SEQUENCELISTING XML FILE

A Sequence Listing is provided herewith as a Sequence Listing XML,“BERK-363DIV2_SEQ_LIST” created on Aug. 25, 2023 and having a size of2,173,365 bytes. The contents of the Sequence Listing XML areincorporated by reference herein in their entirety.

INTRODUCTION

Directed evolution is a powerful discovery approach that isolatesgenetic material with desirable properties from a library of sequencevariants. However, the sequence space that can be explored is limited bythe efficiency of synthesizing and transforming a genetic library. Thisrequirement for efficient transformation rates has confined directedevolution to only a few model organisms. The ability to program a cellto localize increased mutagenesis at user-defined loci would remove theneed to transform a synthesized library of nucleic acids; unfortunately,current in vivo targeted mutagenesis platforms are either confined totargeting a set locus in a specific organism or have a narrow and biasedediting window at user-defined loci.

There is a need in the art for compositions and methods for mutagenizinga target DNA.

SUMMARY

The present disclosure provides a fusion polypeptide comprising: a) anenzymatically active RNA-guided endonuclease that introduces asingle-stranded break in a target DNA; and b) an error-prone DNApolymerase. The present disclosure provides a system comprising: a) afusion polypeptide of the present disclosure; and b) a guide RNA. Thepresent disclosure provides a cell comprising a fusion polypeptide ofthe present disclosure, or a system of the present disclosure. Thepresent disclosure provides a method of mutagenizing a targetpolynucleotide.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic depiction of an example of a fusion polypeptide ofthe present disclosure.

FIG. 2A-2C depict mutator designs (FIG. 2A), and mutational analysis ofvarious mutators (FIGS. 2B and 2C).

FIG. 3 depicts the mutagenesis window length of various mutators.

FIG. 4A-4B depict characterization of the mutation rate, substitutionbias, and mutagenesis window length in bacterial, fungal, and mammaliancells.

FIG. 5A-5F provides amino acid sequences of Streptococcus pyogenes Cas9(FIG. 5A; SEQ ID NO:1219) and variants of Streptococcus pyogenes Cas9(FIG. 5B-5F). FIG. 5B: SEQ ID NO:1220; FIG. 5C: SEQ ID NO:1221; FIG. 5D:SEQ ID NO:1222; FIG. 5E: SEQ ID NO:1223; and FIG. 5F: SEQ ID NO:1210.

FIG. 6 provides an amino acid sequence of Staphylococcus aureus Cas9(SEQ ID No.:1224).

FIG. 7A-7C provide amino acid sequences of Francisella tularensis Cpf1(FIG. 7A; SEQ ID NO:1225), Acidaminococcus sp. BV3L6 Cpf1 (FIG. 7B; SEQID NO:1226), and a variant Cpf1 (FIG. 7C; SEQ ID NO:1227).

FIG. 8A-8D provide amino acid sequences DNA polymerases PolI1M (FIG. 8A;SEQ ID NO:1228), PolI2M (FIG. 8B; SEQ ID NO:1229), PolI3M (FIG. 8C; SEQID NO:1230), and PolI3M-TBD (FIG. 8D; SEQ ID NO:1231)

FIG. 9 provides an amino acid sequence of Phi29 DNA polymerase (SEQ IDNO:1232).

FIG. 10 provides an amino acid sequence of a T5 DNA polymerase (SEQ IDNO:1233).

FIG. 11A-11B provide amino acid sequences of T7 DNA polymerase (FIG.11A; SEQ ID NO:1234) and Sequenase (FIG. 11B; SEQ ID NO:1235).

FIG. 12 provides an amino acid sequence of a Sulfolobus solfataricusDNA-binding protein 7d (Sso7d) (SEQ ID NO:1236).

FIG. 13 provides an amino acid sequence of DNA polymerase Iota (SEQ IDNO:1237).

FIGS. 14A-14B provide an amino acid sequence of DNA polymerase η (SEQ IDNO:1238).

FIGS. 15A-15B provide an amino acid sequence of DNA polymerase κ (SEQ IDNO:1239).

FIGS. 16A-16D provide an amino acid sequence of DNA polymerase θ (SEQ IDNO:1240).

FIGS. 17A-17B provide an amino acid sequence of DNA polymerase ν (SEQ IDNO:1241).

FIG. 18 provides an amino acid sequence of E. coli DNA polymerase IV(SEQ ID NO:1242).

FIG. 19A-19B provide an amino acid sequence of topoisomerase I (SEQ IDNO:1243).

FIG. 20 provides an amino acid sequence of a flap endonuclease (SEQ IDNO:1244).

FIG. 21 provides an amino acid sequence of a T4 DNA ligase (SEQ IDNO:1245).

FIGS. 22A-22E provide a schematic of an example of a fusion polypeptideof the present disclosure, a characterization of substitution frequency,and analysis of mutation rates.

FIGS. 23A-23H provide an analysis of mutation rates, mutagenesis windowlengths, combinatorial mutations, multiplexed targeting, and continuousdiversification of genomic loci.

FIGS. 24A-24D provide characterization of mutations to E. coli'sRibosomal Subunit 5 gene, rpsE, that confer spectinomycin resistance.

FIG. 25 provides an analysis of the direction of mutagenesis relative toa gRNA.

FIG. 26 provides a characterization of the mutation rate of variousmutators at a distance from a nick.

FIG. 27 provides a characterization of the target window length of amore processive DNA polymerase fused to enCas9.

FIG. 28 provides the off-target mutation rate of various mutators.

FIGS. 29A-29B illustrate coupling of mutagenesis by examples of fusionpolypeptides of the present disclosure with a non-selectable geneticscreen.

FIGS. 30A-30C illustrate the viability and growth rate of E. coliexpressing examples of fusion polypeptides of the present disclosure.

FIG. 31 illustrates locations of gRNA targets and mutations relative tothe rpsE gene.

FIGS. 32A-32B illustrate deletions in ribosomal protein S5 and theeffect of the deletions on spectinomycin resistance.

FIG. 33 provides a comparison of E. coli diversification methods.

FIG. 34 provides oligonucleotide sequences.

FIG. 35 provides gRNA protospacer sequences.

FIG. 36 provides plasmid sequences.

FIG. 37 provides amino acid sequences of various Cas9 and DNA polymerasepolypeptides.

FIG. 38 is a schematic depiction of base editing.

FIG. 39A-39D depict use of a system of the present disclosure tointroduce mutations into a target gene in eukaryotic cells.

FIG. 40A-40D depict fluorescence activated cell sorting (FACS) plotsshowing the analysis of a mutation into a target gene in eukaryoticcells.

DEFINITIONS

The terms “polynucleotide” and “nucleic acid,” used interchangeablyherein, refer to a polymeric form of nucleotides of any length, eitherribonucleotides or deoxynucleotides. Thus, this term includes, but isnot limited to, single-, double-, or multi-stranded DNA or RNA, genomicDNA, cDNA, DNA-RNA hybrids, or a polymer comprising purine andpyrimidine bases or other natural, chemically or biochemically modified,non-natural, or derivatized nucleotide bases. The terms “polynucleotide”and “nucleic acid” should be understood to include, as applicable to theembodiment being described, single-stranded (such as sense or antisense)and double-stranded polynucleotides.

The terms “polypeptide,” “peptide,” and “protein”, are usedinterchangeably herein, refer to a polymeric form of amino acids of anylength, which can include genetically coded and non-genetically codedamino acids, chemically or biochemically modified or derivatized aminoacids, and polypeptides having modified peptide backbones. The termincludes fusion proteins, including, but not limited to, fusion proteinswith a heterologous amino acid sequence, fusions with heterologous andhomologous leader sequences, with or without N-terminal methionineresidues; immunologically tagged proteins; and the like.

The term “naturally-occurring” as used herein as applied to a nucleicacid, a protein, a cell, or an organism, refers to a nucleic acid, cell,protein, or organism that is found in nature.

As used herein the term “isolated” is meant to describe apolynucleotide, a polypeptide, or a cell that is in an environmentdifferent from that in which the polynucleotide, the polypeptide, or thecell naturally occurs. An isolated genetically modified host cell may bepresent in a mixed population of genetically modified host cells.

“Heterologous,” as used herein, refers to a nucleotide or amino acidsequence that is not found in the native nucleic acid or protein,respectively. For example, relative to a Cas9 polypeptide, aheterologous polypeptide comprises an amino acid sequence from a proteinother than the Cas9 polypeptide. Thus, for example, a polymerasepolypeptide is heterologous to a Cas9 polypeptide.

“Recombinant,” as used herein, means that a particular nucleic acid (DNAor RNA) is the product of various combinations of cloning, restriction,and/or ligation steps resulting in a construct having a structuralcoding or non-coding sequence distinguishable from endogenous nucleicacids found in natural systems. Generally, nucleotide sequences encodingthe structural coding sequence can be assembled from cDNA fragments andshort oligonucleotide linkers, or from a series of syntheticoligonucleotides, to provide a synthetic nucleic acid which is capableof being expressed from a recombinant transcriptional unit contained ina cell or in a cell-free transcription and translation system. Suchsequences can be provided in the form of an open reading frameuninterrupted by internal non-translated sequences, or introns, whichare typically present in eukaryotic genes. Genomic DNA comprising therelevant nucleotide sequences can also be used in the formation of arecombinant gene or transcriptional unit. Sequences of non-translatedDNA may be present 5′ or 3′ from the open reading frame, where suchsequences do not interfere with manipulation or expression of the codingregions, and may indeed act to modulate production of a desired productby various mechanisms (see “DNA regulatory sequences”, below).

Thus, e.g., the term “recombinant” polynucleotide or “recombinant”nucleic acid refers to one which is not naturally occurring, e.g., ismade by the artificial combination of two otherwise separated segmentsof sequence through human intervention. This artificial combination isoften accomplished by either chemical synthesis means, or by theartificial manipulation of isolated segments of nucleic acids, e.g., bygenetic engineering techniques. Such artificial combination can becarried out to join together nucleic acid segments of desired functionsto generate a desired combination of functions.

Similarly, the term “recombinant” polypeptide refers to a polypeptidewhich is not naturally occurring, e.g., is made by the artificialcombination of two otherwise separated segments of amino acid sequencethrough human intervention. Thus, e.g., a polypeptide that comprises aheterologous amino acid sequence is recombinant.

By “construct” or “vector” is meant a recombinant nucleic acid,generally recombinant DNA, which has been generated for the purpose ofthe expression and/or propagation of a specific nucleotide sequence(s),or is to be used in the construction of other recombinant nucleotidesequences.

The terms “DNA regulatory sequences,” “control elements,” and“regulatory elements,” used interchangeably herein, refer totranscriptional and translational control sequences, such as promoters,enhancers, polyadenylation signals, terminators, protein degradationsignals, and the like, that provide for and/or regulate expression of acoding sequence and/or production of an encoded polypeptide in a hostcell.

The term “transformation” is used interchangeably herein with “geneticmodification” and refers to a permanent or transient genetic changeinduced in a cell following introduction of new nucleic acid (e.g., DNAexogenous to the cell) into the cell. Genetic change (“modification”)can be accomplished either by incorporation of the new nucleic acid intothe genome of the host cell, or by transient or stable maintenance ofthe new nucleic acid as an episomal element. Where the cell is aeukaryotic cell, a permanent genetic change can be achieved byintroduction of new DNA into the genome of the cell. In prokaryoticcells, permanent changes can be introduced into the chromosome or viaextrachromosomal elements such as plasmids and expression vectors, whichmay contain one or more selectable markers to aid in their maintenancein the recombinant host cell. Suitable methods of genetic modificationinclude viral infection, transfection, conjugation, protoplast fusion,electroporation, particle gun technology, calcium phosphateprecipitation, direct microinjection, and the like. The choice of methodis generally dependent on the type of cell being transformed and thecircumstances under which the transformation is taking place (i.e. invitro, ex vivo, or in vivo). A general discussion of these methods canbe found in Ausubel, et al, Short Protocols in Molecular Biology, 3rded., Wiley & Sons, 1995.

“Operably linked” refers to a juxtaposition wherein the components sodescribed are in a relationship permitting them to function in theirintended manner. For instance, a promoter is operably linked to a codingsequence if the promoter affects its transcription or expression. Asused herein, the terms “heterologous promoter” and “heterologous controlregions” refer to promoters and other control regions that are notnormally associated with a particular nucleic acid in nature. Forexample, a “transcriptional control region heterologous to a codingregion” is a transcriptional control region that is not normallyassociated with the coding region in nature.

A “host cell,” as used herein, denotes an in vivo or in vitro eukaryoticcell, a prokaryotic cell, or a cell from a multicellular organism (e.g.,a cell line) cultured as a unicellular entity, which eukaryotic orprokaryotic cells can be, or have been, used as recipients for a nucleicacid (e.g., an expression vector), and include the progeny of theoriginal cell which has been genetically modified by the nucleic acid.It is understood that the progeny of a single cell may not necessarilybe completely identical in morphology or in genomic or total DNAcomplement as the original parent, due to natural, accidental, ordeliberate mutation. A “recombinant host cell” (also referred to as a“genetically modified host cell”) is a host cell into which has beenintroduced a heterologous nucleic acid, e.g., an expression vector. Forexample, a prokaryotic host cell is a genetically modified prokaryotichost cell (e.g., a bacterium), by virtue of introduction into a suitableprokaryotic host cell of a heterologous nucleic acid, e.g., an exogenousnucleic acid that is foreign to (not normally found in nature in) theprokaryotic host cell, or a recombinant nucleic acid that is notnormally found in the prokaryotic host cell; and a eukaryotic host cellis a genetically modified eukaryotic host cell, by virtue ofintroduction into a suitable eukaryotic host cell of a heterologousnucleic acid, e.g., an exogenous nucleic acid that is foreign to theeukaryotic host cell, or a recombinant nucleic acid that is not normallyfound in the eukaryotic host cell.

The term “conservative amino acid substitution” refers to theinterchangeability in proteins of amino acid residues having similarside chains. For example, a group of amino acids having aliphatic sidechains consists of glycine, alanine, valine, leucine, and isoleucine; agroup of amino acids having aliphatic-hydroxyl side chains consists ofserine and threonine; a group of amino acids having amide-containingside chains consists of asparagine and glutamine; a group of amino acidshaving aromatic side chains consists of phenylalanine, tyrosine, andtryptophan; a group of amino acids having basic side chains consists oflysine, arginine, and histidine; and a group of amino acids havingsulfur-containing side chains consists of cysteine and methionine.Exemplary conservative amino acid substitution groups are:valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine,alanine-valine, and asparagine-glutamine.

A polynucleotide or polypeptide has a certain percent “sequenceidentity” to another polynucleotide or polypeptide, meaning that, whenaligned, that percentage of bases or amino acids are the same, and inthe same relative position, when comparing the two sequences. Sequencesimilarity can be determined in a number of different manners. Todetermine sequence identity, sequences can be aligned using the methodsand computer programs, including BLAST, available over the world wideweb at ncbi.nlm.nih.gov/BLAST. See, e.g., Altschul et al. (1990), J.Mol. Biol. 215:403-10. Another alignment algorithm is FASTA, availablein the Genetics Computing Group (GCG) package, from Madison, Wisconsin,USA, a wholly owned subsidiary of Oxford Molecular Group, Inc. Othertechniques for alignment are described in Methods in Enzymology, vol.266: Computer Methods for Macromolecular Sequence Analysis (1996), ed.Doolittle, Academic Press, Inc., a division of Harcourt Brace & Co., SanDiego, California, USA. Of particular interest are alignment programsthat permit gaps in the sequence. The Smith-Waterman is one type ofalgorithm that permits gaps in sequence alignments. See Meth. Mol. Biol.70: 173-187 (1997). Also, the GAP program using the Needleman and Wunschalignment method can be utilized to align sequences. See J. Mol. Biol.48: 443-453 (1970).

Before the present invention is further described, it is to beunderstood that this invention is not limited to particular embodimentsdescribed, as such may, of course, vary. It is also to be understoodthat the terminology used herein is for the purpose of describingparticular embodiments only, and is not intended to be limiting, sincethe scope of the present invention will be limited only by the appendedclaims.

Where a range of values is provided, it is understood that eachintervening value, to the tenth of the unit of the lower limit unlessthe context clearly dictates otherwise, between the upper and lowerlimit of that range and any other stated or intervening value in thatstated range, is encompassed within the invention. The upper and lowerlimits of these smaller ranges may independently be included in thesmaller ranges, and are also encompassed within the invention, subjectto any specifically excluded limit in the stated range. Where the statedrange includes one or both of the limits, ranges excluding either orboth of those included limits are also included in the invention.

Unless defined otherwise, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which this invention belongs. Although any methods andmaterials similar or equivalent to those described herein can also beused in the practice or testing of the present invention, the preferredmethods and materials are now described. All publications mentionedherein are incorporated herein by reference to disclose and describe themethods and/or materials in connection with which the publications arecited.

It must be noted that as used herein and in the appended claims, thesingular forms “a,” “an,” and “the” include plural referents unless thecontext clearly dictates otherwise. Thus, for example, reference to “aguide RNA” includes a plurality of such guide RNAs and reference to “theRNA-guided endonuclease” includes reference to one or more RNA-guidedendonucleases and equivalents thereof known to those skilled in the art,and so forth. It is further noted that the claims may be drafted toexclude any optional element. As such, this statement is intended toserve as antecedent basis for use of such exclusive terminology as“solely,” “only” and the like in connection with the recitation of claimelements, or use of a “negative” limitation.

It is appreciated that certain features of the invention, which are, forclarity, described in the context of separate embodiments, may also beprovided in combination in a single embodiment. Conversely, variousfeatures of the invention, which are, for brevity, described in thecontext of a single embodiment, may also be provided separately or inany suitable sub-combination. All combinations of the embodimentspertaining to the invention are specifically embraced by the presentinvention and are disclosed herein just as if each and every combinationwas individually and explicitly disclosed. In addition, allsub-combinations of the various embodiments and elements thereof arealso specifically embraced by the present invention and are disclosedherein just as if each and every such sub-combination was individuallyand explicitly disclosed herein.

The publications discussed herein are provided solely for theirdisclosure prior to the filing date of the present application. Nothingherein is to be construed as an admission that the present invention isnot entitled to antedate such publication by virtue of prior invention.Further, the dates of publication provided may be different from theactual publication dates which may need to be independently confirmed.

DETAILED DESCRIPTION

The present disclosure provides a fusion polypeptide comprising: a) anenzymatically active RNA-guided endonuclease that introduces asingle-stranded break (a nick) in a target DNA; and b) an error-proneDNA polymerase. The present disclosure provides a system comprising: a)a fusion polypeptide of the present disclosure; and b) a guide RNA. Thepresent disclosure provides a cell comprising a fusion polypeptide ofthe present disclosure, or a system of the present disclosure. Thepresent disclosure provides a method of mutagenizing a targetpolynucleotide.

Fusion Polypeptides

The present disclosure provides a fusion polypeptide comprising: a) anenzymatically active RNA-guided endonuclease that introduces asingle-stranded break in a target DNA; and b) an error-prone DNApolymerase. A fusion polypeptide of the present disclosure is alsoreferred to herein as a “mutator.”

In some cases, a fusion polypeptide of the present disclosure comprises,in order from N-terminus to C-terminus: a) an enzymatically activeRNA-guided endonuclease that introduces a single-stranded break in atarget DNA; and b) an error-prone DNA polymerase. In some cases, afusion polypeptide of the present disclosure comprises, in order fromN-terminus to C-terminus: a) an error-prone DNA polymerase; and b) anenzymatically active RNA-guided endonuclease that introduces asingle-stranded break in a target DNA.

In some cases, a fusion polypeptide of the present disclosure comprises,in order from N-terminus to C-terminus: a) an enzymatically activeRNA-guided endonuclease that introduces a single-stranded break in atarget DNA; b) a peptide linker; and c) an error-prone DNA polymerase.In some instances, the fusion polypeptide comprises one or more nuclearlocalization signals (NLSs). For example, in some cases, the fusionpolypeptide comprises a single NLS at the N-terminus of the fusionpolypeptide. In some cases, the fusion polypeptide comprises 2, 3, or 4NLSs at the N-terminus of the fusion polypeptide. In other instances, insome cases, the fusion polypeptide comprises a single NLS at theC-terminus of the fusion polypeptide. In some cases, the fusionpolypeptide comprises 2, 3, or 4 NLSs at the C-terminus of the fusionpolypeptide.

In some cases, a fusion polypeptide of the present disclosure comprises,in order from N-terminus to C-terminus: a) an error-prone DNApolymerase; b) a peptide linker; and c) an enzymatically activeRNA-guided endonuclease that introduces a single-stranded break in atarget DNA. In some instances, the fusion polypeptide comprises one ormore NLSs. For example, in some cases, the fusion polypeptide comprisesa single NLS at the N-terminus of the fusion polypeptide. In some cases,the fusion polypeptide comprises 2, 3, or 4 NLSs at the N-terminus ofthe fusion polypeptide. In other instances, in some cases, the fusionpolypeptide comprises a single NLS at the C-terminus of the fusionpolypeptide. In some cases, the fusion polypeptide comprises 2, 3, or 4NLSs at the C-terminus of the fusion polypeptide.

The linker polypeptide may have any of a variety of amino acidsequences. Proteins can be joined by a spacer peptide, generally of aflexible nature, although other chemical linkages are not excluded.Suitable linkers include polypeptides of between 4 amino acids and 40amino acids in length, or between 4 amino acids and 25 amino acids inlength. These linkers can be produced by using synthetic,linker-encoding oligonucleotides to couple the proteins, or can beencoded by a nucleic acid sequence encoding the fusion protein. Peptidelinkers with a degree of flexibility can be used. The linking peptidesmay have virtually any amino acid sequence, bearing in mind that thepreferred linkers will have a sequence that results in a generallyflexible peptide. The use of small amino acids, such as glycine andalanine, are of use in creating a flexible peptide. The creation of suchsequences is routine to those of skill in the art. A variety ofdifferent linkers are commercially available and are considered suitablefor use.

Examples of linker polypeptides include glycine polymers (G)_(n),glycine-serine polymers (including, for example, (GS)_(n), (GSGGS)_(n)(SEQ ID NO:1154), (GGSGGS)_(n) (SEQ ID NO:1155), and (GGGS)_(n) (SEQ IDNO:1156), where n is an integer of at least one); glycine-alaninepolymers; and alanine-serine polymers. Exemplary linkers can compriseamino acid sequences including, but not limited to, GGSG (SEQ IDNO:1157), GGSGG (SEQ ID NO:1158), GSGSG (SEQ ID NO:1159), GSGGG (SEQ IDNO:1160), GGGSG (SEQ ID NO:1161), GSSSG (SEQ ID NO:1162), and the like.Also suitable is a linker having the sequence (GGGGS)n, where n is aninteger of from 1 to 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10). Theordinarily skilled artisan will recognize that design of a peptideconjugated to any desired element can include linkers that are all orpartially flexible, such that the linker can include a flexible linkeras well as one or more portions that confer less flexible structure.

A fusion polypeptide of the present disclosure exhibits a high degree ofprocessivity. The processivity of DNA synthesis by a DNA polymerase isdefined as, the number of nucleotides that a polymerase can incorporateinto DNA during a single template-binding event, before dissociatingfrom a DNA template.

In some cases, a fusion polypeptide of the present disclosure, whencomplexed with a guide RNA, exhibits a target mutation rate of from 10⁻⁸to 10⁻² mutations per nucleotide per genome replication event. In somecases, a fusion polypeptide of the present disclosure, when complexedwith a guide RNA, exhibits a target mutation rate of greater than 10⁻⁸mutations per nucleotide per genome replication event, e.g., greaterthan 10⁻⁸, greater than 10⁻⁷, greater than 10⁻⁶, greater than 10⁻⁵,greater than 10⁻⁴, or greater than 10⁻³, mutations per nucleotide pergenome replication event. In some cases, a fusion polypeptide of thepresent disclosure, when complexed with a guide RNA, exhibits a targetmutation rate of from 10⁻⁸ to 10⁻⁷ mutations per nucleotide per genomereplication event. In some cases, a fusion polypeptide of the presentdisclosure, when complexed with a guide RNA, exhibits a target mutationrate of from 10⁻⁷ to 10⁻⁶ mutations per nucleotide per genomereplication event. In some cases, a fusion polypeptide of the presentdisclosure, when complexed with a guide RNA, exhibits a target mutationrate of from 10⁻⁷ to 10⁻⁵ mutations per nucleotide per genomereplication event. In some cases, a fusion polypeptide of the presentdisclosure, when complexed with a guide RNA, exhibits a target mutationrate of from 10⁻⁵ to 10⁻⁴ mutations per nucleotide per genomereplication event. In some cases, a fusion polypeptide of the presentdisclosure, when complexed with a guide RNA, exhibits a target mutationrate of from 10⁻⁴ to 10⁻³ mutations per nucleotide per genomereplication event. In some cases, a fusion polypeptide of the presentdisclosure, when complexed with a guide RNA, exhibits a target mutationrate of from 10⁻³ to 10⁻² mutations per nucleotide per genomereplication event.

In some cases, a fusion polypeptide of the present disclosure, whencomplexed with a guide RNA, exhibits a target mutation rate of 1mutation per nucleotide per genome replication event.

In some cases, a fusion polypeptide of the present disclosure, whencomplexed with a guide RNA, exhibits a ratio of target mutation rate toglobal mutation rate of at least 1.5:1, at least 2:1, at least 5:1, atleast 10:1, at least 25:1, at least 50:1, at least 10²:1, at least5×10²:1, at least 10³:1, at least 5×10³:1, at least 10⁴:1, or more than10⁴:1. In some cases, a fusion polypeptide of the present disclosure,when complexed with a guide RNA, exhibits a ratio of target mutationrate to global mutation rate of from about 1.5:1 to 10⁴:1, e.g., fromabout 1.5:1 to 2:1, from 2:1 to 5:1, from 5:1 to 10:1, from 10:1 to25:1, from 25:1 to 50:1, from 50:1 to 10²:1, from 10²:1 to 5×10²:1, from5×10²:1 to 10³:1, from 10³:1 to 5×10³:1, from 5×10³:1 to 10⁴:1, or morethan 10⁴:1.

In some cases, a fusion polypeptide of the present disclosure, whencomplexed with a guide RNA, exhibits a target mutation rate that is atleast 2-fold higher than the target mutation rate exhibited by theerror-prone DNA polymerase present in the fusion polypeptide when theerror-prone DNA polymerase is not fused to the RNA-guided endonucleasepresent in the fusion polypeptide. In some cases, a fusion polypeptideof the present disclosure, when complexed with a guide RNA, exhibits atarget mutation rate that is at least 2-fold, at least 5-fold, at least10-fold, at least 50-fold, at least 10²-fold, at least 5×10²-fold, atleast 10³-fold, at least 5×10³-fold, or at least 10⁴-fold, higher thanthe target mutation rate exhibited by the error-prone DNA polymerasepresent in the fusion polypeptide when the error-prone DNA polymerase isnot fused to the RNA-guided endonuclease present in the fusionpolypeptide. In some cases, a fusion polypeptide of the presentdisclosure, when complexed with a guide RNA, exhibits a target mutationrate that is more than 10⁴-fold higher than the target mutation rateexhibited by the error-prone DNA polymerase present in the fusionpolypeptide when the error-prone DNA polymerase is not fused to theRNA-guided endonuclease present in the fusion polypeptide.

In some cases, a fusion polypeptide of the present disclosure, whencomplexed with a guide RNA, introduces mutations at a distance of from 1nucleotide to 10⁴ nucleotides from a nick in a target DNA introduced bythe RNA-guided endonuclease. For example, in some cases, a fusionpolypeptide of the present disclosure, when complexed with a guide RNA,introduces mutations at a distance of from 1 nucleotide (nt) to 10nucleotides (nt), from 10 nt to 50 nt, from 50 nt to 100 nt, from 100 ntto 500 nt, from 500 nt to 10³ nt, from 10³ nt to 5×10³ nt, or from 5×10³nt to 10⁴ nt from a nick in a target DNA introduced by the RNA-guidedendonuclease. In some cases, a fusion polypeptide of the presentdisclosure, when complexed with a guide RNA, introduces mutations at adistance of from 1 nt to 10 nt from a nick in a target DNA introduced bythe RNA-guided endonuclease. In some cases, a fusion polypeptide of thepresent disclosure, when complexed with a guide RNA, introducesmutations at a distance of from 1 nt to 25 nt from a nick in a targetDNA introduced by the RNA-guided endonuclease. In some cases, a fusionpolypeptide of the present disclosure, when complexed with a guide RNA,introduces mutations at a distance of from 10 nt to 25 nt from a nick ina target DNA introduced by the RNA-guided endonuclease. In some cases, afusion polypeptide of the present disclosure, when complexed with aguide RNA, introduces mutations at a distance of from 1 nt to 50 nt froma nick in a target DNA introduced by the RNA-guided endonuclease. Insome cases, a fusion polypeptide of the present disclosure, whencomplexed with a guide RNA, introduces mutations at a distance of from10 nt to 50 nt from a nick in a target DNA introduced by the RNA-guidedendonuclease. In some cases, a fusion polypeptide of the presentdisclosure, when complexed with a guide RNA, introduces mutations at adistance of from 25 nt to 50 nt from a nick in a target DNA introducedby the RNA-guided endonuclease. In some cases, a fusion polypeptide ofthe present disclosure, when complexed with a guide RNA, introducesmutations at a distance of from 1 nt to 100 nt from a nick in a targetDNA introduced by the RNA-guided endonuclease. In some cases, a fusionpolypeptide of the present disclosure, when complexed with a guide RNA,introduces mutations at a distance of from 10 nt to 100 nt from a nickin a target DNA introduced by the RNA-guided endonuclease. In somecases, a fusion polypeptide of the present disclosure, when complexedwith a guide RNA, introduces mutations at a distance of from 50 nt to100 nt from a nick in a target DNA introduced by the RNA-guidedendonuclease.

RNA-Guided Endonucleases

A fusion polypeptide of the present disclosure comprises: a) anenzymatically active RNA-guided endonuclease that introduces asingle-stranded break in a target DNA; and b) an error-prone DNApolymerase. An RNA-guided endonuclease is also referred to herein as a“genome-editing nuclease.”

Examples of RNA-guided endonucleases are CRISPR/Cas endonucleases (e.g.,class 2 CRISPR/Cas endonucleases such as a type II, type V, or type VICRISPR/Cas endonucleases). A CRISPR/Cas endonuclease is also referred toas a CRISPR/Cas effector polypeptide. A suitable genome editing nucleaseis a CRISPR/Cas endonuclease (e.g., a class 2 CRISPR/Cas endonucleasesuch as a type II, type V, or type VI CRISPR/Cas endonuclease). In somecases, a suitable RNA-guided endonuclease is a class 2 CRISPR/Casendonuclease. In some cases, a suitable RNA-guided endonuclease is aclass 2 type II CRISPR/Cas endonuclease (e.g., a Cas9 protein). In somecases, a genome targeting composition includes a class 2 type VCRISPR/Cas endonuclease (e.g., a Cpf1 protein, a C2c1 protein, or a C2c3protein). In some cases, a suitable RNA-guided endonuclease is a class 2type VI CRISPR/Cas endonuclease (e.g., a C2c2 protein; also referred toas a “Cas13a” protein). Also suitable for use is a CasX protein. Alsosuitable for use is a CasY protein.

In some cases, the genome-editing endonuclease is a Type II CRISPR/Casendonuclease. In some cases, the genome-editing endonuclease is a Cas9polypeptide. The Cas9 protein is guided to a target site (e.g.,stabilized at a target site) within a target nucleic acid sequence(e.g., a chromosomal sequence or an extrachromosomal sequence, e.g., anepisomal sequence, a minicircle sequence, a mitochondrial sequence, achloroplast sequence, etc.) by virtue of its association with theprotein-binding segment of the Cas9 guide RNA. In some cases, a Cas9polypeptide comprises an amino acid sequence having at least 50%, atleast 60%, at least 70%, at least 80%, at least 90%, at least 95%, atleast 98%, at least 99%, or more than 99%, amino acid sequence identityto the Streptococcus pyogenes Cas9 depicted in FIG. 5A. In some cases, aCas9 polypeptide comprises the amino acid sequence depicted in one ofFIG. 5A-5F.

In some cases, the Cas9 polypeptide used in a composition or method ofthe present disclosure is a Staphylococcus aureus Cas9 (saCas9)polypeptide. In some cases, the saCas9 polypeptide comprises an aminoacid sequence having at least 85%, at least 90%, at least 95%, at least98%, at least 99%, or 100%, amino acid sequence identity to the saCas9amino acid sequence depicted in FIG. 6 .

In some cases, the Cas9 polypeptide used in a composition or method ofthe present disclosure is a Campylobacter jejuni Cas9 (CjCas9)polypeptide. CjCas9 recognizes the 5-NNNVRYM-3′ as theprotospacer-adjacent motif (PAM). The amino acid sequence of CjCas9 isset forth in SEQ ID NO:50. In some cases, a Cas9 polypeptide suitablefor use in a composition or method of the present disclosure comprisesan amino acid sequence having at least 50%, at least 60%, at least 70%,at least 80%, at least 90%, at least 95%, at least 98%, at least 99%, ormore than 99%, amino acid sequence identity to the CjCas9 amino acidsequence set forth in SEQ ID NO:50.

In some cases, a suitable Cas9 polypeptide is a high-fidelity (HF) Cas9polypeptide. Kleinstiver et al. (2016) Nature 529:490. For example,amino acids N497, R661, Q695, and Q926 of the amino acid sequencedepicted in FIG. 5A are substituted, e.g., with alanine. For example, anHF Cas9 polypeptide can comprise an amino acid sequence having at least90%, at least 95%, at least 98%, at least 99%, or 100%, amino acidsequence identity to the amino acid sequence depicted in FIG. 5A, whereamino acids N497, R661, Q695, and Q926 are substituted, e.g., withalanine.

In some cases, a suitable Cas9 polypeptide exhibits altered PAMspecificity. See, e.g., Kleinstiver et al. (2015) Nature 523:481.

In some cases, the genome-editing endonuclease is a type V CRISPR/Casendonuclease. In some cases a type V CRISPR/Cas endonuclease is a Cpf1protein. In some cases, a Cpf1 protein comprises an amino acid sequencehaving at least 30%, at least 35%, at least 40%, at least 45%, at least50%, at least 55%, at least 60%, at least 65%, at least 70%, at least75%, at least 80%, at least 85%, at least 90%, at least 95%, at least90%, or 100%, amino acid sequence identity to the Cpf1 amino acidsequence depicted in FIG. 7A, FIG. 7B, or FIG. 7C.

In some cases, the genome-editing endonuclease is a CasX or a CasYpolypeptide. CasX and CasY polypeptides are described in Burstein et al.(2017) Nature 542:237.

RNA-Guided Endonucleases

An RNA-guided endonuclease is also referred to herein as a “genomeediting nuclease.” Examples of suitable genome editing nucleases areCRISPR/Cas endonucleases (e.g., class 2 CRISPR/Cas endonucleases such asa type II, type V, or type VI CRISPR/Cas endonucleases). A suitablegenome editing nuclease is a CRISPR/Cas endonuclease (e.g., a class 2CRISPR/Cas endonuclease such as a type II, type V, or type VI CRISPR/Casendonuclease). In some cases, a genome targeting composition includes aclass 2 CRISPR/Cas endonuclease. In some cases, a genome targetingcomposition includes a class 2 type II CRISPR/Cas endonuclease (e.g., aCas9 protein). In some cases, a genome targeting composition includes aclass 2 type V CRISPR/Cas endonuclease (e.g., a Cpf1 protein, a C2c1protein, or a C2c3 protein). In some cases, a genome targetingcomposition includes a class 2 type VI CRISPR/Cas endonuclease (e.g., aC2c2 protein; also referred to as a “Cas13a” protein). Also suitable foruse is a CasX protein. Also suitable for use is a CasY protein.

In some cases, a genome editing nuclease is a fusion protein that isfused to a heterologous polypeptide (also referred to as a “fusionpartner”). In some cases, a genome editing nuclease is fused to an aminoacid sequence (a fusion partner) that provides for subcellularlocalization, i.e., the fusion partner is a subcellular localizationsequence (e.g., one or more nuclear localization signals (NLSs) fortargeting to the nucleus, two or more NLSs, three or more NLSs, etc.).

In some cases, the genome-editing endonuclease is a Type II CRISPR/Caseendonuclease. In some cases, the genome-editing endonuclease is a Cas9polypeptide. The Cas9 protein is guided to a target site (e.g.,stabilized at a target site) within a target nucleic acid sequence(e.g., a chromosomal sequence or an extrachromosomal sequence, e.g., anepisomal sequence, a minicircle sequence, a mitochondrial sequence, achloroplast sequence, etc.) by virtue of its association with theprotein-binding segment of the Cas9 guide RNA. In some cases, a Cas9polypeptide comprises an amino acid sequence having at least 50%, atleast 60%, at least 70%, at least 80%, at least 90%, at least 95%, atleast 98%, at least 99%, or more than 99%, amino acid sequence identityto the Streptococcus pyogenes Cas9 depicted in FIG. 5A. In some cases,the Cas9 polypeptide used in a composition or method of the presentdisclosure is a Staphylococcus aureus Cas9 (saCas9) polypeptide. In somecases, the saCas9 polypeptide comprises an amino acid sequence having atleast 85%, at least 90%, at least 95%, at least 98%, at least 99%, or100%, amino acid sequence identity to the saCas9 amino acid sequencedepicted in FIG. 6 .

In some cases, a suitable Cas9 polypeptide is a high-fidelity (HF) Cas9polypeptide. Kleinstiver et al. (2016) Nature 529:490. For example,amino acids N497, R661, Q695, and Q926 of the amino acid sequencedepicted in FIG. 5A are substituted, e.g., with alanine. For example, anHF Cas9 polypeptide can comprise an amino acid sequence having at least90%, at least 95%, at least 98%, at least 99%, or 100%, amino acidsequence identity to the amino acid sequence depicted in FIG. 5A, whereamino acids N497, R661, Q695, and Q926 are substituted, e.g., withalanine.

In some cases, a suitable Cas9 polypeptide exhibits altered PAMspecificity. See, e.g., Kleinstiver et al. (2015) Nature 523:481.

In some cases, the genome-editing endonuclease is a type V CRISPR/Casendonuclease. In some cases, a type V CRISPR/Cas endonuclease is a Cpf1protein. In some cases, a Cpf1 protein comprises an amino acid sequencehaving at least 30%, at least 35%, at least 40%, at least 45%, at least50%, at least 55%, at least 60%, at least 65%, at least 70%, at least75%, at least 80%, at least 85%, at least 90%, at least 95%, at least90%, or 100%, amino acid sequence identity to the Cpf1 amino acidsequence depicted in FIG. 7A. In some cases, a Cpf1 protein comprises anamino acid sequence having at least 30%, at least 35%, at least 40%, atleast 45%, at least 50%, at least 55%, at least 60%, at least 65%, atleast 70%, at least 75%, at least 80%, at least 85%, at least 90%, atleast 95%, at least 90%, or 100%, amino acid sequence identity to theCpf1 amino acid sequence depicted in FIG. 7B. In some cases, a Cpf1protein comprises an amino acid sequence having at least 30%, at least35%, at least 40%, at least 45%, at least 50%, at least 55%, at least60%, at least 65%, at least 70%, at least 75%, at least 80%, at least85%, at least 90%, at least 95%, at least 90%, or 100%, amino acidsequence identity to the Cpf1 amino acid sequence depicted in FIG. 7C.

A nucleic acid that binds to a class 2 CRISPR/Cas endonuclease (e.g., aCas9 protein; a type V or type VI CRISPR/Cas protein; a Cpf1 protein;etc.) and targets the complex to a specific location within a targetnucleic acid is referred to herein as a “guide RNA” or “CRISPR/Cas guidenucleic acid” or “CRISPR/Cas guide RNA.” A guide RNA provides targetspecificity to the complex (the RNP complex) by including a targetingsegment, which includes a guide sequence (also referred to herein as atargeting sequence), which is a nucleotide sequence that iscomplementary to a sequence of a target nucleic acid.

In some cases, a guide RNA includes two separate nucleic acid molecules:an “activator” and a “targeter” and is referred to herein as a “dualguide RNA”, a “double-molecule guide RNA”, a “two-molecule guide RNA”,or a “dgRNA.” In some cases, the guide RNA is one molecule (e.g., forsome class 2 CRISPR/Cas proteins, the corresponding guide RNA is asingle molecule; and in some cases, an activator and targeter arecovalently linked to one another, e.g., via intervening nucleotides),and the guide RNA is referred to as a “single guide RNA”, a“single-molecule guide RNA,” a “one-molecule guide RNA”, or simply“sgRNA.”

In some cases, a composition of the present disclosure comprises anRNA-guided endonuclease, or both an RNA-guided endonuclease and a guideRNA. In some cases, e.g., where a target nucleic acid comprises adeleterious mutation in a defective allele (e.g., a deleterious mutationin a retinal cell target nucleic acid), the RNA-guidedendonuclease/guide RNA complex, together with a donor nucleic acidcomprising a nucleotide sequence that corrects the deleterious mutation(e.g., a donor nucleic acid comprising a nucleotide sequence thatencodes a functional copy of the protein encoded by the defectiveallele), can be used to correct the deleterious mutation, e.g., viahomology-directed repair (HDR).

In some cases, a composition of the present disclosure comprises: i) anRNA-guided endonuclease; and ii) one guide RNA. In some cases, the guideRNA is a single-molecule (or “single guide”) guide RNA (an “sgRNA”). Insome cases, the guide RNA is a dual-molecule (or “dual-guide”) guide RNA(“dgRNA”).

In some cases, a composition of the present disclosure comprises: i) anRNA-guided endonuclease; and ii) 2 separate sgRNAs, where the 2 separatesgRNAs provide for deletion of a target nucleic acid via non-homologousend joining (NHEJ). In some cases, the guide RNAs are sgRNAs. In somecases, the guide RNAs are dgRNAs.

In some cases, a composition of the present disclosure comprises: i) aCpf1 polypeptide; and ii) a guide RNA precursor; in these cases, theprecursor can be cleaved by the Cpf1 polypeptide to generate 2 or moreguide RNAs.

Class 2 CRISPR/Cas Endonucleases

RNA-mediated adaptive immune systems in bacteria and archaea rely onClustered Regularly Interspaced Short Palindromic Repeat (CRISPR)genomic loci and CRISPR-associated (Cas) proteins that function togetherto provide protection from invading viruses and plasmids. In class 2CRISPR systems, the functions of the effector complex (e.g., thecleavage of target DNA) are carried out by a single endonuclease (e.g.,see Zetsche et al., Cell. 2015 Oct. 22; 163(3):759-71; Makarova et al.,Nat Rev Microbiol. 2015 November; 13(11):722-36; Shmakov et al., MolCell. 2015 Nov. 5; 60(3):385-97); and Shmakov et al. (2017) NatureReviews Microbiology 15:169. As such, the term “class 2 CRISPR/Casprotein” is used herein to encompass the endonuclease (the targetnucleic acid cleaving protein) from class 2 CRISPR systems. Thus, theterm “class 2 CRISPR/Cas endonuclease” as used herein encompasses typeII CRISPR/Cas proteins (e.g., Cas9); type V-A CRISPR/Cas proteins (e.g.,Cpf1 (also referred to a “Cas12a”)); type V-B CRISPR/Cas proteins (e.g.,C2c1 (also referred to as “Cas12b”)); type V-C CRISPR/Cas proteins(e.g., C2c3 (also referred to as “Cas12c”)); type V-U1 CRISPR/Casproteins (e.g., C2c4); type V-U2 CRISPR/Cas proteins (e.g., C2c8); typeV-U5 CRISPR/Cas proteins (e.g., C2c5); type V-U4 CRISPR/Cas proteins(e.g., C2c9); type V-U3 CRISPR/Cas proteins (e.g., C2c10); type VI-ACRISPR/Cas proteins (e.g., C2c2 (also known as “Cas13a”)); type VI-BCRISPR/Cas proteins (e.g., Cas13b (also known as C2c4)); and type VI-CCRISPR/Cas proteins (e.g., Cas13c (also known as C2c7)). To date, class2 CRISPR/Cas proteins encompass type II, type V, and type VI CRISPR/Casproteins, but the term is also meant to encompass any class 2 CRISPR/Casprotein suitable for binding to a corresponding guide RNA and forming anRNP complex.

Type II CRISPR/Cas Endonucleases (e.g., Cas 9)

In natural Type II CRISPR/Cas systems, Cas9 functions as an RNA-guidedendonuclease that uses a dual-guide RNA having a crRNA andtrans-activating crRNA (tracrRNA) for target recognition and cleavage bya mechanism involving two nuclease active sites in Cas9 that togethergenerate double-stranded DNA breaks (DSBs), or can individually generatesingle-stranded DNA breaks (SSBs). The Type II CRISPR endonuclease Cas9and engineered dual-(dgRNA) or single guide RNA (sgRNA) form aribonucleoprotein (RNP) complex that can be targeted to a desired DNAsequence. Guided by a dual-RNA complex or a chimeric single-guide RNA,Cas9 generates site-specific DSBs or SSBs within double-stranded DNA(dsDNA) target nucleic acids, which are repaired either bynon-homologous end joining (NHEJ) or homology-directed recombination(HDR).

A type II CRISPR/Cas endonuclease is a type of class 2 CRISPR/Casendonuclease. In some cases, the type II CRISPR/Cas endonuclease is aCas9 protein. A Cas9 protein forms a complex with a Cas9 guide RNA. Theguide RNA provides target specificity to a Cas9-guide RNA complex byhaving a nucleotide sequence (a guide sequence) that is complementary toa sequence (the target site) of a target nucleic acid (as describedelsewhere herein). The Cas9 protein of the complex provides thesite-specific activity. In other words, the Cas9 protein is guided to atarget site (e.g., stabilized at a target site) within a target nucleicacid sequence (e.g. a chromosomal sequence or an extrachromosomalsequence, e.g., an episomal sequence, a minicircle sequence, amitochondrial sequence, a chloroplast sequence, etc.) by virtue of itsassociation with the protein-binding segment of the Cas9 guide RNA.

A Cas9 protein can bind and/or modify (e.g., cleave, nick, methylate,demethylate, etc.) a target nucleic acid and/or a polypeptide associatedwith target nucleic acid (e.g., methylation or acetylation of a histonetail)(e.g., when the Cas9 protein includes a fusion partner with anactivity). In some cases, the Cas9 protein is a naturally-occurringprotein (e.g., naturally occurs in bacterial and/or archaeal cells). Inother cases, the Cas9 protein is not a naturally-occurring polypeptide(e.g., the Cas9 protein is a variant Cas9 protein, a chimeric protein,and the like).

Examples of suitable Cas9 proteins include, but are not limited to,those set forth in SEQ ID NOs: 5-816. Naturally occurring Cas9 proteinsbind a Cas9 guide RNA, are thereby directed to a specific sequencewithin a target nucleic acid (a target site), and cleave the targetnucleic acid (e.g., cleave dsDNA to generate a double strand break,cleave ssDNA, cleave ssRNA, etc.). A chimeric Cas9 protein is a fusionprotein comprising a Cas9 polypeptide that is fused to a heterologousprotein (referred to as a fusion partner), where the heterologousprotein provides an activity (e.g., one that is not provided by the Cas9protein). The fusion partner can provide an activity, e.g., enzymaticactivity (e.g., nuclease activity, activity for DNA and/or RNAmethylation, activity for DNA and/or RNA cleavage, activity for histoneacetylation, activity for histone methylation, activity for RNAmodification, activity for RNA-binding, activity for RNA splicing etc.).In some cases, a portion of the Cas9 protein (e.g., the RuvC domainand/or the HNH domain) exhibits reduced nuclease activity relative tothe corresponding portion of a wild type Cas9 protein (e.g., in somecases the Cas9 protein is a nickase). In some cases, the Cas9 protein isenzymatically inactive, or has reduced enzymatic activity relative to awild-type Cas9 protein (e.g., relative to Streptococcus pyogenes Cas9).

In some cases, a fusion protein comprises: a) a catalytically inactiveCas9 protein (or other catalytically inactive CRISPR effectorpolypeptide); and b) a catalytically active endonuclease. For example,in some cases, the catalytically active endonuclease is a FokIpolypeptide. As one non-limiting example, in some cases, a fusionprotein comprises: a) a catalytically inactive Cas9 protein (or othercatalytically inactive CRISPR effector polypeptide); and b) is a FokInuclease comprising an amino acid sequence having at least at least 85%,at least 90%, at least 95%, at least 98%, at least 99%, or 100%, aminoacid sequence identity to the FokI amino acid sequence provided below;where the FokI nuclease has a length of from about 195 amino acids toabout 200 amino acids.

FokI Nuclease Amino Acid Sequence:

(SEQ ID NO: 1214) QLVKSELEEKKSELRHKLKYVPHEYIELIEIARNSTQDRILEMKVMEFFMKVYGYRGKHLGGSRKPDGAIYTVGSPIDYGVIVDTKAYSGGYNLPIGQADEMQRYVEENQTRNKHINPNEWWKVYPSSVTEFKFLFVSGHFKGNYKAQLTRLNHITNCNGAVLSVEELLIGGEMIKAGTLTLEEVRRKFNNGEINF.

Assays to determine whether given protein interacts with a Cas9 guideRNA can be any convenient binding assay that tests for binding between aprotein and a nucleic acid. Suitable binding assays (e.g., gel shiftassays) will be known to one of ordinary skill in the art (e.g., assaysthat include adding a Cas9 guide RNA and a protein to a target nucleicacid).

Assays to determine whether a protein has an activity (e.g., todetermine if the protein has nuclease activity that cleaves a targetnucleic acid and/or some heterologous activity) can be any convenientassay (e.g., any convenient nucleic acid cleavage assay that tests fornucleic acid cleavage). Suitable assays (e.g., cleavage assays) will beknown to one of ordinary skill in the art and can include adding a Cas9guide RNA and a protein to a target nucleic acid.

Many Cas9 orthologs from a wide variety of species have been identifiedand in some cases the proteins share only a few identical amino acids.Identified Cas9 orthologs have similar domain architecture with acentral HNH endonuclease domain and a split RuvC/RNaseH domain (e.g.,RuvCI, RuvCII, and RuvCIII) (e.g., see Table 1). For example, a Cas9protein can have 3 different regions (sometimes referred to as RuvC-I,RuvC-II, and RucC-III), that are not contiguous with respect to theprimary amino acid sequence of the Cas9 protein, but fold together toform a RuvC domain once the protein is produced and folds. Thus, Cas9proteins can be said to share at least 4 key motifs with a conservedarchitecture. Motifs 1, 2, and 4 are RuvC like motifs while motif 3 isan HNH-motif. The motifs set forth in Table 1 may not represent theentire RuvC-like and/or HNH domains as accepted in the art, but Table 1does present motifs that can be used to help determine whether a givenprotein is a Cas9 protein.

TABLE 1 Table 1 lists 4 motifs that are present in Cas9sequences from various species. The amino acidslisted in Table 1 are from the Cas9 from S. pyogenes (SEQ ID NO: 5).Motif  Amino acids Highly # Motif (residue #s) conserved 1 RuvC-likeIGLDIGTNSVGWAVI D10, G12, I (7-21) G17 (SEQ ID NO: 1) 2 RuvC-likeIVIEMARE (759-766) E762 II (SEQ ID NO: 2) 3 HNH-motif DVDHIVPQSFLKDDSIDNH840, N854, KVLTRSDKN (837-863) N863 (SEQ ID NO: 3) 4 RuvC-likeHHAHDAYL (982-989) H982, H983, III (SEQ ID NO: 4) A984, D986, A987

In some cases, a suitable Cas9 protein comprises an amino acid sequencehaving 4 motifs, each of motifs 1-4 having 60% or more, 70% or more, 75%or more, 80% or more, 85% or more, 90% or more, 95% or more, 99% or moreor 100% amino acid sequence identity to motifs 1-4 as set forth in SEQID NOs: 1-4, respectively (e.g., see Table 1), or to the correspondingportions in any of the amino acid sequences set forth in SEQ ID NOs:5-816.

In other words, in some cases, a suitable Cas9 polypeptide comprises anamino acid sequence having 4 motifs, each of motifs 1-4 having 60% ormore, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more,95% or more, 99% or more or 100% amino acid sequence identity to motifs1-4 of the Cas9 amino acid sequence set forth in SEQ ID NO: 5 (e.g., thesequences set forth in SEQ ID NOs: 1-4, e.g., see Table 1), or to thecorresponding portions in any of the amino acid sequences set forth inSEQ ID NOs: 6-816.

In some cases, a suitable Cas9 protein comprises an amino acid sequencehaving 4 motifs, each of motifs 1-4 having 60% or more amino acidsequence identity to motifs 1-4 of the Cas9 amino acid sequence setforth as SEQ ID NO: 5 (the motifs are in Table 1, and are set forth asSEQ ID NOs: 1-4, respectively), or to the corresponding portions in anyof the amino acid sequences set forth in SEQ ID NOs: 6-816. In somecases, a suitable Cas9 protein comprises an amino acid sequence having 4motifs, each of motifs 1-4 having 70% or more amino acid sequenceidentity to motifs 1-4 of the Cas9 amino acid sequence set forth as SEQID NO: 5 (the motifs are in Table 1, and are set forth as SEQ ID NOs:1-4, respectively), or to the corresponding portions in any of the aminoacid sequences set forth in SEQ ID NOs: 6-816. In some cases, a suitableCas9 protein comprises an amino acid sequence having 4 motifs, each ofmotifs 1-4 having 75% or more amino acid sequence identity to motifs 1-4of the Cas9 amino acid sequence set forth as SEQ ID NO: 5 (the motifsare in Table 1, and are set forth as SEQ ID NOs: 1-4, respectively), orto the corresponding portions in any of the amino acid sequences setforth in SEQ ID NOs: 6-816. In some cases, a suitable Cas9 proteincomprises an amino acid sequence having 4 motifs, each of motifs 1-4having 80% or more amino acid sequence identity to motifs 1-4 of theCas9 amino acid sequence set forth as SEQ ID NO: 5 (the motifs are inTable 1, and are set forth as SEQ ID NOs: 1-4, respectively), or to thecorresponding portions in any of the amino acid sequences set forth inSEQ ID NOs: 6-816. In some cases, a suitable Cas9 protein comprises anamino acid sequence having 4 motifs, each of motifs 1-4 having 85% ormore amino acid sequence identity to motifs 1-4 of the Cas9 amino acidsequence set forth as SEQ ID NO: 5 (the motifs are in Table 1, and areset forth as SEQ ID NOs: 1-4, respectively), or to the correspondingportions in any of the amino acid sequences set forth in SEQ ID NOs:6-816. In some cases, a suitable Cas9 protein comprises an amino acidsequence having 4 motifs, each of motifs 1-4 having 90% or more aminoacid sequence identity to motifs 1-4 of the Cas9 amino acid sequence setforth as SEQ ID NO: 5 (the motifs are in Table 1, and are set forth asSEQ ID NOs: 1-4, respectively), or to the corresponding portions in anyof the amino acid sequences set forth in SEQ ID NOs: 6-816. In somecases, a suitable Cas9 protein comprises an amino acid sequence having 4motifs, each of motifs 1-4 having 95% or more amino acid sequenceidentity to motifs 1-4 of the Cas9 amino acid sequence set forth as SEQID NO: 5 (the motifs are in Table 1, and are set forth as SEQ ID NOs:1-4, respectively), or to the corresponding portions in any of the aminoacid sequences set forth in SEQ ID NOs: 6-816. In some cases, a suitableCas9 protein comprises an amino acid sequence having 4 motifs, each ofmotifs 1-4 having 99% or more amino acid sequence identity to motifs 1-4of the Cas9 amino acid sequence set forth as SEQ ID NO: 5 (the motifsare in Table 1, and are set forth as SEQ ID NOs: 1-4, respectively), orto the corresponding portions in any of the amino acid sequences setforth in SEQ ID NOs: 6-816. In some cases, a suitable Cas9 proteincomprises an amino acid sequence having 4 motifs, each of motifs 1-4having 100% amino acid sequence identity to motifs 1-4 of the Cas9 aminoacid sequence set forth as SEQ ID NO: 5 (the motifs are in Table 1, andare set forth as SEQ ID NOs: 1-4, respectively), or to the correspondingportions in any of the amino acid sequences set forth in SEQ ID NOs:6-816. Any Cas9 protein as defined above can be used as a Cas9polypeptide, as part of a chimeric Cas9 polypeptide (e.g., a Cas9 fusionprotein), any of which can be used in an RNP of the present disclosure.

In some cases, a suitable Cas9 protein comprises an amino acid sequencehaving 60% or more, 70% or more, 75% or more, 80% or more, 85% or more,90% or more, 95% or more, 99% or more or 100% amino acid sequenceidentity to amino acids 7-166 or 731-1003 of the Cas9 amino acidsequence set forth in SEQ ID NO: 5, or to the corresponding portions inany of the amino acid sequences set forth as SEQ ID NOs: 6-816.

In some cases, a suitable Cas9 protein comprises an amino acid sequencehaving 60% or more amino acid sequence identity to amino acids 7-166 or731-1003 of the Cas9 amino acid sequence set forth in SEQ ID NO: 5, orto the corresponding portions in any of the amino acid sequences setforth as SEQ ID NOs: 6-816. In some cases, a suitable Cas9 proteincomprises an amino acid sequence having 70% or more amino acid sequenceidentity to amino acids 7-166 or 731-1003 of the Cas9 amino acidsequence set forth in SEQ ID NO: 5, or to the corresponding portions inany of the amino acid sequences set forth as SEQ ID NOs: 6-816. In somecases, a suitable Cas9 protein comprises an amino acid sequence having75% or more amino acid sequence identity to amino acids 7-166 or731-1003 of the Cas9 amino acid sequence set forth in SEQ ID NO: 5, orto the corresponding portions in any of the amino acid sequences setforth as SEQ ID NOs: 6-816. In some cases, a suitable Cas9 proteincomprises an amino acid sequence having 80% or more amino acid sequenceidentity to amino acids 7-166 or 731-1003 of the Cas9 amino acidsequence set forth in SEQ ID NO: 5, or to the corresponding portions inany of the amino acid sequences set forth as SEQ ID NOs: 6-816. In somecases, a suitable Cas9 protein comprises an amino acid sequence having85% or more amino acid sequence identity to amino acids 7-166 or731-1003 of the Cas9 amino acid sequence set forth in SEQ ID NO: 5, orto the corresponding portions in any of the amino acid sequences setforth as SEQ ID NOs: 6-816. In some cases, a suitable Cas9 proteincomprises an amino acid sequence having 90% or more amino acid sequenceidentity to amino acids 7-166 or 731-1003 of the Cas9 amino acidsequence set forth in SEQ ID NO: 5, or to the corresponding portions inany of the amino acid sequences set forth as SEQ ID NOs: 6-816. In somecases, a suitable Cas9 protein comprises an amino acid sequence having95% or more amino acid sequence identity to amino acids 7-166 or731-1003 of the Cas9 amino acid sequence set forth in SEQ ID NO: 5, orto the corresponding portions in any of the amino acid sequences setforth as SEQ ID NOs: 6-816. In some cases, a suitable Cas9 proteincomprises an amino acid sequence having 99% or more amino acid sequenceidentity to amino acids 7-166 or 731-1003 of the Cas9 amino acidsequence set forth in SEQ ID NO: 5, or to the corresponding portions inany of the amino acid sequences set forth as SEQ ID NOs: 6-816. In somecases, a suitable Cas9 protein comprises an amino acid sequence having100% amino acid sequence identity to amino acids 7-166 or 731-1003 ofthe Cas9 amino acid sequence set forth in SEQ ID NO: 5, or to thecorresponding portions in any of the amino acid sequences set forth asSEQ ID NOs: 6-816. Any Cas9 protein as defined above can be used as aCas9 polypeptide, as part of a chimeric Cas9 polypeptide (e.g., a Cas9fusion protein), any of which can be used in an RNP of the presentdisclosure.

In some cases, a suitable Cas9 protein comprises an amino acid sequencehaving 60% or more, 70% or more, 75% or more, 80% or more, 85% or more,90% or more, 95% or more, 99% or more or 100% amino acid sequenceidentity to the Cas9 amino acid sequence set forth in SEQ ID NO: 5, orto any of the amino acid sequences set forth as SEQ ID NOs: 6-816.

In some cases, a suitable Cas9 protein comprises an amino acid sequencehaving 60% or more amino acid sequence identity to the Cas9 amino acidsequence set forth in SEQ ID NO: 5, or to any of the amino acidsequences set forth as SEQ ID NOs: 6-816. In some cases, a suitable Cas9protein comprises an amino acid sequence having 70% or more amino acidsequence identity to the Cas9 amino acid sequence set forth in SEQ IDNO: 5, or to any of the amino acid sequences set forth as SEQ ID NOs:6-816. In some cases, a suitable Cas9 protein comprises an amino acidsequence having 75% or more amino acid sequence identity to the Cas9amino acid sequence set forth in SEQ ID NO: 5, or to any of the aminoacid sequences set forth as SEQ ID NOs: 6-816. In some cases, a suitableCas9 protein comprises an amino acid sequence having 80% or more aminoacid sequence identity to the Cas9 amino acid sequence set forth in SEQID NO: 5, or to any of the amino acid sequences set forth as SEQ ID NOs:6-816. In some cases, a suitable Cas9 protein comprises an amino acidsequence having 85% or more amino acid sequence identity to the Cas9amino acid sequence set forth in SEQ ID NO: 5, or to any of the aminoacid sequences set forth as SEQ ID NOs: 6-816. In some cases, a suitableCas9 protein comprises an amino acid sequence having 90% or more aminoacid sequence identity to the Cas9 amino acid sequence set forth in SEQID NO: 5, or to any of the amino acid sequences set forth as SEQ ID NOs:6-816. In some cases, a suitable Cas9 protein comprises an amino acidsequence having 95% or more amino acid sequence identity to the Cas9amino acid sequence set forth in SEQ ID NO: 5, or to any of the aminoacid sequences set forth as SEQ ID NOs: 6-816. In some cases, a suitableCas9 protein comprises an amino acid sequence having 99% or more aminoacid sequence identity to the Cas9 amino acid sequence set forth in SEQID NO: 5, or to any of the amino acid sequences set forth as SEQ ID NOs:6-816. In some cases, a suitable Cas9 protein comprises an amino acidsequence having 100% amino acid sequence identity to the Cas9 amino acidsequence set forth in SEQ ID NO: 5, or to any of the amino acidsequences set forth as SEQ ID NOs: 6-816. Any Cas9 protein as definedabove can be used as a Cas9 polypeptide, as part of a chimeric Cas9polypeptide (e.g., a Cas9 fusion protein), any of which can be used inan RNP of the present disclosure.

In some cases, a Cas9 protein comprises 4 motifs (as listed in Table 1),at least one with (or each with) amino acid sequences having 75% ormore, 80% or more, 85% or more, 90% or more, 95% or more, 99% or more or100% amino acid sequence identity to each of the 4 motifs listed inTable 1 (SEQ ID NOs:1-4), or to the corresponding portions in any of theamino acid sequences set forth as SEQ ID NOs: 6-816.

Examples of various Cas9 proteins (and Cas9 domain structure) and Cas9guide RNAs (as well as information regarding requirements related toprotospacer adjacent motif (PAM) sequences present in targeted nucleicacids) can be found in the art, for example, see Jinek et al., Science.2012 Aug. 17; 337(6096):816-21; Chylinski et al., RNA Biol. 2013 May;10(5):726-37; Ma et al., Biomed Res Int. 2013; 2013:270805; Hou et al.,Proc Natl Acad Sci USA. 2013 Sep. 24; 110(39):15644-9; Jinek et al.,Elife. 2013; 2:e00471; Pattanayak et al., Nat Biotechnol. 2013September; 31(9):839-43; Qi et al., Cell. 2013 Feb. 28; 152(5):1173-83;Wang et al., Cell. 2013 May 9; 153(4):910-8; Auer et al., Genome Res.2013 Oct. 31; Chen et al., Nucleic Acids Res. 2013 Nov. 1; 41(20):e19;Cheng et al., Cell Res. 2013 October; 23(10):1163-71; Cho et al.,Genetics. 2013 November; 195(3):1177-80; DiCarlo et al., Nucleic AcidsRes. 2013 April; 41(7):4336-43; Dickinson et al., Nat Methods. 2013October; 10(10):1028-34; Ebina et al., Sci Rep. 2013; 3:2510; Fujii etal., Nucleic Acids Res. 2013 Nov. 1; 41(20):e187; Hu et al., Cell Res.2013 November; 23(11):1322-5; Jiang et al., Nucleic Acids Res. 2013 Nov.1; 41(20):e188; Larson et al., Nat Protoc. 2013 November; 8(11):2180-96;Mali et al., Nat Methods. 2013 October; 10(10):957-63; Nakayama et al.,Genesis. 2013 December; 51(12):835-43; Ran et al., Nat Protoc. 2013November; 8(11):2281-308; Ran et al., Cell. 2013 Sep. 12; 154(6):1380-9;Upadhyay et al., G3 (Bethesda). 2013 Dec. 9; 3(12):2233-8; Walsh et al.,Proc Natl Acad Sci USA. 2013 Sep. 24; 110(39):15514-5; Xie et al., MolPlant. 2013 Oct. 9; Yang et al., Cell. 2013 Sep. 12; 154(6):1370-9;Briner et al., Mol Cell. 2014 Oct. 23; 56(2):333-9; Shmakov et al., NatRev Microbiol. 2017 March; 15(3):169-182; and U.S. patents and patentapplications: U.S. Pat. Nos. 8,906,616; 8,895,308; 8,889,418; 8,889,356;8,871,445; 8,865,406; 8,795,965; 8,771,945; 8,697,359; 20140068797;20140170753; 20140179006; 20140179770; 20140186843; 20140186919;20140186958; 20140189896; 20140227787; 20140234972; 20140242664;20140242699; 20140242700; 20140242702; 20140248702; 20140256046;20140273037; 20140273226; 20140273230; 20140273231; 20140273232;20140273233; 20140273234; 20140273235; 20140287938; 20140295556;20140295557; 20140298547; 20140304853; 20140309487; 20140310828;20140310830; 20140315985; 20140335063; 20140335620; 20140342456;20140342457; 20140342458; 20140349400; 20140349405; 20140356867;20140356956; 20140356958; 20140356959; 20140357523; 20140357530;20140364333; and 20140377868; each of which is hereby incorporated byreference in its entirety.

Variant Cas9 Proteins—Nickases and dCas9

In some cases, a Cas9 protein is a variant Cas9 protein. A variant Cas9protein has an amino acid sequence that is different by at least oneamino acid (e.g., has a deletion, insertion, substitution, fusion) whencompared to the amino acid sequence of a corresponding wild type Cas9protein. In some instances, the variant Cas9 protein has an amino acidchange (e.g., deletion, insertion, or substitution) that reduces thenuclease activity of the Cas9 protein. For example, in some instances,the variant Cas9 protein has 50% or less, 40% or less, 30% or less, 20%or less, 10% or less, 5% or less, or 1% or less of the nuclease activityof the corresponding wild-type Cas9 protein. In some cases, the variantCas9 protein has no substantial nuclease activity. When a Cas9 proteinis a variant Cas9 protein that has no substantial nuclease activity, itcan be referred to as a nuclease defective Cas9 protein or “dCas9” for“dead” Cas9. A protein (e.g., a class 2 CRISPR/Cas protein, e.g., a Cas9protein) that cleaves one strand but not the other of a double strandedtarget nucleic acid is referred to herein as a “nickase” (e.g., a“nickase Cas9”).

In some cases, a variant Cas9 protein can cleave the complementarystrand (sometimes referred to in the art as the target strand) of atarget nucleic acid but has reduced ability to cleave thenon-complementary strand (sometimes referred to in the art as thenon-target strand) of a target nucleic acid. For example, the variantCas9 protein can have a mutation (amino acid substitution) that reducesthe function of the RuvC domain. Thus, the Cas9 protein can be a nickasethat cleaves the complementary strand, but does not cleave thenon-complementary strand. As a non-limiting example, in someembodiments, a variant Cas9 protein has a mutation at an amino acidposition corresponding to residue D10 (e.g., D10A, aspartate to alanine)of SEQ ID NO: 5 (or the corresponding position of any of the proteinsset forth in SEQ ID NOs: 6-261 and 264-816) and can therefore cleave thecomplementary strand of a double stranded target nucleic acid but hasreduced ability to cleave the non-complementary strand of a doublestranded target nucleic acid (thus resulting in a single strand break(SSB) instead of a double strand break (DSB) when the variant Cas9protein cleaves a double stranded target nucleic acid) (see, forexample, Jinek et al., Science. 2012 Aug. 17; 337(6096):816-21). See,e.g., SEQ ID NO: 262.

In some cases, a variant Cas9 protein can cleave the non-complementarystrand of a target nucleic acid but has reduced ability to cleave thecomplementary strand of the target nucleic acid. For example, thevariant Cas9 protein can have a mutation (amino acid substitution) thatreduces the function of the HNH domain. Thus, the Cas9 protein can be anickase that cleaves the non-complementary strand, but does not cleavethe complementary strand. As a non-limiting example, in someembodiments, the variant Cas9 protein has a mutation at an amino acidposition corresponding to residue H840 (e.g., an H840A mutation,histidine to alanine) of SEQ ID NO: 5 (or the corresponding position ofany of the proteins set forth as SEQ ID NOs: 6-261 and 264-816) and cantherefore cleave the non-complementary strand of the target nucleic acidbut has reduced ability to cleave (e.g., does not cleave) thecomplementary strand of the target nucleic acid. Such a Cas9 protein hasa reduced ability to cleave a target nucleic acid (e.g., a singlestranded target nucleic acid) but retains the ability to bind a targetnucleic acid (e.g., a single stranded target nucleic acid). See, e.g.,SEQ ID NO: 263.

In some cases, a variant Cas9 protein has a reduced ability to cleaveboth the complementary and the non-complementary strands of a doublestranded target nucleic acid. As a non-limiting example, in some cases,the variant Cas9 protein harbors mutations at amino acid positionscorresponding to residues D10 and H840 (e.g., D10A and H840A) of SEQ IDNO: 5 (or the corresponding residues of any of the proteins set forth asSEQ ID NOs: 6-261 and 264-816) such that the polypeptide has a reducedability to cleave (e.g., does not cleave) both the complementary and thenon-complementary strands of a target nucleic acid. Such a Cas9 proteinhas a reduced ability to cleave a target nucleic acid (e.g., a singlestranded or double stranded target nucleic acid) but retains the abilityto bind a target nucleic acid. A Cas9 protein that cannot cleave targetnucleic acid (e.g., due to one or more mutations, e.g., in the catalyticdomains of the RuvC and HNH domains) is referred to as a “dead” Cas9 orsimply “dCas9.” See, e.g., SEQ ID NO: 264.

Other residues can be mutated to achieve the above effects (i.e.inactivate one or the other nuclease portions). As non-limitingexamples, residues D10, G12, G17, E762, H840, N854, N863, H982, H983,A984, D986, and/or A987 of SEQ ID NO: 5 (or the corresponding mutationsof any of the proteins set forth as SEQ ID NOs: 6-816) can be altered(i.e., substituted). Also, mutations other than alanine substitutionsare suitable.

In some embodiments, a variant Cas9 protein that has reduced catalyticactivity (e.g., when a Cas9 protein has a D10, G12, G17, E762, H840,N854, N863, H982, H983, A984, D986, and/or a A987 mutation of SEQ ID NO:5 or the corresponding mutations of any of the proteins set forth as SEQID NOs: 6-816, e.g., D10A, G12A, G17A, E762A, H840A, N854A, N863A,H982A, H983A, A984A, and/or D986A), the variant Cas9 protein can stillbind to target nucleic acid in a site-specific manner (because it isstill guided to a target nucleic acid sequence by a Cas9 guide RNA) aslong as it retains the ability to interact with the Cas9 guide RNA.

In addition to the above, a variant Cas9 protein can have the sameparameters for sequence identity as described above for Cas9 proteins.Thus, in some cases, a suitable variant Cas9 protein comprises an aminoacid sequence having 4 motifs, each of motifs 1-4 having 60% or more,70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% ormore, 99% or more or 100% amino acid sequence identity to motifs 1-4 ofthe Cas9 amino acid sequence set forth as SEQ ID NO: 5 (the motifs arein Table 1, above, and are set forth as SEQ ID NOs: 1-4, respectively),or to the corresponding portions in any of the amino acid sequences setforth in SEQ ID NOs: 6-816.

In some cases, a suitable variant Cas9 protein comprises an amino acidsequence having 4 motifs, each of motifs 1-4 having 60% or more aminoacid sequence identity to motifs 1-4 of the Cas9 amino acid sequence setforth as SEQ ID NO: 5 (the motifs are in Table 1, above, and are setforth as SEQ ID NOs: 1-4, respectively), or to the correspondingportions in any of the amino acid sequences set forth in SEQ ID NOs:6-816. In some cases, a suitable variant Cas9 protein comprises an aminoacid sequence having 4 motifs, each of motifs 1-4 having 70% or moreamino acid sequence identity to motifs 1-4 of the Cas9 amino acidsequence set forth as SEQ ID NO: 5 (the motifs are in Table 1, above,and are set forth as SEQ ID NOs: 1-4, respectively), or to thecorresponding portions in any of the amino acid sequences set forth inSEQ ID NOs: 6-816. In some cases, a suitable variant Cas9 proteincomprises an amino acid sequence having 4 motifs, each of motifs 1-4having 75% or more amino acid sequence identity to motifs 1-4 of theCas9 amino acid sequence set forth as SEQ ID NO: 5 (the motifs are inTable 1, above, and are set forth as SEQ ID NOs: 1-4, respectively), orto the corresponding portions in any of the amino acid sequences setforth in SEQ ID NOs: 6-816. In some cases, a suitable variant Cas9protein comprises an amino acid sequence having 4 motifs, each of motifs1-4 having 80% or more amino acid sequence identity to motifs 1-4 of theCas9 amino acid sequence set forth as SEQ ID NO: 5 (the motifs are inTable 1, above, and are set forth as SEQ ID NOs: 1-4, respectively), orto the corresponding portions in any of the amino acid sequences setforth in SEQ ID NOs: 6-816. In some cases, a suitable variant Cas9protein comprises an amino acid sequence having 4 motifs, each of motifs1-4 having 85% or more amino acid sequence identity to motifs 1-4 of theCas9 amino acid sequence set forth as SEQ ID NO: 5 (the motifs are inTable 1, above, and are set forth as SEQ ID NOs: 1-4, respectively), orto the corresponding portions in any of the amino acid sequences setforth in SEQ ID NOs: 6-816. In some cases, a suitable variant Cas9protein comprises an amino acid sequence having 4 motifs, each of motifs1-4 having 90% or more amino acid sequence identity to motifs 1-4 of theCas9 amino acid sequence set forth as SEQ ID NO: 5 (the motifs are inTable 1, above, and are set forth as SEQ ID NOs: 1-4, respectively), orto the corresponding portions in any of the amino acid sequences setforth in SEQ ID NOs: 6-816. In some cases, a suitable variant Cas9protein comprises an amino acid sequence having 4 motifs, each of motifs1-4 having 95% or more amino acid sequence identity to motifs 1-4 of theCas9 amino acid sequence set forth as SEQ ID NO: 5 (the motifs are inTable 1, above, and are set forth as SEQ ID NOs: 1-4, respectively), orto the corresponding portions in any of the amino acid sequences setforth in SEQ ID NOs: 6-816. In some cases, a suitable variant Cas9protein comprises an amino acid sequence having 4 motifs, each of motifs1-4 having 99% or more amino acid sequence identity to motifs 1-4 of theCas9 amino acid sequence set forth as SEQ ID NO: 5 (the motifs are inTable 1, above, and are set forth as SEQ ID NOs: 1-4, respectively), orto the corresponding portions in any of the amino acid sequences setforth in SEQ ID NOs: 6-816. In some cases, a suitable variant Cas9protein comprises an amino acid sequence having 4 motifs, each of motifs1-4 having 100% amino acid sequence identity to motifs 1-4 of the Cas9amino acid sequence set forth as SEQ ID NO: 5 (the motifs are in Table1, above, and are set forth as SEQ ID NOs: 1-4, respectively), or to thecorresponding portions in any of the amino acid sequences set forth inSEQ ID NOs: 6-816.

In some cases, a suitable variant Cas9 protein comprises an amino acidsequence having 60% or more, 70% or more, 75% or more, 80% or more, 85%or more, 90% or more, 95% or more, 99% or more, or 100% amino acidsequence identity to amino acids 7-166 or 731-1003 of the Cas9 aminoacid sequence set forth in SEQ ID NO: 5, or to the correspondingportions in any of the amino acid sequences set forth as SEQ ID NOs:6-816.

In some cases, a suitable variant Cas9 protein comprises an amino acidsequence having 60% or more amino acid sequence identity to amino acids7-166 or 731-1003 of the Cas9 amino acid sequence set forth in SEQ IDNO: 5, or to the corresponding portions in any of the amino acidsequences set forth as SEQ ID NOs: 6-816. In some cases, a suitablevariant Cas9 protein comprises an amino acid sequence having 70% or moreamino acid sequence identity to amino acids 7-166 or 731-1003 of theCas9 amino acid sequence set forth in SEQ ID NO: 5, or to thecorresponding portions in any of the amino acid sequences set forth asSEQ ID NOs: 6-816. In some cases, a suitable variant Cas9 proteincomprises an amino acid sequence having 75% or more amino acid sequenceidentity to amino acids 7-166 or 731-1003 of the Cas9 amino acidsequence set forth in SEQ ID NO: 5, or to the corresponding portions inany of the amino acid sequences set forth as SEQ ID NOs: 6-816. In somecases, a suitable variant Cas9 protein comprises an amino acid sequencehaving 80% or more amino acid sequence identity to amino acids 7-166 or731-1003 of the Cas9 amino acid sequence set forth in SEQ ID NO: 5, orto the corresponding portions in any of the amino acid sequences setforth as SEQ ID NOs: 6-816. In some cases, a suitable variant Cas9protein comprises an amino acid sequence having 85% or more amino acidsequence identity to amino acids 7-166 or 731-1003 of the Cas9 aminoacid sequence set forth in SEQ ID NO: 5, or to the correspondingportions in any of the amino acid sequences set forth as SEQ ID NOs:6-816. In some cases, a suitable variant Cas9 protein comprises an aminoacid sequence having 90% or more amino acid sequence identity to aminoacids 7-166 or 731-1003 of the Cas9 amino acid sequence set forth in SEQID NO: 5, or to the corresponding portions in any of the amino acidsequences set forth as SEQ ID NOs: 6-816. In some cases, a suitablevariant Cas9 protein comprises an amino acid sequence having 95% or moreamino acid sequence identity to amino acids 7-166 or 731-1003 of theCas9 amino acid sequence set forth in SEQ ID NO: 5, or to thecorresponding portions in any of the amino acid sequences set forth asSEQ ID NOs: 6-816. In some cases, a suitable variant Cas9 proteincomprises an amino acid sequence having 99% or more amino acid sequenceidentity to amino acids 7-166 or 731-1003 of the Cas9 amino acidsequence set forth in SEQ ID NO: 5, or to the corresponding portions inany of the amino acid sequences set forth as SEQ ID NOs: 6-816. In somecases, a suitable variant Cas9 protein comprises an amino acid sequencehaving 100% amino acid sequence identity to amino acids 7-166 or731-1003 of the Cas9 amino acid sequence set forth in SEQ ID NO: 5, orto the corresponding portions in any of the amino acid sequences setforth as SEQ ID NOs: 6-816.

In some cases, a suitable variant Cas9 protein comprises an amino acidsequence having 60% or more, 70% or more, 75% or more, 80% or more, 85%or more, 90% or more, 95% or more, 99% or more, or 100% amino acidsequence identity to the Cas9 amino acid sequence set forth in SEQ IDNO: 5, or to any of the amino acid sequences set forth as SEQ ID NOs:6-816. In some cases, a suitable variant Cas9 protein comprises an aminoacid sequence having 60% or more amino acid sequence identity to theCas9 amino acid sequence set forth in SEQ ID NO: 5, or to any of theamino acid sequences set forth as SEQ ID NOs: 6-816. In some cases, asuitable variant Cas9 protein comprises an amino acid sequence having70% or more amino acid sequence identity to the Cas9 amino acid sequenceset forth in SEQ ID NO: 5, or to any of the amino acid sequences setforth as SEQ ID NOs: 6-816. In some cases, a suitable variant Cas9protein comprises an amino acid sequence having 75% or more amino acidsequence identity to the Cas9 amino acid sequence set forth in SEQ IDNO: 5, or to any of the amino acid sequences set forth as SEQ ID NOs:6-816. In some cases, a suitable variant Cas9 protein comprises an aminoacid sequence having 80% or more amino acid sequence identity to theCas9 amino acid sequence set forth in SEQ ID NO: 5, or to any of theamino acid sequences set forth as SEQ ID NOs: 6-816. In some cases, asuitable variant Cas9 protein comprises an amino acid sequence having85% or more amino acid sequence identity to the Cas9 amino acid sequenceset forth in SEQ ID NO: 5, or to any of the amino acid sequences setforth as SEQ ID NOs: 6-816. In some cases, a suitable variant Cas9protein comprises an amino acid sequence having 90% or more amino acidsequence identity to the Cas9 amino acid sequence set forth in SEQ IDNO: 5, or to any of the amino acid sequences set forth as SEQ ID NOs:6-816. In some cases, a suitable variant Cas9 protein comprises an aminoacid sequence having 95% or more amino acid sequence identity to theCas9 amino acid sequence set forth in SEQ ID NO: 5, or to any of theamino acid sequences set forth as SEQ ID NOs: 6-816. In some cases, asuitable variant Cas9 protein comprises an amino acid sequence having99% or more amino acid sequence identity to the Cas9 amino acid sequenceset forth in SEQ ID NO: 5, or to any of the amino acid sequences setforth as SEQ ID NOs: 6-816. In some cases, a suitable variant Cas9protein comprises an amino acid sequence having 100% amino acid sequenceidentity to the Cas9 amino acid sequence set forth in SEQ ID NO: 5, orto any of the amino acid sequences set forth as SEQ ID NOs: 6-816.

Type V and Type VI CRISPR/Cas Endonucleases

In some cases, a genome targeting composition of the present disclosureincludes a type V or type VI CRISPR/Cas endonuclease (i.e., the genomeediting endonuclease is a type V or type VI CRISPR/Cas endonuclease)(e.g., Cpf1, C2c1, C2c2, C2c3). Type V and type VI CRISPR/Casendonucleases are a type of class 2 CRISPR/Cas endonuclease. Examples oftype V CRISPR/Cas endonucleases include but are not limited to: Cpf1,C2c1, and C2c3. An example of a type VI CRISPR/Cas endonuclease is C2c2.In some cases, a subject genome targeting composition includes a type VCRISPR/Cas endonuclease (e.g., Cpf1, C2c1, C2c3). In some cases, a TypeV CRISPR/Cas endonuclease is a Cpf1 protein. In some cases, a subjectgenome targeting composition includes a type VI CRISPR/Cas endonuclease(e.g., Cas13a).

Like type II CRISPR/Cas endonucleases, type V and VI CRISPR/Casendonucleases form a complex with a corresponding guide RNA. The guideRNA provides target specificity to an endonuclease-guide RNA RNP complexby having a nucleotide sequence (a guide sequence) that is complementaryto a sequence (the target site) of a target nucleic acid (as describedelsewhere herein). The endonuclease of the complex provides thesite-specific activity. In other words, the endonuclease is guided to atarget site (e.g., stabilized at a target site) within a target nucleicacid sequence (e.g. a chromosomal sequence or an extrachromosomalsequence, e.g., an episomal sequence, a minicircle sequence, amitochondrial sequence, a chloroplast sequence, etc.) by virtue of itsassociation with the protein-binding segment of the guide RNA.

Examples and guidance related to type V and type VI CRISPR/Cas proteins(e.g., Cpf1, C2c1, C2c2, and C2c3 guide RNAs) can be found in the art,for example, see Zetsche et al., Cell. 2015 Oct. 22; 163(3):759-71;Makarova et al., Nat Rev Microbiol. 2015 November; 13(11):722-36;Shmakov et al., Mol Cell. 2015 Nov. 5; 60(3):385-97; and Shmakov et al.(2017) Nature Reviews Microbiology 15:169.

In some cases, the Type V or type VI CRISPR/Cas endonuclease (e.g.,Cpf1, C2c1, C2c2, C2c3) is enzymatically active, e.g., the Type V ortype VI CRISPR/Cas polypeptide, when bound to a guide RNA, cleaves atarget nucleic acid. In some cases, the Type V or type VI CRISPR/Casendonuclease (e.g., Cpf1, C2c1, C2c2, C2c3) exhibits reduced enzymaticactivity relative to a corresponding wild-type a Type V or type VICRISPR/Cas endonuclease (e.g., Cpf1, C2c1, C2c2, C2c3), and retains DNAbinding activity.

In some cases a type V CRISPR/Cas endonuclease is a Cpf1 protein. Insome cases, a Cpf1 protein comprises an amino acid sequence having atleast 30%, at least 35%, at least 40%, at least 45%, at least 50%, atleast 55%, at least 60%, at least 65%, at least 70%, at least 75%, atleast 80%, at least 85%, at least 90%, at least 95%, at least 90%, or100%, amino acid sequence identity to the Cpf1 amino acid sequence setforth in any of SEQ ID NOs: 818-822. In some cases, a Cpf1 proteincomprises an amino acid sequence having at least 30%, at least 35%, atleast 40%, at least 45%, at least 50%, at least 55%, at least 60%, atleast 65%, at least 70%, at least 75%, at least 80%, at least 85%, atleast 90%, at least 95%, at least 90%, or 100%, amino acid sequenceidentity to a contiguous stretch of from 100 amino acids to 200 aminoacids (aa), from 200 aa to 400 aa, from 400 aa to 600 aa, from 600 aa to800 aa, from 800 aa to 1000 aa, from 1000 aa to 1100 aa, from 1100 aa to1200 aa, or from 1200 aa to 1300 aa, of the Cpf1 amino acid sequence setforth in any of SEQ ID NOs:818-822.

In some cases, a Cpf1 protein comprises an amino acid sequence having atleast 30%, at least 35%, at least 40%, at least 45%, at least 50%, atleast 55%, at least 60%, at least 65%, at least 70%, at least 75%, atleast 80%, at least 85%, at least 90%, at least 95%, at least 90%, or100%, amino acid sequence identity to the RuvCI domain of the Cpf1 aminoacid sequence set forth in any of SEQ ID NOs: 818-822. In some cases, aCpf1 protein comprises an amino acid sequence having at least 30%, atleast 35%, at least 40%, at least 45%, at least 50%, at least 55%, atleast 60%, at least 65%, at least 70%, at least 75%, at least 80%, atleast 85%, at least 90%, at least 95%, at least 90%, or 100%, amino acidsequence identity to the RuvCII domain of the Cpf1 amino acid sequenceset forth in any of SEQ ID NOs: 818-822. In some cases, a Cpf1 proteincomprises an amino acid sequence having at least 30%, at least 35%, atleast 40%, at least 45%, at least 50%, at least 55%, at least 60%, atleast 65%, at least 70%, at least 75%, at least 80%, at least 85%, atleast 90%, at least 95%, at least 90%, or 100%, amino acid sequenceidentity to the RuvCIII domain of the Cpf1 amino acid sequence set forthin any of SEQ ID NOs: 818-822. In some cases, a Cpf1 protein comprisesan amino acid sequence having at least 30%, at least 35%, at least 40%,at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, atleast 70%, at least 75%, at least 80%, at least 85%, at least 90%, atleast 95%, at least 90%, or 100%, amino acid sequence identity to theRuvCI, RuvCII, and RuvCIII domains of the Cpf1 amino acid sequence setforth in any of SEQ ID NOs: 818-822.

In some cases, the Cpf1 protein exhibits reduced enzymatic activityrelative to a wild-type Cpf1 protein (e.g., relative to a Cpf1 proteincomprising the amino acid sequence set forth in any of SEQ ID NOs:818-822), and retains DNA binding activity. In some cases, a Cpf1protein comprises an amino acid sequence having at least 30%, at least35%, at least 40%, at least 45%, at least 50%, at least 55%, at least60%, at least 65%, at least 70%, at least 75%, at least 80%, at least85%, at least 90%, at least 95%, at least 90%, or 100%, amino acidsequence identity to the Cpf1 amino acid sequence set forth in any ofSEQ ID NOs: 818-822; and comprises an amino acid substitution (e.g., aD→A substitution) at an amino acid residue corresponding to amino acid917 of the Cpf1 amino acid sequence set forth in SEQ ID NO: 818. In somecases, a Cpf1 protein comprises an amino acid sequence having at least30%, at least 35%, at least 40%, at least 45%, at least 50%, at least55%, at least 60%, at least 65%, at least 70%, at least 75%, at least80%, at least 85%, at least 90%, at least 95%, at least 90%, or 100%,amino acid sequence identity to the Cpf1 amino acid sequence set forthin any of SEQ ID NOs: 818-822; and comprises an amino acid substitution(e.g., an E→A substitution) at an amino acid residue corresponding toamino acid 1006 of the Cpf1 amino acid sequence set forth in SEQ ID NO:818. In some cases, a Cpf1 protein comprises an amino acid sequencehaving at least 30%, at least 35%, at least 40%, at least 45%, at least50%, at least 55%, at least 60%, at least 65%, at least 70%, at least75%, at least 80%, at least 85%, at least 90%, at least 95%, at least90%, or 100%, amino acid sequence identity to the Cpf1 amino acidsequence set forth in any of SEQ ID NOs: 818-822; and comprises an aminoacid substitution (e.g., a D→A substitution) at an amino acid residuecorresponding to amino acid 1255 of the Cpf1 amino acid sequence setforth in SEQ ID NO: 818.

In some cases, a suitable Cpf1 protein comprises an amino acid sequencehaving at least 30%, at least 35%, at least 40%, at least 45%, at least50%, at least 55%, at least 60%, at least 65%, at least 70%, at least75%, at least 80%, at least 85%, at least 90%, at least 95%, at least90%, or 100%, amino acid sequence identity to the Cpf1 amino acidsequence set forth in any of SEQ ID NOs: 818-822.

In some cases a type V CRISPR/Cas endonuclease is a C2c1 protein(examples include those set forth as SEQ ID NOs: 823-830). In somecases, a C2c1 protein comprises an amino acid sequence having at least30%, at least 35%, at least 40%, at least 45%, at least 50%, at least55%, at least 60%, at least 65%, at least 70%, at least 75%, at least80%, at least 85%, at least 90%, at least 95%, at least 90%, or 100%,amino acid sequence identity to the C2c1 amino acid sequence set forthin any of SEQ ID NOs: 823-830. In some cases, a C2c1 protein comprisesan amino acid sequence having at least 30%, at least 35%, at least 40%,at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, atleast 70%, at least 75%, at least 80%, at least 85%, at least 90%, atleast 95%, at least 90%, or 100%, amino acid sequence identity to acontiguous stretch of from 100 amino acids to 200 amino acids (aa), from200 aa to 400 aa, from 400 aa to 600 aa, from 600 aa to 800 aa, from 800aa to 1000 aa, from 1000 aa to 1100 aa, from 1100 aa to 1200 aa, or from1200 aa to 1300 aa, of the C2c1 amino acid sequence set forth in any ofSEQ ID NOs: 823-830.

In some cases, a C2c1 protein comprises an amino acid sequence having atleast 30%, at least 35%, at least 40%, at least 45%, at least 50%, atleast 55%, at least 60%, at least 65%, at least 70%, at least 75%, atleast 80%, at least 85%, at least 90%, at least 95%, at least 90%, or100%, amino acid sequence identity to the RuvCI domain of the C2c1 aminoacid sequences set forth in any of SEQ ID NOs: 823-830). In some cases,a C2c1 protein comprises an amino acid sequence having at least 30%, atleast 35%, at least 40%, at least 45%, at least 50%, at least 55%, atleast 60%, at least 65%, at least 70%, at least 75%, at least 80%, atleast 85%, at least 90%, at least 95%, at least 90%, or 100%, amino acidsequence identity to the RuvCII domain of the C2c1 amino acid sequenceset forth in any of SEQ ID NOs: 823-830. In some cases, a C2c1 proteincomprises an amino acid sequence having at least 30%, at least 35%, atleast 40%, at least 45%, at least 50%, at least 55%, at least 60%, atleast 65%, at least 70%, at least 75%, at least 80%, at least 85%, atleast 90%, at least 95%, at least 90%, or 100%, amino acid sequenceidentity to the RuvCIII domain of the C2c1 amino acid sequence set forthin any of SEQ ID NOs: 823-830. In some cases, a C2c1 protein comprisesan amino acid sequence having at least 30%, at least 35%, at least 40%,at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, atleast 70%, at least 75%, at least 80%, at least 85%, at least 90%, atleast 95%, at least 90%, or 100%, amino acid sequence identity to theRuvCI, RuvCII, and RuvCIII domains of the C2c1 amino acid sequence setforth in any of SEQ ID NOs: 823-830.

In some cases, the C2c1 protein exhibits reduced enzymatic activityrelative to a wild-type C2c1 protein (e.g., relative to a C2c1 proteincomprising the amino acid sequence set forth in any of SEQ ID NOs:823-830), and retains DNA binding activity. In some cases, a suitableC2c1 protein comprises an amino acid sequence having at least 30%, atleast 35%, at least 40%, at least 45%, at least 50%, at least 55%, atleast 60%, at least 65%, at least 70%, at least 75%, at least 80%, atleast 85%, at least 90%, at least 95%, at least 90%, or 100%, amino acidsequence identity to the C2c1 amino acid sequence set forth in any ofSEQ ID NOs: 823-830.

In some cases a type V CRISPR/Cas endonuclease is a C2c3 protein(examples include those set forth as SEQ ID NOs: 831-834). In somecases, a C2c3 protein comprises an amino acid sequence having at least30%, at least 35%, at least 40%, at least 45%, at least 50%, at least55%, at least 60%, at least 65%, at least 70%, at least 75%, at least80%, at least 85%, at least 90%, at least 95%, at least 90%, or 100%,amino acid sequence identity to the C2c3 amino acid sequence set forthin any of SEQ ID NOs: 831-834. In some cases, a C2c3 protein comprisesan amino acid sequence having at least 30%, at least 35%, at least 40%,at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, atleast 70%, at least 75%, at least 80%, at least 85%, at least 90%, atleast 95%, at least 90%, or 100%, amino acid sequence identity to acontiguous stretch of from 100 amino acids to 200 amino acids (aa), from200 aa to 400 aa, from 400 aa to 600 aa, from 600 aa to 800 aa, from 800aa to 1000 aa, from 1000 aa to 1100 aa, from 1100 aa to 1200 aa, or from1200 aa to 1300 aa, of the C2c3 amino acid sequence set forth in any ofSEQ ID NOs: 831-834.

In some cases, a C2c3 protein comprises an amino acid sequence having atleast 30%, at least 35%, at least 40%, at least 45%, at least 50%, atleast 55%, at least 60%, at least 65%, at least 70%, at least 75%, atleast 80%, at least 85%, at least 90%, at least 95%, at least 90%, or100%, amino acid sequence identity to the RuvCI domain of the C2c3 aminoacid sequence set forth in any of SEQ ID NOs: 831-834. In some cases, aC2c3 protein comprises an amino acid sequence having at least 30%, atleast 35%, at least 40%, at least 45%, at least 50%, at least 55%, atleast 60%, at least 65%, at least 70%, at least 75%, at least 80%, atleast 85%, at least 90%, at least 95%, at least 90%, or 100%, amino acidsequence identity to the RuvCII domain of the C2c3 amino acid sequenceset forth in any of SEQ ID NOs: 831-834. In some cases, a C2c3 proteincomprises an amino acid sequence having at least 30%, at least 35%, atleast 40%, at least 45%, at least 50%, at least 55%, at least 60%, atleast 65%, at least 70%, at least 75%, at least 80%, at least 85%, atleast 90%, at least 95%, at least 90%, or 100%, amino acid sequenceidentity to the RuvCIII domain of the C2c3 amino acid sequence set forthin any of SEQ ID NOs: 831-834. In some cases, a C2c3 protein comprisesan amino acid sequence having at least 30%, at least 35%, at least 40%,at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, atleast 70%, at least 75%, at least 80%, at least 85%, at least 90%, atleast 95%, at least 90%, or 100%, amino acid sequence identity to theRuvCI, RuvCII, and RuvCIII domains of the C2c3 amino acid sequence setforth in any of SEQ ID NOs: 831-834.

In some cases, the C2c3 protein exhibits reduced enzymatic activityrelative to a wild-type C2c3 protein (e.g., relative to a C2c3 proteincomprising the amino acid sequence set forth in any of SEQ ID NOs:831-834), and retains DNA binding activity. In some cases, a suitableC2c3 protein comprises an amino acid sequence having at least 30%, atleast 35%, at least 40%, at least 45%, at least 50%, at least 55%, atleast 60%, at least 65%, at least 70%, at least 75%, at least 80%, atleast 85%, at least 90%, at least 95%, at least 90%, or 100%, amino acidsequence identity to the C2c3 amino acid sequence set forth in any ofSEQ ID NOs: 831-834.

In some cases a type VI CRISPR/Cas endonuclease is a C2c2 protein(examples include those set forth as SEQ ID NOs: 835-846). In somecases, a C2c2 protein comprises an amino acid sequence having at least30%, at least 35%, at least 40%, at least 45%, at least 50%, at least55%, at least 60%, at least 65%, at least 70%, at least 75%, at least80%, at least 85%, at least 90%, at least 95%, at least 90%, or 100%,amino acid sequence identity to the C2c2 amino acid sequence set forthin any of SEQ ID NOs: 835-846. In some cases, a C2c2 protein comprisesan amino acid sequence having at least 30%, at least 35%, at least 40%,at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, atleast 70%, at least 75%, at least 80%, at least 85%, at least 90%, atleast 95%, at least 90%, or 100%, amino acid sequence identity to acontiguous stretch of from 100 amino acids to 200 amino acids (aa), from200 aa to 400 aa, from 400 aa to 600 aa, from 600 aa to 800 aa, from 800aa to 1000 aa, from 1000 aa to 1100 aa, from 1100 aa to 1200 aa, or from1200 aa to 1300 aa, of the C2c2 amino acid sequence set forth in any ofSEQ ID NOs: 835-846.

In some cases, a C2c2 protein comprises an amino acid sequence having atleast 30%, at least 35%, at least 40%, at least 45%, at least 50%, atleast 55%, at least 60%, at least 65%, at least 70%, at least 75%, atleast 80%, at least 85%, at least 90%, at least 95%, at least 90%, or100%, amino acid sequence identity to the RuvCI domain of the C2c2 aminoacid sequence set forth in any of SEQ ID NOs: 835-846. In some cases, aC2c2 protein comprises an amino acid sequence having at least 30%, atleast 35%, at least 40%, at least 45%, at least 50%, at least 55%, atleast 60%, at least 65%, at least 70%, at least 75%, at least 80%, atleast 85%, at least 90%, at least 95%, at least 90%, or 100%, amino acidsequence identity to the RuvCII domain of the C2c2 amino acid sequenceset forth in any of SEQ ID NOs: 835-846. In some cases, a C2c2 proteincomprises an amino acid sequence having at least 30%, at least 35%, atleast 40%, at least 45%, at least 50%, at least 55%, at least 60%, atleast 65%, at least 70%, at least 75%, at least 80%, at least 85%, atleast 90%, at least 95%, at least 90%, or 100%, amino acid sequenceidentity to the RuvCIII domain of the C2c2 amino acid sequence set forthin any of SEQ ID NOs: 835-846. In some cases, a C2c2 protein comprisesan amino acid sequence having at least 30%, at least 35%, at least 40%,at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, atleast 70%, at least 75%, at least 80%, at least 85%, at least 90%, atleast 95%, at least 90%, or 100%, amino acid sequence identity to theRuvCI, RuvCII, and RuvCIII domains of the C2c2 amino acid sequence setforth in any of SEQ ID NOs: 835-846.

In some cases, the C2c2 protein exhibits reduced enzymatic activityrelative to a wild-type C2c2 protein (e.g., relative to a C2c2 proteincomprising the amino acid sequence set forth in any of SEQ ID NOs:835-846), and retains DNA binding activity. In some cases, a suitableC2c2 protein comprises an amino acid sequence having at least 30%, atleast 35%, at least 40%, at least 45%, at least 50%, at least 55%, atleast 60%, at least 65%, at least 70%, at least 75%, at least 80%, atleast 85%, at least 90%, at least 95%, at least 90%, or 100%, amino acidsequence identity to the C2c2 amino acid sequence set forth in any ofSEQ ID NOs: 835-846.

Examples and guidance related to type V or type VI CRISPR/Casendonucleases (including domain structure) and guide RNAs (as well asinformation regarding requirements related to protospacer adjacent motif(PAM) sequences present in targeted nucleic acids) can be found in theart, for example, see Zetsche et al., Cell. 2015 Oct. 22; 163(3):759-71;Makarova et al., Nat Rev Microbiol. 2015 November; 13(11):722-36;Shmakov et al., Mol Cell. 2015 Nov. 5; 60(3):385-97; and Shmakov et al.,Nat Rev Microbiol. 2017 March; 15(3):169-182; and U.S. patents andpatent applications: 9,580,701; 20170073695, 20170058272, 20160362668,20160362667, 20160298078, 20160289637, 20160215300, 20160208243, and20160208241, each of which is hereby incorporated by reference in itsentirety.

CasX and CasY Proteins

Suitable RNA-guided endonucleases include CasX and CasY proteins. See,e.g., Burstein et al. (2017) Nature 542:237.

Cas9 Guide RNA

A nucleic acid molecule that binds to a Cas9 protein and targets thecomplex to a specific location within a target nucleic acid is referredto herein as a “Cas9 guide RNA.”

A Cas9 guide RNA (can be said to include two segments, a first segment(referred to herein as a “targeting segment”); and a second segment(referred to herein as a “protein-binding segment”). By “segment” it ismeant a segment/section/region of a molecule, e.g., a contiguous stretchof nucleotides in a nucleic acid molecule. A segment can also mean aregion/section of a complex such that a segment may comprise regions ofmore than one molecule.

The first segment (targeting segment) of a Cas9 guide RNA includes anucleotide sequence (a guide sequence) that is complementary to (andtherefore hybridizes with) a specific sequence (a target site) within atarget nucleic acid (e.g., a target ssRNA, a target ssDNA, thecomplementary strand of a double stranded target DNA, etc.). Theprotein-binding segment (or “protein-binding sequence”) interacts with(binds to) a Cas9 polypeptide. The protein-binding segment of a subjectCas9 guide RNA includes two complementary stretches of nucleotides thathybridize to one another to form a double stranded RNA duplex (dsRNAduplex). Site-specific binding and/or cleavage of a target nucleic acid(e.g., genomic DNA) can occur at locations (e.g., target sequence of atarget locus) determined by base-pairing complementarity between theCas9 guide RNA (the guide sequence of the Cas9 guide RNA) and the targetnucleic acid.

A Cas9 guide RNA and a Cas9 protein form a complex (e.g., bind vianon-covalent interactions). The Cas9 guide RNA provides targetspecificity to the complex by including a targeting segment, whichincludes a guide sequence (a nucleotide sequence that is complementaryto a sequence of a target nucleic acid). The Cas9 protein of the complexprovides the site-specific activity (e.g., cleavage activity or anactivity provided by the Cas9 protein when the Cas9 protein is a Cas9fusion polypeptide, i.e., has a fusion partner). In other words, theCas9 protein is guided to a target nucleic acid sequence (e.g. a targetsequence in a chromosomal nucleic acid, e.g., a chromosome; a targetsequence in an extrachromosomal nucleic acid, e.g. an episomal nucleicacid, a minicircle, an ssRNA, an ssDNA, etc.; a target sequence in amitochondrial nucleic acid; a target sequence in a chloroplast nucleicacid; a target sequence in a plasmid; a target sequence in a viralnucleic acid; etc.) by virtue of its association with the Cas9 guideRNA.

The “guide sequence” also referred to as the “targeting sequence” of aCas9 guide RNA can be modified so that the Cas9 guide RNA can target aCas9 protein to any desired sequence of any desired target nucleic acid,with the exception that the protospacer adjacent motif (PAM) sequencecan be taken into account. Thus, for example, a Cas9 guide RNA can havea targeting segment with a sequence (a guide sequence) that hascomplementarity with (e.g., can hybridize to) a sequence in a nucleicacid in a eukaryotic cell, e.g., a viral nucleic acid, a eukaryoticnucleic acid (e.g., a eukaryotic chromosome, chromosomal sequence, aeukaryotic RNA, etc.), and the like.

In some embodiments, a Cas9 guide RNA includes two separate nucleic acidmolecules: an “activator” and a “targeter” and is referred to herein asa “dual Cas9 guide RNA”, a “double-molecule Cas9 guide RNA”, or a“two-molecule Cas9 guide RNA” a “dual guide RNA”, or a “dgRNA.” In someembodiments, the activator and targeter are covalently linked to oneanother (e.g., via intervening nucleotides) and the guide RNA isreferred to as a “single guide RNA”, a “Cas9 single guide RNA”, a“single-molecule Cas9 guide RNA,” or a “one-molecule Cas9 guide RNA”, orsimply “sgRNA.”

A Cas9 guide RNA comprises a crRNA-like (“CRISPRRNA”/“targeter”/“crRNA”/“crRNA repeat”) molecule and a correspondingtracrRNA-like (“trans-acting CRISPR RNA”/“activator”/“tracrRNA”)molecule. A crRNA-like molecule (targeter) comprises both the targetingsegment (single stranded) of the Cas9 guide RNA and a stretch(“duplex-forming segment”) of nucleotides that forms one half of thedsRNA duplex of the protein-binding segment of the Cas9 guide RNA. Acorresponding tracrRNA-like molecule (activator/tracrRNA) comprises astretch of nucleotides (duplex-forming segment) that forms the otherhalf of the dsRNA duplex of the protein-binding segment of the guidenucleic acid. In other words, a stretch of nucleotides of a crRNA-likemolecule are complementary to and hybridize with a stretch ofnucleotides of a tracrRNA-like molecule to form the dsRNA duplex of theprotein-binding domain of the Cas9 guide RNA. As such, each targetermolecule can be said to have a corresponding activator molecule (whichhas a region that hybridizes with the targeter). The targeter moleculeadditionally provides the targeting segment. Thus, a targeter and anactivator molecule (as a corresponding pair) hybridize to form a Cas9guide RNA. The exact sequence of a given crRNA or tracrRNA molecule ischaracteristic of the species in which the RNA molecules are found. Asubject dual Cas9 guide RNA can include any corresponding activator andtargeter pair.

The term “activator” or “activator RNA” is used herein to mean atracrRNA-like molecule (tracrRNA: “trans-acting CRISPR RNA”) of a Cas9dual guide RNA (and therefore of a Cas9 single guide RNA when the“activator” and the “targeter” are linked together by, e.g., interveningnucleotides). Thus, for example, a Cas9 guide RNA (dgRNA or sgRNA)comprises an activator sequence (e.g., a tracrRNA sequence). A tracrmolecule (a tracrRNA) is a naturally existing molecule that hybridizeswith a CRISPR RNA molecule (a crRNA) to form a Cas9 dual guide RNA. Theterm “activator” is used herein to encompass naturally existingtracrRNAs, but also to encompass tracrRNAs with modifications (e.g.,truncations, sequence variations, base modifications, backbonemodifications, linkage modifications, etc.) where the activator retainsat least one function of a tracrRNA (e.g., contributes to the dsRNAduplex to which Cas9 protein binds). In some cases the activatorprovides one or more stem loops that can interact with Cas9 protein. Anactivator can be referred to as having a tracr sequence (tracrRNAsequence) and in some cases is a tracrRNA, but the term “activator” isnot limited to naturally existing tracrRNAs.

The term “targeter” or “targeter RNA” is used herein to refer to acrRNA-like molecule (crRNA: “CRISPR RNA”) of a Cas9 dual guide RNA (andtherefore of a Cas9 single guide RNA when the “activator” and the“targeter” are linked together, e.g., by intervening nucleotides). Thus,for example, a Cas9 guide RNA (dgRNA or sgRNA) comprises a targetingsegment (which includes nucleotides that hybridize with (arecomplementary to) a target nucleic acid, and a duplex-forming segment(e.g., a duplex forming segment of a crRNA, which can also be referredto as a crRNA repeat). Because the sequence of a targeting segment (thesegment that hybridizes with a target sequence of a target nucleic acid)of a targeter is modified by a user to hybridize with a desired targetnucleic acid, the sequence of a targeter will often be a non-naturallyoccurring sequence. However, the duplex-forming segment of a targeter(described in more detail below), which hybridizes with theduplex-forming segment of an activator, can include a naturally existingsequence (e.g., can include the sequence of a duplex-forming segment ofa naturally existing crRNA, which can also be referred to as a crRNArepeat). Thus, the term targeter is used herein to distinguish fromnaturally occurring crRNAs, despite the fact that part of a targeter(e.g., the duplex-forming segment) often includes a naturally occurringsequence from a crRNA. However, the term “targeter” encompassesnaturally occurring crRNAs.

A Cas9 guide RNA can also be said to include 3 parts: (i) a targetingsequence (a nucleotide sequence that hybridizes with a sequence of thetarget nucleic acid); (ii) an activator sequence (as described above)(insome cases, referred to as a tracr sequence); and (iii) a sequence thathybridizes to at least a portion of the activator sequence to form adouble stranded duplex. A targeter has (i) and (iii); while an activatorhas (ii).

A Cas9 guide RNA (e.g. a dual guide RNA or a single guide RNA) can becomprised of any corresponding activator and targeter pair. In somecases, the duplex forming segments can be swapped between the activatorand the targeter. In other words, in some cases, the targeter includes asequence of nucleotides from a duplex forming segment of a tracrRNA(which sequence would normally be part of an activator) while theactivator includes a sequence of nucleotides from a duplex formingsegment of a crRNA (which sequence would normally be part of atargeter).

As noted above, a targeter comprises both the targeting segment (singlestranded) of the Cas9 guide RNA and a stretch (“duplex-forming segment”)of nucleotides that forms one half of the dsRNA duplex of theprotein-binding segment of the Cas9 guide RNA. A correspondingtracrRNA-like molecule (activator) comprises a stretch of nucleotides (aduplex-forming segment) that forms the other half of the dsRNA duplex ofthe protein-binding segment of the Cas9 guide RNA. In other words, astretch of nucleotides of the targeter is complementary to andhybridizes with a stretch of nucleotides of the activator to form thedsRNA duplex of the protein-binding segment of a Cas9 guide RNA. Assuch, each targeter can be said to have a corresponding activator (whichhas a region that hybridizes with the targeter). The targeter moleculeadditionally provides the targeting segment. Thus, a targeter and anactivator (as a corresponding pair) hybridize to form a Cas9 guide RNA.The particular sequence of a given naturally existing crRNA or tracrRNAmolecule is characteristic of the species in which the RNA molecules arefound. Examples of suitable activator and targeter are well known in theart.

A Cas9 guide RNA (e.g. a dual guide RNA or a single guide RNA) can becomprised of any corresponding activator and targeter pair. Non-limitingexamples of nucleotide sequences that can be included in a Cas9 guideRNA (dgRNA or sgRNA) include sequences set forth in SEQ ID NOs:847-1095, or complements thereof. For example, in some cases, sequencesfrom SEQ ID NOs: 847-977 (which are from tracrRNAs) or complementsthereof, can pair with sequences from SEQ ID NOs: 867-1095 (which arefrom crRNAs), or complements thereof, to form a dsRNA duplex of aprotein binding segment.

Targeting Segment of a Cas9 Guide RNA

The first segment of a subject guide nucleic acid includes a guidesequence (i.e., a targeting sequence)(a nucleotide sequence that iscomplementary to a sequence (a target site) in a target nucleic acid).In other words, the targeting segment of a subject guide nucleic acidcan interact with a target nucleic acid (e.g., double stranded DNA(dsDNA)) in a sequence-specific manner via hybridization (i.e., basepairing). As such, the nucleotide sequence of the targeting segment mayvary (depending on the target) and can determine the location within thetarget nucleic acid that the Cas9 guide RNA and the target nucleic acidwill interact. The targeting segment of a Cas9 guide RNA can be modified(e.g., by genetic engineering)/designed to hybridize to any desiredsequence (target site) within a target nucleic acid (e.g., a eukaryotictarget nucleic acid such as genomic DNA).

The targeting segment can have a length of 7 or more nucleotides (nt)(e.g., 8 or more, 9 or more, 10 or more, 12 or more, 15 or more, 20 ormore, 25 or more, 30 or more, or 40 or more nucleotides). In some cases,the targeting segment can have a length of from 7 to 100 nucleotides(nt) (e.g., from 7 to 80 nt, from 7 to 60 nt, from 7 to 40 nt, from 7 to30 nt, from 7 to 25 nt, from 7 to 22 nt, from 7 to 20 nt, from 7 to 18nt, from 8 to 80 nt, from 8 to 60 nt, from 8 to 40 nt, from 8 to 30 nt,from 8 to 25 nt, from 8 to 22 nt, from 8 to 20 nt, from 8 to 18 nt, from10 to 100 nt, from 10 to 80 nt, from 10 to 60 nt, from 10 to 40 nt, from10 to 30 nt, from 10 to 25 nt, from 10 to 22 nt, from 10 to 20 nt, from10 to 18 nt, from 12 to 100 nt, from 12 to 80 nt, from 12 to 60 nt, from12 to 40 nt, from 12 to 30 nt, from 12 to 25 nt, from 12 to 22 nt, from12 to 20 nt, from 12 to 18 nt, from 14 to 100 nt, from 14 to 80 nt, from14 to 60 nt, from 14 to 40 nt, from 14 to 30 nt, from 14 to 25 nt, from14 to 22 nt, from 14 to 20 nt, from 14 to 18 nt, from 16 to 100 nt, from16 to 80 nt, from 16 to 60 nt, from 16 to 40 nt, from 16 to 30 nt, from16 to 25 nt, from 16 to 22 nt, from 16 to 20 nt, from 16 to 18 nt, from18 to 100 nt, from 18 to 80 nt, from 18 to 60 nt, from 18 to 40 nt, from18 to 30 nt, from 18 to 25 nt, from 18 to 22 nt, or from 18 to 20 nt).

The nucleotide sequence (the targeting sequence) of the targetingsegment that is complementary to a nucleotide sequence (target site) ofthe target nucleic acid can have a length of 10 nt or more. For example,the targeting sequence of the targeting segment that is complementary toa target site of the target nucleic acid can have a length of 12 nt ormore, 15 nt or more, 18 nt or more, 19 nt or more, or 20 nt or more. Insome cases, the nucleotide sequence (the targeting sequence) of thetargeting segment that is complementary to a nucleotide sequence (targetsite) of the target nucleic acid has a length of 12 nt or more. In somecases, the nucleotide sequence (the targeting sequence) of the targetingsegment that is complementary to a nucleotide sequence (target site) ofthe target nucleic acid has a length of 18 nt or more.

For example, the targeting sequence of the targeting segment that iscomplementary to a target sequence of the target nucleic acid can have alength of from 10 to 100 nucleotides (nt) (e.g., from 10 to 90 nt, from10 to 75 nt, from 10 to 60 nt, from 10 to 50 nt, from 10 to 35 nt, from10 to 30 nt, from 10 to 25 nt, from 10 to 22 nt, from 10 to 20 nt, from12 to 100 nt, from 12 to 90 nt, from 12 to 75 nt, from 12 to 60 nt, from12 to 50 nt, from 12 to 35 nt, from 12 to 30 nt, from 12 to 25 nt, from12 to 22 nt, from 12 to 20 nt, from 15 to 100 nt, from 15 to 90 nt, from15 to 75 nt, from 15 to 60 nt, from 15 to 50 nt, from 15 to 35 nt, from15 to 30 nt, from 15 to 25 nt, from 15 to 22 nt, from 15 to 20 nt, from17 to 100 nt, from 17 to 90 nt, from 17 to 75 nt, from 17 to 60 nt, from17 to 50 nt, from 17 to 35 nt, from 17 to 30 nt, from 17 to 25 nt, from17 to 22 nt, from 17 to 20 nt, from 18 to 100 nt, from 18 to 90 nt, from18 to 75 nt, from 18 to 60 nt, from 18 to 50 nt, from 18 to 35 nt, from18 to 30 nt, from 18 to 25 nt, from 18 to 22 nt, or from 18 to 20 nt).In some cases, the targeting sequence of the targeting segment that iscomplementary to a target sequence of the target nucleic acid has alength of from 15 nt to 30 nt. In some cases, the targeting sequence ofthe targeting segment that is complementary to a target sequence of thetarget nucleic acid has a length of from 15 nt to 25 nt. In some cases,the targeting sequence of the targeting segment that is complementary toa target sequence of the target nucleic acid has a length of from 18 ntto 30 nt. In some cases, the targeting sequence of the targeting segmentthat is complementary to a target sequence of the target nucleic acidhas a length of from 18 nt to 25 nt. In some cases, the targetingsequence of the targeting segment that is complementary to a targetsequence of the target nucleic acid has a length of from 18 nt to 22 nt.In some cases, the targeting sequence of the targeting segment that iscomplementary to a target site of the target nucleic acid is 20nucleotides in length. In some cases, the targeting sequence of thetargeting segment that is complementary to a target site of the targetnucleic acid is 19 nucleotides in length.

The percent complementarity between the targeting sequence (guidesequence) of the targeting segment and the target site of the targetnucleic acid can be 60% or more (e.g., 65% or more, 70% or more, 75% ormore, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more,98% or more, 99% or more, or 100%). In some cases, the percentcomplementarity between the targeting sequence of the targeting segmentand the target site of the target nucleic acid is 100% over the sevencontiguous 5′-most nucleotides of the target site of the target nucleicacid. In some cases, the percent complementarity between the targetingsequence of the targeting segment and the target site of the targetnucleic acid is 60% or more over about 20 contiguous nucleotides. Insome cases, the percent complementarity between the targeting sequenceof the targeting segment and the target site of the target nucleic acidis 100% over the fourteen contiguous 5′-most nucleotides of the targetsite of the target nucleic acid and as low as 0% or more over theremainder. In such a case, the targeting sequence can be considered tobe 14 nucleotides in length. In some cases, the percent complementaritybetween the targeting sequence of the targeting segment and the targetsite of the target nucleic acid is 100% over the seven contiguous5′-most nucleotides of the target site of the target nucleic acid and aslow as 0% or more over the remainder. In such a case, the targetingsequence can be considered to be 20 nucleotides in length.

In some cases, the percent complementarity between the targetingsequence of the targeting segment and the target site of the targetnucleic acid is 100% over the 7 contiguous 5′-most nucleotides of thetarget site of the target nucleic acid (which can be complementary tothe 3′-most nucleotides of the targeting sequence of the Cas9 guideRNA). In some cases, the percent complementarity between the targetingsequence of the targeting segment and the target site of the targetnucleic acid is 100% over the 8 contiguous 5′-most nucleotides of thetarget site of the target nucleic acid (which can be complementary tothe 3′-most nucleotides of the targeting sequence of the Cas9 guideRNA). In some cases, the percent complementarity between the targetingsequence of the targeting segment and the target site of the targetnucleic acid is 100% over the 9 contiguous 5′-most nucleotides of thetarget site of the target nucleic acid (which can be complementary tothe 3′-most nucleotides of the targeting sequence of the Cas9 guideRNA). In some cases, the percent complementarity between the targetingsequence of the targeting segment and the target site of the targetnucleic acid is 100% over the 10 contiguous 5′-most nucleotides of thetarget site of the target nucleic acid (which can be complementary tothe 3′-most nucleotides of the targeting sequence of the Cas9 guideRNA). In some cases, the percent complementarity between the targetingsequence of the targeting segment and the target site of the targetnucleic acid is 100% over the 17 contiguous 5′-most nucleotides of thetarget site of the target nucleic acid (which can be complementary tothe 3′-most nucleotides of the targeting sequence of the Cas9 guideRNA). In some cases, the percent complementarity between the targetingsequence of the targeting segment and the target site of the targetnucleic acid is 100% over the 18 contiguous 5′-most nucleotides of thetarget site of the target nucleic acid (which can be complementary tothe 3′-most nucleotides of the targeting sequence of the Cas9 guideRNA). In some cases, the percent complementarity between the targetingsequence of the targeting segment and the target site of the targetnucleic acid is 60% or more (e.g., e.g., 65% or more, 70% or more, 75%or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% ormore, 98% or more, 99% or more, or 100%) over about 20 contiguousnucleotides.

In some cases, the percent complementarity between the targetingsequence of the targeting segment and the target site of the targetnucleic acid is 100% over the 7 contiguous 5′-most nucleotides of thetarget site of the target nucleic acid and as low as 0% or more over theremainder. In such a case, the targeting sequence can be considered tobe 7 nucleotides in length. In some cases, the percent complementaritybetween the targeting sequence of the targeting segment and the targetsite of the target nucleic acid is 100% over the 8 contiguous 5′-mostnucleotides of the target site of the target nucleic acid and as low as0% or more over the remainder. In such a case, the targeting sequencecan be considered to be 8 nucleotides in length. In some cases, thepercent complementarity between the targeting sequence of the targetingsegment and the target site of the target nucleic acid is 100% over the9 contiguous 5′-most nucleotides of the target site of the targetnucleic acid and as low as 0% or more over the remainder. In such acase, the targeting sequence can be considered to be 9 nucleotides inlength. In some cases, the percent complementarity between the targetingsequence of the targeting segment and the target site of the targetnucleic acid is 100% over the 10 contiguous 5′-most nucleotides of thetarget site of the target nucleic acid and as low as 0% or more over theremainder. In such a case, the targeting sequence can be considered tobe 10 nucleotides in length. In some cases, the percent complementaritybetween the targeting sequence of the targeting segment and the targetsite of the target nucleic acid is 100% over the 11 contiguous 5′-mostnucleotides of the target site of the target nucleic acid and as low as0% or more over the remainder. In such a case, the targeting sequencecan be considered to be 11 nucleotides in length. In some cases, thepercent complementarity between the targeting sequence of the targetingsegment and the target site of the target nucleic acid is 100% over the12 contiguous 5′-most nucleotides of the target site of the targetnucleic acid and as low as 0% or more over the remainder. In such acase, the targeting sequence can be considered to be 12 nucleotides inlength. In some cases, the percent complementarity between the targetingsequence of the targeting segment and the target site of the targetnucleic acid is 100% over the 13 contiguous 5′-most nucleotides of thetarget site of the target nucleic acid and as low as 0% or more over theremainder. In such a case, the targeting sequence can be considered tobe 13 nucleotides in length. In some cases, the percent complementaritybetween the targeting sequence of the targeting segment and the targetsite of the target nucleic acid is 100% over the 14 contiguous 5′-mostnucleotides of the target site of the target nucleic acid and as low as0% or more over the remainder. In such a case, the targeting sequencecan be considered to be 14 nucleotides in length. In some cases, thepercent complementarity between the targeting sequence of the targetingsegment and the target site of the target nucleic acid is 100% over the17 contiguous 5′-most nucleotides of the target site of the targetnucleic acid and as low as 0% or more over the remainder. In such acase, the targeting sequence can be considered to be 17 nucleotides inlength. In some cases, the percent complementarity between the targetingsequence of the targeting segment and the target site of the targetnucleic acid is 100% over the 18 contiguous 5′-most nucleotides of thetarget site of the target nucleic acid and as low as 0% or more over theremainder. In such a case, the targeting sequence can be considered tobe 18 nucleotides in length.

Examples of various Cas9 proteins and Cas9 guide RNAs (as well asinformation regarding requirements related to protospacer adjacent motif(PAM) sequences present in targeted nucleic acids) can be found in theart, for example, see Jinek et al., Science. 2012 Aug. 17;337(6096):816-21; Chylinski et al., RNA Biol. 2013 May; 10(5):726-37; Maet al., Biomed Res Int. 2013; 2013:270805; Hou et al., Proc Natl AcadSci USA. 2013 Sep. 24; 110(39):15644-9; Jinek et al., Elife. 2013;2:e00471; Pattanayak et al., Nat Biotechnol. 2013 September;31(9):839-43; Qi et al., Cell. 2013 Feb. 28; 152(5):1173-83; Wang etal., Cell. 2013 May 9; 153(4):910-8; Auer et al., Genome Res. 2013 Oct.31; Chen et al., Nucleic Acids Res. 2013 Nov. 1; 41(20):e19; Cheng etal., Cell Res. 2013 October; 23(10):1163-71; Cho et al., Genetics. 2013November; 195(3):1177-80; DiCarlo et al., Nucleic Acids Res. 2013 April;41(7):4336-43; Dickinson et al., Nat Methods. 2013 October;10(10):1028-34; Ebina et al., Sci Rep. 2013; 3:2510; Fujii et al.,Nucleic Acids Res. 2013 Nov. 1; 41(20):e187; Hu et al., Cell Res. 2013November; 23(11):1322-5; Jiang et al., Nucleic Acids Res. 2013 Nov. 1;41(20):e188; Larson et al., Nat Protoc. 2013 November; 8(11):2180-96;Mali et al., Nat Methods. 2013 October; 10(10):957-63; Nakayama et al.,Genesis. 2013 December; 51(12):835-43; Ran et al., Nat Protoc. 2013November; 8(11):2281-308; Ran et al., Cell. 2013 Sep. 12; 154(6):1380-9;Upadhyay et al., G3 (Bethesda). 2013 Dec. 9; 3(12):2233-8; Walsh et al.,Proc Natl Acad Sci USA. 2013 Sep. 24; 110(39):15514-5; Xie et al., MolPlant. 2013 Oct. 9; Yang et al., Cell. 2013 Sep. 12; 154(6):1370-9;Briner et al., Mol Cell. 2014 Oct. 23; 56(2):333-9; and U.S. patents andpatent applications: U.S. Pat. Nos. 8,906,616; 8,895,308; 8,889,418;8,889,356; 8,871,445; 8,865,406; 8,795,965; 8,771,945; 8,697,359;20140068797; 20140170753; 20140179006; 20140179770; 20140186843;20140186919; 20140186958; 20140189896; 20140227787; 20140234972;20140242664; 20140242699; 20140242700; 20140242702; 20140248702;20140256046; 20140273037; 20140273226; 20140273230; 20140273231;20140273232; 20140273233; 20140273234; 20140273235; 20140287938;20140295556; 20140295557; 20140298547; 20140304853; 20140309487;20140310828; 20140310830; 20140315985; 20140335063; 20140335620;20140342456; 20140342457; 20140342458; 20140349400; 20140349405;20140356867; 20140356956; 20140356958; 20140356959; 20140357523;20140357530; 20140364333; and 20140377868; all of which are herebyincorporated by reference in their entirety.

Guide RNAs Corresponding to Type V and Type VI CRISPR/Cas Endonucleases(e.g., Cpf1 Guide RNA)

A guide RNA that binds to a type V or type VI CRISPR/Cas protein (e.g.,Cpf1, C2c1, C2c2, C2c3), and targets the complex to a specific locationwithin a target nucleic acid is referred to herein generally as a “typeV or type VI CRISPR/Cas guide RNA”. An example of a more specific termis a “Cpf1 guide RNA.”

A type V or type VI CRISPR/Cas guide RNA (e.g., cpf1 guide RNA) can havea total length of from 30 nucleotides (nt) to 200 nt, e.g., from 30 ntto 180 nt, from 30 nt to 160 nt, from 30 nt to 150 nt, from 30 nt to 125nt, from 30 nt to 100 nt, from 30 nt to 90 nt, from 30 nt to 80 nt, from30 nt to 70 nt, from 30 nt to 60 nt, from 30 nt to 50 nt, from 50 nt to200 nt, from 50 nt to 180 nt, from 50 nt to 160 nt, from 50 nt to 150nt, from 50 nt to 125 nt, from 50 nt to 100 nt, from 50 nt to 90 nt,from 50 nt to 80 nt, from 50 nt to 70 nt, from 50 nt to 60 nt, from 70nt to 200 nt, from 70 nt to 180 nt, from 70 nt to 160 nt, from 70 nt to150 nt, from 70 nt to 125 nt, from 70 nt to 100 nt, from 70 nt to 90 nt,or from 70 nt to 80 nt). In some cases, a type V or type VI CRISPR/Casguide RNA (e.g., cpf1 guide RNA) has a total length of at least 30 nt(e.g., at least 40 nt, at least 50 nt, at least 60 nt, at least 70 nt,at least 80 nt, at least 90 nt, at least 100 nt, or at least 120 nt).

In some cases, a Cpf1 guide RNA has a total length of 35 nt, 36 nt, 37nt, 38 nt, 39 nt, 40 nt, 41 nt, 42 nt, 43 nt, 44 nt, 45 nt, 46 nt, 47nt, 48 nt, 49 nt, or 50 nt.

Like a Cas9 guide RNA, a type V or type VI CRISPR/Cas guide RNA (e.g.,cpf1 guide RNA) can include a target nucleic acid-binding segment and aduplex-forming region (e.g., in some cases formed from twoduplex-forming segments, i.e., two stretches of nucleotides thathybridize to one another to form a duplex).

The target nucleic acid-binding segment of a type V or type VICRISPR/Cas guide RNA (e.g., cpf1 guide RNA) can have a length of from 15nt to 30 nt, e.g., 15 nt, 16 nt, 17 nt, 18 nt, 19 nt, 20 nt, 21 nt, 22nt, 23 nt, 24 nt, 25 nt, 26 nt, 27 nt, 28 nt, 29 nt, or 30 nt. In somecases, the target nucleic acid-binding segment has a length of 23 nt. Insome cases, the target nucleic acid-binding segment has a length of 24nt. In some cases, the target nucleic acid-binding segment has a lengthof 25 nt.

The guide sequence of a type V or type VI CRISPR/Cas guide RNA (e.g.,cpf1 guide RNA) can have a length of from 15 nt to 30 nt (e.g., 15 to 25nt, 15 to 24 nt, 15 to 23 nt, 15 to 22 nt, 15 to 21 nt, 15 to 20 nt, 15to 19 nt, 15 to 18 nt, 17 to 30 nt, 17 to 25 nt, 17 to 24 nt, 17 to 23nt, 17 to 22 nt, 17 to 21 nt, 17 to 20 nt, 17 to 19 nt, 17 to 18 nt, 18to 30 nt, 18 to 25 nt, 18 to 24 nt, 18 to 23 nt, 18 to 22 nt, 18 to 21nt, 18 to 20 nt, 18 to 19 nt, 19 to 30 nt, 19 to 25 nt, 19 to 24 nt, 19to 23 nt, 19 to 22 nt, 19 to 21 nt, 19 to 20 nt, 20 to 30 nt, 20 to 25nt, 20 to 24 nt, 20 to 23 nt, 20 to 22 nt, 20 to 21 nt, 15 nt, 16 nt, 17nt, 18 nt, 19 nt, 20 nt, 21 nt, 22 nt, 23 nt, 24 nt, 25 nt, 26 nt, 27nt, 28 nt, 29 nt, or 30 nt). In some cases, the guide sequence has alength of 17 nt. In some cases, the guide sequence has a length of 18nt. In some cases, the guide sequence has a length of 19 nt. In somecases, the guide sequence has a length of 20 nt. In some cases, theguide sequence has a length of 21 nt. In some cases, the guide sequencehas a length of 22 nt. In some cases, the guide sequence has a length of23 nt. In some cases, the guide sequence has a length of 24 nt.

The guide sequence of a type V or type VI CRISPR/Cas guide RNA (e.g.,cpf1 guide RNA) can have 100% complementarity with a correspondinglength of target nucleic acid sequence. The guide sequence can have lessthan 100% complementarity with a corresponding length of target nucleicacid sequence. For example, the guide sequence of a type V or type VICRISPR/Cas guide RNA (e.g., cpf1 guide RNA) can have 1, 2, 3, 4, or 5nucleotides that are not complementary to the target nucleic acidsequence. For example, in some cases, where a guide sequence has alength of 25 nucleotides, and the target nucleic acid sequence has alength of 25 nucleotides, in some cases, the target nucleic acid-bindingsegment has 100% complementarity to the target nucleic acid sequence. Asanother example, in some cases, where a guide sequence has a length of25 nucleotides, and the target nucleic acid sequence has a length of 25nucleotides, in some cases, the target nucleic acid-binding segment has1 non-complementary nucleotide and 24 complementary nucleotides with thetarget nucleic acid sequence. As another example, in some cases, where aguide sequence has a length of 25 nucleotides, and the target nucleicacid sequence has a length of 25 nucleotides, in some cases, the targetnucleic acid-binding segment has 2 non-complementary nucleotides and 23complementary nucleotides with the target nucleic acid sequence.

The duplex-forming segment of a type V or type VI CRISPR/Cas guide RNA(e.g., cpf1 guide RNA) (e.g., of a targeter RNA or an activator RNA) canhave a length of from 15 nt to 25 nt (e.g., 15 nt, 16 nt, 17 nt, 18 nt,19 nt, 20 nt, 21 nt, 22 nt, 23 nt, 24 nt, or 25 nt).

The RNA duplex of a type V or type VI CRISPR/Cas guide RNA (e.g., cpf1guide RNA) can have a length of from 5 base pairs (bp) to 40 bp (e.g.,from 5 to 35 bp, 5 to 30 bp, 5 to 25 bp, 5 to 20 bp, 5 to 15 bp, 5-12bp, 5-10 bp, 5-8 bp, 6 to 40 bp, 6 to 35 bp, 6 to 30 bp, 6 to 25 bp, 6to 20 bp, 6 to 15 bp, 6 to 12 bp, 6 to 10 bp, 6 to 8 bp, 7 to 40 bp, 7to 35 bp, 7 to 30 bp, 7 to 25 bp, 7 to 20 bp, 7 to 15 bp, 7 to 12 bp, 7to 10 bp, 8 to 40 bp, 8 to 35 bp, 8 to 30 bp, 8 to 25 bp, 8 to 20 bp, 8to 15 bp, 8 to 12 bp, 8 to 10 bp, 9 to 40 bp, 9 to 35 bp, 9 to 30 bp, 9to 25 bp, 9 to 20 bp, 9 to 15 bp, 9 to 12 bp, 9 to 10 bp, 10 to 40 bp,10 to 35 bp, 10 to 30 bp, 10 to 25 bp, 10 to 20 bp, 10 to 15 bp, or 10to 12 bp).

As an example, a duplex-forming segment of a Cpf1 guide RNA can comprisea nucleotide sequence selected from (5′ to 3′): AAUUUCUACUGUUGUAGAU (SEQID NO: 1096), AAUUUCUGCUGUUGCAGAU (SEQ ID NO: 1097), AAUUUCCACUGUUGUGGAU(SEQ ID NO: 1098), AAUUCCUACUGUUGUAGGU (SEQ ID NO: 1099),AAUUUCUACUAUUGUAGAU (SEQ ID NO: 1100), AAUUUCUACUGCUGUAGAU (SEQ ID NO:1101), AAUUUCUACUUUGUAGAU (SEQ ID NO: 1102), and AAUUUCUACUUGUAGAU (SEQID NO: 1103). The guide sequence can then follow (5′ to 3′) the duplexforming segment.

A non-limiting example of an activator RNA (e.g. tracrRNA) of a C2c1guide RNA (dual guide or single guide) is an RNA that includes thenucleotide sequenceGAAUUUUUCAACGGGUGUGCCAAUGGCCACUUUCCAGGUGGCAAAGCCCGUUGA GCUUCUCAAAAAG(SEQ ID NO: 1104). In some cases, a C2c1 guide RNA (dual guide or singleguide) is an RNA that includes the nucleotide sequence In some cases, aC2c1 guide RNA (dual guide or single guide) is an RNA that includes thenucleotide sequenceGUCUAGAGGACAGAAUUUUUCAACGGGUGUGCCAAUGGCCACUUUCCAGGUGGCAAAGCCCGUUGAGCUUCUCAAAAAG (SEQ ID NO: 1105). In some cases, a C2c1 guideRNA (dual guide or single guide) is an RNA that includes the nucleotidesequence UCUAGAGGACAGAAUUUUUCAACGGGUGUGCCAAUGGCCACUUUCCAGGUGGCAAAGCCCGUUGAGCUUCUCAAAAAG (SEQ ID NO: 1106). A non-limiting example of anactivator RNA (e.g. tracrRNA) of a C2c1 guide RNA (dual guide or singleguide) is an RNA that includes the nucleotide sequenceACUUUCCAGGCAAAGCCCGUUGAGCUUCUCAAAAAG (SEQ ID NO: 1107). In some cases, aduplex forming segment of a C2c1 guide RNA (dual guide or single guide)of an activator RNA (e.g. tracrRNA) includes the nucleotide sequenceAGCUUCUCA (SEQ ID NO 11098) or the nucleotide sequence GCUUCUCA (theduplex forming segment from a naturally existing tracrRNA.

A non-limiting example of a targeter RNA (e.g. crRNA) of a C2c1 guideRNA (dual guide or single guide) is an RNA with the nucleotide sequenceCUGAGAAGUGGCACNNNNNNNNNNNNNNNNNNNN (SEQ ID NO: 1110), where the Nsrepresent the guide sequence, which will vary depending on the targetsequence, and although 20 Ns are depicted a range of different lengthsare acceptable. In some cases, a duplex forming segment of a C2c1 guideRNA (dual guide or single guide) of a targeter RNA (e.g. crRNA) includesthe nucleotide sequence CUGAGAAGUGGCAC (SEQ ID NO: 1111) or includes thenucleotide sequence CUGAGAAGU or includes the nucleotide sequenceUGAGAAGUGGCAC (SEQ ID NO: 1113) or includes the nucleotide sequenceUGAGAAGU.

Examples and guidance related to type V or type VI CRISPR/Casendonucleases and guide RNAs (as well as information regardingrequirements related to protospacer adjacent motif (PAM) sequencespresent in targeted nucleic acids) can be found in the art, for example,see Zetsche et al., Cell. 2015 Oct. 22; 163(3):759-71; Makarova et al.,Nat Rev Microbiol. 2015 November; 13(11):722-36; and Shmakov et al., MolCell. 2015 Nov. 5; 60(3):385-97.

Nucleic Acid Modifications

In some embodiments, a subject nucleic acid (e.g., a DNA or an RNAencoding a fusion polypeptide of the present disclosure; a DNA or RNAencoding an RNA guided endonuclease; a guide RNA, etc.) has one or moremodifications, e.g., a base modification, a backbone modification, asugar modification, etc., to provide the nucleic acid with a new orenhanced feature (e.g., improved stability). A nucleoside is abase-sugar combination. The base portion of the nucleoside is normally aheterocyclic base. The two most common classes of such heterocyclicbases are the purines and the pyrimidines. Nucleotides are nucleosidesthat further include a phosphate group covalently linked to the sugarportion of the nucleoside. For those nucleosides that include apentofuranosyl sugar, the phosphate group can be linked to the 2′, the3′, or the 5′ hydroxyl moiety of the sugar. In forming oligonucleotides,the phosphate groups covalently link adjacent nucleosides to one anotherto form a linear polymeric compound. In turn, the respective ends ofthis linear polymeric compound can be further joined to form a circularcompound, however, linear compounds are suitable. In addition, linearcompounds may have internal nucleotide base complementarity and maytherefore fold in a manner as to produce a fully or partiallydouble-stranded compound. Within oligonucleotides, the phosphate groupsare commonly referred to as forming the internucleoside backbone of theoligonucleotide. The normal linkage or backbone of RNA and DNA is a 3′to 5′ phosphodiester linkage.

Suitable nucleic acid modifications include, but are not limited to:2′Omethyl modified nucleotides, 2′ Fluoro modified nucleotides, lockednucleic acid (LNA) modified nucleotides, peptide nucleic acid (PNA)modified nucleotides, nucleotides with phosphorothioate linkages, and a5′ cap (e.g., a 7-methylguanylate cap (m7G)). Additional details andadditional modifications are described below.

In some cases, 2% or more of the nucleotides of a nucleic acid (e.g., aguide RNA, etc.) are modified (e.g., 3% or more, 5% or more, 7.5% ormore, 10% or more, 15% or more, 20% or more, 25% or more, 30% or more,35% or more, 40% or more, 45% or more, 50% or more, 55% or more, 60% ormore, 65% or more, 75% or more, 80% or more, 85% or more, 90% or more,95% or more, or 100% of the nucleotides of a subject nucleic acid aremodified). In some cases, 2% or more of the nucleotides of a subjectguide RNA are modified (e.g., 3% or more, 5% or more, 7.5% or more, 10%or more, 15% or more, 20% or more, 25% or more, 30% or more, 35% ormore, 40% or more, 45% or more, 50% or more, 55% or more, 60% or more,65% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% ormore, or 100% of the nucleotides of a subject guide RNA are modified).In some cases, 2% or more of the nucleotides of a guide RNA are modified(e.g., 3% or more, 5% or more, 7.5% or more, 10% or more, 15% or more,20% or more, 25% or more, 30% or more, 35% or more, 40% or more, 45% ormore, 50% or more, 55% or more, 60% or more, 65% or more, 75% or more,80% or more, 85% or more, 90% or more, 95% or more, or 100% of thenucleotides of a guide RNA are modified).

In some cases, the number of nucleotides of a subject nucleic acidnucleic acid (e.g., a guide RNA, etc.) that are modified is in a rangeof from 3% to 100% (e.g., 3% to 100%, 3% to 95%, 3% to 90%, 3% to 85%,3% to 80%, 3% to 75%, 3% to 70%, 3% to 65%, 3% to 60%, 3% to 55%, 3% to50%, 3% to 45%, 3% to 40%, 5% to 100%, 5% to 95%, 5% to 90%, 5% to 85%,5% to 80%, 5% to 75%, 5% to 70%, 5% to 65%, 5% to 60%, 5% to 55%, 5% to50%, 5% to 45%, 5% to 40%, 10% to 100%, 10% to 95%, 10% to 90%, 10% to85%, 10% to 80%, 10% to 75%, 10% to 70%, 10% to 65%, 10% to 60%, 10% to55%, 10% to 50%, 10% to 45%, or 10% to 40%). In some cases, the numberof nucleotides of a subject that are modified is in a range of from 3%to 100% (e.g., 3% to 100%, 3% to 95%, 3% to 90%, 3% to 85%, 3% to 80%,3% to 75%, 3% to 70%, 3% to 65%, 3% to 60%, 3% to 55%, 3% to 50%, 3% to45%, 3% to 40%, 5% to 100%, 5% to 95%, 5% to 90%, 5% to 85%, 5% to 80%,5% to 75%, 5% to 70%, 5% to 65%, 5% to 60%, 5% to 55%, 5% to 50%, 5% to45%, 5% to 40%, 10% to 100%, 10% to 95%, 10% to 90%, 10% to 85%, 10% to80%, 10% to 75%, 10% to 70%, 10% to 65%, 10% to 60%, 10% to 55%, 10% to50%, 10% to 45%, or 10% to 40%). In some cases, the number ofnucleotides of a guide RNA that are modified is in a range of from 3% to100% (e.g., 3% to 100%, 3% to 95%, 3% to 90%, 3% to 85%, 3% to 80%, 3%to 75%, 3% to 70%, 3% to 65%, 3% to 60%, 3% to 55%, 3% to 50%, 3% to45%, 3% to 40%, 5% to 100%, 5% to 95%, 5% to 90%, 5% to 85%, 5% to 80%,5% to 75%, 5% to 70%, 5% to 65%, 5% to 60%, 5% to 55%, 5% to 50%, 5% to45%, 5% to 40%, 10% to 100%, 10% to 95%, 10% to 90%, 10% to 85%, 10% to80%, 10% to 75%, 10% to 70%, 10% to 65%, 10% to 60%, 10% to 55%, 10% to50%, 10% to 45%, or 10% to 40%).

In some cases, one or more of the nucleotides of a nucleic acid (e.g., aguide RNA, etc.) are modified (e.g., 2 or more, 3 or more, 4 or more, 5or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 ormore, 12 or more, 13 or more, 14 or more, 15 or more, 16 or more, 17 ormore, 18 or more, 19 or more, 20 or more, 21 or more, 22 or more, or allof the nucleotides of a subject nucleic acid are modified). In somecases, one or more of the nucleotides of a subject guide RNA aremodified (e.g., 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, 13 ormore, 14 or more, 15 or more, 16 or more, 17 or more, 18 or more, 19 ormore, 20 or more, 21 or more, 22 or more, or all of the nucleotides of asubject guide RNA are modified). In some cases, one or more of thenucleotides of a guide RNA are modified (e.g., 2 or more, 3 or more, 4or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 ormore, 11 or more, 12 or more, 13 or more, 14 or more, 15 or more, 16 ormore, 17 or more, 18 or more, 19 or more, 20 or more, 21 or more, 22 ormore, or all of the nucleotides of a guide RNA are modified).

In some cases, 99% or less of the nucleotides of a nucleic acid (e.g., aguide RNA, etc.) are modified (e.g., 99% or less, 95% or less, 90% orless, 85% or less, 80% or less, 75% or less, 70% or less, 65% or less,60% or less, 55% or less, 50% or less, or 45% or less of the nucleotidesof a subject nucleic acid are modified). In some cases, 99% or less ofthe nucleotides of a subject guide RNA are modified (e.g., e.g., 99% orless, 95% or less, 90% or less, 85% or less, 80% or less, 75% or less,70% or less, 65% or less, 60% or less, 55% or less, 50% or less, or 45%or less of the nucleotides of a subject guide RNA are modified). In somecases, 99% or less of the nucleotides of a guide RNA are modified (e.g.,99% or less, 95% or less, 90% or less, 85% or less, 80% or less, 75% orless, 70% or less, 65% or less, 60% or less, 55% or less, 50% or less,or 45% or less of the nucleotides of a guide RNA are modified).

In some cases, the number of nucleotides of a nucleic acid nucleic acid(e.g., a guide RNA, etc.) that are modified is in a range of from 1 to30 (e.g., 1 to 25, 1 to 20, 1 to 18, 1 to 15, 1 to 10, 2 to 25, 2 to 20,2 to 18, 2 to 15, 2 to 10, 3 to 25, 3 to 20, 3 to 18, 3 to 15, or 3 to10). In some cases, the number of nucleotides of a subject guide RNAthat are modified is in a range of from 1 to 30 (e.g., 1 to 25, 1 to 20,1 to 18, 1 to 15, 1 to 10, 2 to 25, 2 to 20, 2 to 18, 2 to 15, 2 to 10,3 to 25, 3 to 20, 3 to 18, 3 to 15, or 3 to 10). In some cases, thenumber of nucleotides of a guide RNA that are modified is in a range offrom 1 to 30 (e.g., 1 to 25, 1 to 20, 1 to 18, 1 to 15, 1 to 10, 2 to25, 2 to 20, 2 to 18, 2 to 15, 2 to 10, 3 to 25, 3 to 20, 3 to 18, 3 to15, or 3 to 10).

In some cases, 20 or fewer of the nucleotides of a nucleic acid (e.g., aguide RNA, etc.) are modified (e.g., 19 or fewer, 18 or fewer, 17 orfewer, 16 or fewer, 15 or fewer, 14 or fewer, 13 or fewer, 12 or fewer,11 or fewer, 10 or fewer, 9 or fewer, 8 or fewer, 7 or fewer, 6 orfewer, 5 or fewer, 4 or fewer, 3 or fewer, 2 or fewer, or one, of thenucleotides of a subject nucleic acid are modified). In some cases, 20or fewer of the nucleotides of a subject guide RNA are modified (e.g.,19 or fewer, 18 or fewer, 17 or fewer, 16 or fewer, 15 or fewer, 14 orfewer, 13 or fewer, 12 or fewer, 11 or fewer, 10 or fewer, 9 or fewer, 8or fewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 or fewer, 2or fewer, or one, of the nucleotides of a subject guide RNA aremodified). In some cases, 20 or fewer of the nucleotides of a guide RNAare modified (e.g., 19 or fewer, 18 or fewer, 17 or fewer, 16 or fewer,15 or fewer, 14 or fewer, 13 or fewer, 12 or fewer, 11 or fewer, 10 orfewer, 9 or fewer, 8 or fewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 orfewer, 3 or fewer, 2 or fewer, or one, of the nucleotides of a guide RNAare modified).

A 2′-O-Methyl modified nucleotide (also referred to as 2′-O-Methyl RNA)is a naturally occurring modification of RNA found in tRNA and othersmall RNAs that arises as a post-transcriptional modification.Oligonucleotides can be directly synthesized that contain 2′-O-MethylRNA. This modification increases Tm of RNA:RNA duplexes but results inonly small changes in RNA:DNA stability. It is stable with respect toattack by single-stranded ribonucleases and is typically 5 to 10-foldless susceptible to DNases than DNA. It is commonly used in antisenseoligos as a means to increase stability and binding affinity to thetarget message.

In some cases, 2% or more of the nucleotides of a nucleic acid (e.g., aguide RNA, etc.) are 2′-O-Methyl modified (e.g., 3% or more, 5% or more,7.5% or more, 10% or more, 15% or more, 20% or more, 25% or more, 30% ormore, 35% or more, 40% or more, 45% or more, 50% or more, 55% or more,60% or more, 65% or more, 75% or more, 80% or more, 85% or more, 90% ormore, 95% or more, or 100% of the nucleotides of a subject nucleic acidare 2′-O-Methyl modified). In some cases, 2% or more of the nucleotidesof a subject guide RNA are 2′-O-Methyl modified (e.g., 3% or more, 5% ormore, 7.5% or more, 10% or more, 15% or more, 20% or more, 25% or more,30% or more, 35% or more, 40% or more, 45% or more, 50% or more, 55% ormore, 60% or more, 65% or more, 75% or more, 80% or more, 85% or more,90% or more, 95% or more, or 100% of the nucleotides of a subject guideRNA are 2′-O-Methyl modified). In some cases, 2% or more of thenucleotides of a guide RNA are 2′-O-Methyl modified (e.g., 3% or more,5% or more, 7.5% or more, 10% or more, 15% or more, 20% or more, 25% ormore, 30% or more, 35% or more, 40% or more, 45% or more, 50% or more,55% or more, 60% or more, 65% or more, 75% or more, 80% or more, 85% ormore, 90% or more, 95% or more, or 100% of the nucleotides of a guideRNA are 2′-O-Methyl modified).

In some cases, the number of nucleotides of a nucleic acid nucleic acid(e.g., a guide RNA, etc.) that are 2′-O-Methyl modified is in a range offrom 3% to 100% (e.g., 3% to 100%, 3% to 95%, 3% to 90%, 3% to 85%, 3%to 80%, 3% to 75%, 3% to 70%, 3% to 65%, 3% to 60%, 3% to 55%, 3% to50%, 3% to 45%, 3% to 40%, 5% to 100%, 5% to 95%, 5% to 90%, 5% to 85%,5% to 80%, 5% to 75%, 5% to 70%, 5% to 65%, 5% to 60%, 5% to 55%, 5% to50%, 5% to 45%, 5% to 40%, 10% to 100%, 10% to 95%, 10% to 90%, 10% to85%, 10% to 80%, 10% to 75%, 10% to 70%, 10% to 65%, 10% to 60%, 10% to55%, 10% to 50%, 10% to 45%, or 10% to 40%). In some cases, the numberof nucleotides of a guide RNA that are 2′-O-Methyl modified is in arange of from 3% to 100% (e.g., 3% to 100%, 3% to 95%, 3% to 90%, 3% to85%, 3% to 80%, 3% to 75%, 3% to 70%, 3% to 65%, 3% to 60%, 3% to 55%,3% to 50%, 3% to 45%, 3% to 40%, 5% to 100%, 5% to 95%, 5% to 90%, 5% to85%, 5% to 80%, 5% to 75%, 5% to 70%, 5% to 65%, 5% to 60%, 5% to 55%,5% to 50%, 5% to 45%, 5% to 40%, 10% to 100%, 10% to 95%, 10% to 90%,10% to 85%, 10% to 80%, 10% to 75%, 10% to 70%, 10% to 65%, 10% to 60%,10% to 55%, 10% to 50%, 10% to 45%, or 10% to 40%). In some cases, thenumber of nucleotides of a guide RNA that are 2′-O-Methyl modified is ina range of from 3% to 100% (e.g., 3% to 100%, 3% to 95%, 3% to 90%, 3%to 85%, 3% to 80%, 3% to 75%, 3% to 70%, 3% to 65%, 3% to 60%, 3% to55%, 3% to 50%, 3% to 45%, 3% to 40%, 5% to 100%, 5% to 95%, 5% to 90%,5% to 85%, 5% to 80%, 5% to 75%, 5% to 70%, 5% to 65%, 5% to 60%, 5% to55%, 5% to 50%, 5% to 45%, 5% to 40%, 10% to 100%, 10% to 95%, 10% to90%, 10% to 85%, 10% to 80%, 10% to 75%, 10% to 70%, 10% to 65%, 10% to60%, 10% to 55%, 10% to 50%, 10% to 45%, or 10% to 40%).

In some cases, one or more of the nucleotides of a nucleic acid (e.g., aguide RNA, etc.) are 2′-O-Methyl modified (e.g., 2 or more, 3 or more, 4or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 ormore, 11 or more, 12 or more, 13 or more, 14 or more, 15 or more, 16 ormore, 17 or more, 18 or more, 19 or more, 20 or more, 21 or more, 22 ormore, or all of the nucleotides of a subject nucleic acid are2′-O-Methyl modified). In some cases, one or more of the nucleotides ofa guide RNA are 2′-O-Methyl modified (e.g., 2 or more, 3 or more, 4 ormore, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more,11 or more, 12 or more, 13 or more, 14 or more, 15 or more, 16 or more,17 or more, 18 or more, 19 or more, 20 or more, 21 or more, 22 or more,or all of the nucleotides of a subject guide RNA are 2′-O-Methylmodified). In some cases, one or more of the nucleotides of a guide RNAare 2′-O-Methyl modified (e.g., 2 or more, 3 or more, 4 or more, 5 ormore, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 ormore, 12 or more, 13 or more, 14 or more, 15 or more, 16 or more, 17 ormore, 18 or more, 19 or more, 20 or more, 21 or more, 22 or more, or allof the nucleotides of a guide RNA are 2′-O-Methyl modified).

In some cases, 99% or less of the nucleotides of a nucleic acid (e.g., aguide RNA, etc.) are 2′-O-Methyl modified (e.g., 99% or less, 95% orless, 90% or less, 85% or less, 80% or less, 75% or less, 70% or less,65% or less, 60% or less, 55% or less, 50% or less, or 45% or less ofthe nucleotides of a subject nucleic acid are 2′-O-Methyl modified). Insome cases, 99% or less of the nucleotides of a subject guide RNA are2′-O-Methyl modified (e.g., e.g., 99% or less, 95% or less, 90% or less,85% or less, 80% or less, 75% or less, 70% or less, 65% or less, 60% orless, 55% or less, 50% or less, or 45% or less of the nucleotides of asubject guide RNA are 2′-O-Methyl modified). In some cases, 99% or lessof the nucleotides of a guide RNA are 2′-O-Methyl modified (e.g., 99% orless, 95% or less, 90% or less, 85% or less, 80% or less, 75% or less,70% or less, 65% or less, 60% or less, 55% or less, 50% or less, or 45%or less of the nucleotides of a guide RNA are 2′-O-Methyl modified).

In some cases, the number of nucleotides of a nucleic acid nucleic acid(e.g., a guide RNA, etc.) that are 2′-O-Methyl modified is in a range offrom 1 to 30 (e.g., 1 to 25, 1 to 20, 1 to 18, 1 to 15, 1 to 10, 2 to25, 2 to 20, 2 to 18, 2 to 15, 2 to 10, 3 to 25, 3 to 20, 3 to 18, 3 to15, or 3 to 10). In some cases, the number of nucleotides of a subjectguide RNA that are 2′-O-Methyl modified is in a range of from 1 to 30(e.g., 1 to 25, 1 to 20, 1 to 18, 1 to 15, 1 to 10, 2 to 25, 2 to 20, 2to 18, 2 to 15, 2 to 10, 3 to 25, 3 to 20, 3 to 18, 3 to 15, or 3 to10). In some cases, the number of nucleotides of a guide RNA that are2′-O-Methyl modified is in a range of from 1 to 30 (e.g., 1 to 25, 1 to20, 1 to 18, 1 to 15, 1 to 10, 2 to 25, 2 to 20, 2 to 18, 2 to 15, 2 to10, 3 to 25, 3 to 20, 3 to 18, 3 to 15, or 3 to 10).

In some cases, 20 or fewer of the nucleotides of a nucleic acid (e.g., aguide RNA, etc.) are 2′-O-Methyl modified (e.g., 19 or fewer, 18 orfewer, 17 or fewer, 16 or fewer, 15 or fewer, 14 or fewer, 13 or fewer,12 or fewer, 11 or fewer, 10 or fewer, 9 or fewer, 8 or fewer, 7 orfewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 or fewer, 2 or fewer, orone, of the nucleotides of a subject nucleic acid are 2′-O-Methylmodified). In some cases, 20 or fewer of the nucleotides of a subjectguide RNA are 2′-O-Methyl modified (e.g., 19 or fewer, 18 or fewer, 17or fewer, 16 or fewer, 15 or fewer, 14 or fewer, 13 or fewer, 12 orfewer, 11 or fewer, 10 or fewer, 9 or fewer, 8 or fewer, 7 or fewer, 6or fewer, 5 or fewer, 4 or fewer, 3 or fewer, 2 or fewer, or one, of thenucleotides of a subject guide RNA are 2′-O-Methyl modified). In somecases, 20 or fewer of the nucleotides of a guide RNA are 2′-O-Methylmodified (e.g., 19 or fewer, 18 or fewer, 17 or fewer, 16 or fewer, 15or fewer, 14 or fewer, 13 or fewer, 12 or fewer, 11 or fewer, 10 orfewer, 9 or fewer, 8 or fewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 orfewer, 3 or fewer, 2 or fewer, or one, of the nucleotides of a guide RNAare 2′-O-Methyl modified).

2′ Fluoro modified nucleotides (e.g., 2′ Fluoro bases) have a fluorinemodified ribose which increases binding affinity (Tm) and also conferssome relative nuclease resistance when compared to native RNA. Thesemodifications are commonly employed in ribozymes and siRNAs to improvestability in serum or other biological fluids.

In some cases, 2% or more of the nucleotides of a nucleic acid (e.g., aguide RNA, etc.) are 2′ Fluoro modified (e.g., 3% or more, 5% or more,7.5% or more, 10% or more, 15% or more, 20% or more, 25% or more, 30% ormore, 35% or more, 40% or more, 45% or more, 50% or more, 55% or more,60% or more, 65% or more, 75% or more, 80% or more, 85% or more, 90% ormore, 95% or more, or 100% of the nucleotides of a subject nucleic acidare 2′ Fluoro modified). In some cases, 2% or more of the nucleotides ofa subject guide RNA are 2′ Fluoro modified (e.g., 3% or more, 5% ormore, 7.5% or more, 10% or more, 15% or more, 20% or more, 25% or more,30% or more, 35% or more, 40% or more, 45% or more, 50% or more, 55% ormore, 60% or more, 65% or more, 75% or more, 80% or more, 85% or more,90% or more, 95% or more, or 100% of the nucleotides of a subject guideRNA are 2′ Fluoro modified). In some cases, 2% or more of thenucleotides of a guide RNA are 2′ Fluoro modified (e.g., 3% or more, 5%or more, 7.5% or more, 10% or more, 15% or more, 20% or more, 25% ormore, 30% or more, 35% or more, 40% or more, 45% or more, 50% or more,55% or more, 60% or more, 65% or more, 75% or more, 80% or more, 85% ormore, 90% or more, 95% or more, or 100% of the nucleotides of a guideRNA are 2′ Fluoro modified).

In some cases, the number of nucleotides of a nucleic acid nucleic acid(e.g., a guide RNA, etc.) that are 2′ Fluoro modified is in a range offrom 3% to 100% (e.g., 3% to 100%, 3% to 95%, 3% to 90%, 3% to 85%, 3%to 80%, 3% to 75%, 3% to 70%, 3% to 65%, 3% to 60%, 3% to 55%, 3% to50%, 3% to 45%, 3% to 40%, 5% to 100%, 5% to 95%, 5% to 90%, 5% to 85%,5% to 80%, 5% to 75%, 5% to 70%, 5% to 65%, 5% to 60%, 5% to 55%, 5% to50%, 5% to 45%, 5% to 40%, 10% to 100%, 10% to 95%, 10% to 90%, 10% to85%, 10% to 80%, 10% to 75%, 10% to 70%, 10% to 65%, 10% to 60%, 10% to55%, 10% to 50%, 10% to 45%, or 10% to 40%). In some cases, the numberof nucleotides of a guide RNA that are 2′ Fluoro modified is in a rangeof from 3% to 100% (e.g., 3% to 100%, 3% to 95%, 3% to 90%, 3% to 85%,3% to 80%, 3% to 75%, 3% to 70%, 3% to 65%, 3% to 60%, 3% to 55%, 3% to50%, 3% to 45%, 3% to 40%, 5% to 100%, 5% to 95%, 5% to 90%, 5% to 85%,5% to 80%, 5% to 75%, 5% to 70%, 5% to 65%, 5% to 60%, 5% to 55%, 5% to50%, 5% to 45%, 5% to 40%, 10% to 100%, 10% to 95%, 10% to 90%, 10% to85%, 10% to 80%, 10% to 75%, 10% to 70%, 10% to 65%, 10% to 60%, 10% to55%, 10% to 50%, 10% to 45%, or 10% to 40%). In some cases, the numberof nucleotides of a guide RNA that are 2′ Fluoro modified is in a rangeof from 3% to 100% (e.g., 3% to 100%, 3% to 95%, 3% to 90%, 3% to 85%,3% to 80%, 3% to 75%, 3% to 70%, 3% to 65%, 3% to 60%, 3% to 55%, 3% to50%, 3% to 45%, 3% to 40%, 5% to 100%, 5% to 95%, 5% to 90%, 5% to 85%,5% to 80%, 5% to 75%, 5% to 70%, 5% to 65%, 5% to 60%, 5% to 55%, 5% to50%, 5% to 45%, 5% to 40%, 10% to 100%, 10% to 95%, 10% to 90%, 10% to85%, 10% to 80%, 10% to 75%, 10% to 70%, 10% to 65%, 10% to 60%, 10% to55%, 10% to 50%, 10% to 45%, or 10% to 40%).

In some cases, one or more of the nucleotides of a nucleic acid (e.g., aguide RNA, etc.) are 2′ Fluoro modified (e.g., 2 or more, 3 or more, 4or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 ormore, 11 or more, 12 or more, 13 or more, 14 or more, 15 or more, 16 ormore, 17 or more, 18 or more, 19 or more, 20 or more, 21 or more, 22 ormore, or all of the nucleotides of a subject nucleic acid are 2′ Fluoromodified). In some cases, one or more of the nucleotides of a subjectguide RNA are 2′ Fluoro modified (e.g., 2 or more, 3 or more, 4 or more,5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 ormore, 12 or more, 13 or more, 14 or more, 15 or more, 16 or more, 17 ormore, 18 or more, 19 or more, 20 or more, 21 or more, 22 or more, or allof the nucleotides of a guide RNA are 2′ Fluoro modified). In somecases, one or more of the nucleotides of a guide RNA are 2′ Fluoromodified (e.g., 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, 13 ormore, 14 or more, 15 or more, 16 or more, 17 or more, 18 or more, 19 ormore, 20 or more, 21 or more, 22 or more, or all of the nucleotides of aguide RNA are 2′ Fluoro modified).

In some cases, 99% or less of the nucleotides of a nucleic acid (e.g., aguide RNA, etc.) are 2′ Fluoro modified (e.g., 99% or less, 95% or less,90% or less, 85% or less, 80% or less, 75% or less, 70% or less, 65% orless, 60% or less, 55% or less, 50% or less, or 45% or less of thenucleotides of a subject nucleic acid are 2′ Fluoro modified). In somecases, 99% or less of the nucleotides of a subject guide RNA are 2′Fluoro modified (e.g., e.g., 99% or less, 95% or less, 90% or less, 85%or less, 80% or less, 75% or less, 70% or less, 65% or less, 60% orless, 55% or less, 50% or less, or 45% or less of the nucleotides of asubject guide RNA are 2′ Fluoro modified). In some cases, 99% or less ofthe nucleotides of a guide RNA are 2′ Fluoro modified (e.g., 99% orless, 95% or less, 90% or less, 85% or less, 80% or less, 75% or less,70% or less, 65% or less, 60% or less, 55% or less, 50% or less, or 45%or less of the nucleotides of a guide RNA are 2′ Fluoro modified).

In some cases, the number of nucleotides of a nucleic acid nucleic acid(e.g., a guide RNA, etc.) that are 2′ Fluoro modified is in a range offrom 1 to 30 (e.g., 1 to 25, 1 to 20, 1 to 18, 1 to 15, 1 to 10, 2 to25, 2 to 20, 2 to 18, 2 to 15, 2 to 10, 3 to 25, 3 to 20, 3 to 18, 3 to15, or 3 to 10). In some cases, the number of nucleotides of a subjectguide RNA that are 2′ Fluoro modified is in a range of from 1 to 30(e.g., 1 to 25, 1 to 20, 1 to 18, 1 to 15, 1 to 10, 2 to 25, 2 to 20, 2to 18, 2 to 15, 2 to 10, 3 to 25, 3 to 20, 3 to 18, 3 to 15, or 3 to10). In some cases, the number of nucleotides of a guide RNA that are 2′Fluoro modified is in a range of from 1 to 30 (e.g., 1 to 25, 1 to 20, 1to 18, 1 to 15, 1 to 10, 2 to 25, 2 to 20, 2 to 18, 2 to 15, 2 to 10, 3to 25, 3 to 20, 3 to 18, 3 to 15, or 3 to 10).

In some cases, 20 or fewer of the nucleotides of a nucleic acid (e.g., aguide RNA, etc.) are 2′ Fluoro modified (e.g., 19 or fewer, 18 or fewer,17 or fewer, 16 or fewer, 15 or fewer, 14 or fewer, 13 or fewer, 12 orfewer, 11 or fewer, 10 or fewer, 9 or fewer, 8 or fewer, 7 or fewer, 6or fewer, 5 or fewer, 4 or fewer, 3 or fewer, 2 or fewer, or one, of thenucleotides of a subject nucleic acid are 2′ Fluoro modified). In somecases, 20 or fewer of the nucleotides of a subject guide RNA are 2′Fluoro modified (e.g., 19 or fewer, 18 or fewer, 17 or fewer, 16 orfewer, 15 or fewer, 14 or fewer, 13 or fewer, 12 or fewer, 11 or fewer,10 or fewer, 9 or fewer, 8 or fewer, 7 or fewer, 6 or fewer, 5 or fewer,4 or fewer, 3 or fewer, 2 or fewer, or one, of the nucleotides of asubject guide RNA are 2′ Fluoro modified). In some cases, 20 or fewer ofthe nucleotides of a guide RNA are 2′ Fluoro modified (e.g., 19 orfewer, 18 or fewer, 17 or fewer, 16 or fewer, 15 or fewer, 14 or fewer,13 or fewer, 12 or fewer, 11 or fewer, 10 or fewer, 9 or fewer, 8 orfewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 or fewer, 2 orfewer, or one, of the nucleotides of a guide RNA are 2′ Fluoromodified).

LNA bases have a modification to the ribose backbone that locks the basein the C3′-endo position, which favors RNA A-type helix duplex geometry.This modification significantly increases Tm and is also very nucleaseresistant. Multiple LNA insertions can be placed in an oligo at anyposition except the 3′-end. Applications have been described rangingfrom antisense oligos to hybridization probes to SNP detection andallele specific PCR. Due to the large increase in Tm conferred by LNAs,they also can cause an increase in primer dimer formation as well asself-hairpin formation. In some cases, the number of LNAs incorporatedinto a single oligo is 10 bases or less.

In some cases, the number of nucleotides of a nucleic acid nucleic acid(e.g., a guide RNA, etc.) that have an LNA base is in a range of from 3%to 99% (e.g., 3% to 99%, 3% to 95%, 3% to 90%, 3% to 85%, 3% to 80%, 3%to 75%, 3% to 70%, 3% to 65%, 3% to 60%, 3% to 55%, 3% to 50%, 3% to45%, 3% to 40%, 5% to 99%, 5% to 95%, 5% to 90%, 5% to 85%, 5% to 80%,5% to 75%, 5% to 70%, 5% to 65%, 5% to 60%, 5% to 55%, 5% to 50%, 5% to45%, 5% to 40%, 10% to 99%, 10% to 95%, 10% to 90%, 10% to 85%, 10% to80%, 10% to 75%, 10% to 70%, 10% to 65%, 10% to 60%, 10% to 55%, 10% to50%, 10% to 45%, or 10% to 40%). In some cases, the number ofnucleotides of a guide RNA that have an LNA base is in a range of from3% to 99% (e.g., 3% to 99%, 3% to 95%, 3% to 90%, 3% to 85%, 3% to 80%,3% to 75%, 3% to 70%, 3% to 65%, 3% to 60%, 3% to 55%, 3% to 50%, 3% to45%, 3% to 40%, 5% to 99%, 5% to 95%, 5% to 90%, 5% to 85%, 5% to 80%,5% to 75%, 5% to 70%, 5% to 65%, 5% to 60%, 5% to 55%, 5% to 50%, 5% to45%, 5% to 40%, 10% to 99%, 10% to 95%, 10% to 90%, 10% to 85%, 10% to80%, 10% to 75%, 10% to 70%, 10% to 65%, 10% to 60%, 10% to 55%, 10% to50%, 10% to 45%, or 10% to 40%). In some cases, the number ofnucleotides of a guide RNA that have an LNA base is in a range of from3% to 99% (e.g., 3% to 99%, 3% to 95%, 3% to 90%, 3% to 85%, 3% to 80%,3% to 75%, 3% to 70%, 3% to 65%, 3% to 60%, 3% to 55%, 3% to 50%, 3% to45%, 3% to 40%, 5% to 99%, 5% to 95%, 5% to 90%, 5% to 85%, 5% to 80%,5% to 75%, 5% to 70%, 5% to 65%, 5% to 60%, 5% to 55%, 5% to 50%, 5% to45%, 5% to 40%, 10% to 99%, 10% to 95%, 10% to 90%, 10% to 85%, 10% to80%, 10% to 75%, 10% to 70%, 10% to 65%, 10% to 60%, 10% to 55%, 10% to50%, 10% to 45%, or 10% to 40%).

In some cases, one or more of the nucleotides of a nucleic acid (e.g., aguide RNA, etc.) have an LNA base (e.g., 2 or more, 3 or more, 4 ormore, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more,11 or more, 12 or more, 13 or more, 14 or more, 15 or more, 16 or more,17 or more, 18 or more, 19 or more, 20 or more, 21 or more, 22 or more,or all of the nucleotides of a subject nucleic acid have an LNA base).In some cases, one or more of the nucleotides of a subject guide RNAhave an LNA base (e.g., 2 or more, 3 or more, 4 or more, 5 or more, 6 ormore, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 ormore, 13 or more, 14 or more, 15 or more, 16 or more, 17 or more, 18 ormore, 19 or more, 20 or more, 21 or more, 22 or more, or all of thenucleotides of a subject guide RNA have an LNA base). In some cases, oneor more of the nucleotides of a guide RNA have an LNA base (e.g., 2 ormore, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more,9 or more, 10 or more, 11 or more, 12 or more, 13 or more, 14 or more,15 or more, 16 or more, 17 or more, 18 or more, 19 or more, 20 or more,21 or more, 22 or more, or all of the nucleotides of a guide RNA have anLNA base).

In some cases, 99% or less of the nucleotides of a nucleic acid (e.g., aguide RNA, etc.) have an LNA base (e.g., 99% or less, 95% or less, 90%or less, 85% or less, 80% or less, 75% or less, 70% or less, 65% orless, 60% or less, 55% or less, 50% or less, or 45% or less of thenucleotides of a subject nucleic acid have an LNA base). In some cases,99% or less of the nucleotides of a guide RNA have an LNA base (e.g.,e.g., 99% or less, 95% or less, 90% or less, 85% or less, 80% or less,75% or less, 70% or less, 65% or less, 60% or less, 55% or less, 50% orless, or 45% or less of the nucleotides of a guide RNA have an LNAbase). In some cases, 99% or less of the nucleotides of a guide RNA havean LNA base (e.g., 99% or less, 95% or less, 90% or less, 85% or less,80% or less, 75% or less, 70% or less, 65% or less, 60% or less, 55% orless, 50% or less, or 45% or less of the nucleotides of a guide RNA havean LNA base).

In some cases, the number of nucleotides of a nucleic acid nucleic acid(e.g., a guide RNA, etc.) that have an LNA base is in a range of from 1to 30 (e.g., 1 to 25, 1 to 20, 1 to 18, 1 to 15, 1 to 10, 2 to 25, 2 to20, 2 to 18, 2 to 15, 2 to 10, 3 to 25, 3 to 20, 3 to 18, 3 to 15, or 3to 10). In some cases, the number of nucleotides of a guide RNA thathave an LNA base is in a range of from 1 to 30 (e.g., 1 to 25, 1 to 20,1 to 18, 1 to 15, 1 to 10, 2 to 25, 2 to 20, 2 to 18, 2 to 15, 2 to 10,3 to 25, 3 to 20, 3 to 18, 3 to 15, or 3 to 10). In some cases, thenumber of nucleotides of a guide RNA that have an LNA base is in a rangeof from 1 to 30 (e.g., 1 to 25, 1 to 20, 1 to 18, 1 to 15, 1 to 10, 2 to25, 2 to 20, 2 to 18, 2 to 15, 2 to 10, 3 to 25, 3 to 20, 3 to 18, 3 to15, or 3 to 10).

In some cases, 20 or fewer of the nucleotides of a nucleic acid (e.g., aguide RNA, etc.) have an LNA base (e.g., 19 or fewer, 18 or fewer, 17 orfewer, 16 or fewer, 15 or fewer, 14 or fewer, 13 or fewer, 12 or fewer,11 or fewer, 10 or fewer, 9 or fewer, 8 or fewer, 7 or fewer, 6 orfewer, 5 or fewer, 4 or fewer, 3 or fewer, 2 or fewer, or one, of thenucleotides of a subject nucleic acid have an LNA base). In some cases,20 or fewer of the nucleotides of a subject guide RNA have an LNA base(e.g., 19 or fewer, 18 or fewer, 17 or fewer, 16 or fewer, 15 or fewer,14 or fewer, 13 or fewer, 12 or fewer, 11 or fewer, 10 or fewer, 9 orfewer, 8 or fewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 orfewer, 2 or fewer, or one, of the nucleotides of a subject guide RNAhave an LNA base). In some cases, 20 or fewer of the nucleotides of aguide RNA have an LNA base (e.g., 19 or fewer, 18 or fewer, 17 or fewer,16 or fewer, 15 or fewer, 14 or fewer, 13 or fewer, 12 or fewer, 11 orfewer, 10 or fewer, 9 or fewer, 8 or fewer, 7 or fewer, 6 or fewer, 5 orfewer, 4 or fewer, 3 or fewer, 2 or fewer, or one, of the nucleotides ofa guide RNA have an LNA base).

The phosphorothioate (PS) bond (i.e., a phosphorothioate linkage)substitutes a sulfur atom for a non-bridging oxygen in the phosphatebackbone of a nucleic acid (e.g., an oligo). This modification rendersthe internucleotide linkage resistant to nuclease degradation.Phosphorothioate bonds can be introduced between the last 3-5nucleotides at the 5′- or 3′-end of the oligo to inhibit exonucleasedegradation. Including phosphorothioate bonds within the oligo (e.g.,throughout the entire oligo) can help reduce attack by endonucleases aswell.

In some cases, the number of nucleotides of a nucleic acid nucleic acid(e.g., a guide RNA, etc.) that have a phosphorothioate linkage is in arange of from 3% to 99% (e.g., 3% to 99%, 3% to 95%, 3% to 90%, 3% to85%, 3% to 80%, 3% to 75%, 3% to 70%, 3% to 65%, 3% to 60%, 3% to 55%,3% to 50%, 3% to 45%, 3% to 40%, 5% to 99%, 5% to 95%, 5% to 90%, 5% to85%, 5% to 80%, 5% to 75%, 5% to 70%, 5% to 65%, 5% to 60%, 5% to 55%,5% to 50%, 5% to 45%, 5% to 40%, 10% to 99%, 10% to 95%, 10% to 90%, 10%to 85%, 10% to 80%, 10% to 75%, 10% to 70%, 10% to 65%, 10% to 60%, 10%to 55%, 10% to 50%, 10% to 45%, or 10% to 40%). In some cases, thenumber of nucleotides of a guide RNA that have a phosphorothioatelinkage is in a range of from 3% to 99% (e.g., 3% to 99%, 3% to 95%, 3%to 90%, 3% to 85%, 3% to 80%, 3% to 75%, 3% to 70%, 3% to 65%, 3% to60%, 3% to 55%, 3% to 50%, 3% to 45%, 3% to 40%, 5% to 99%, 5% to 95%,5% to 90%, 5% to 85%, 5% to 80%, 5% to 75%, 5% to 70%, 5% to 65%, 5% to60%, 5% to 55%, 5% to 50%, 5% to 45%, 5% to 40%, 10% to 99%, 10% to 95%,10% to 90%, 10% to 85%, 10% to 80%, 10% to 75%, 10% to 70%, 10% to 65%,10% to 60%, 10% to 55%, 10% to 50%, 10% to 45%, or 10% to 40%). In somecases, the number of nucleotides of a guide RNA that have aphosphorothioate linkage is in a range of from 3% to 99% (e.g., 3% to99%, 3% to 95%, 3% to 90%, 3% to 85%, 3% to 80%, 3% to 75%, 3% to 70%,3% to 65%, 3% to 60%, 3% to 55%, 3% to 50%, 3% to 45%, 3% to 40%, 5% to99%, 5% to 95%, 5% to 90%, 5% to 85%, 5% to 80%, 5% to 75%, 5% to 70%,5% to 65%, 5% to 60%, 5% to 55%, 5% to 50%, 5% to 45%, 5% to 40%, 10% to99%, 10% to 95%, 10% to 90%, 10% to 85%, 10% to 80%, 10% to 75%, 10% to70%, 10% to 65%, 10% to 60%, 10% to 55%, 10% to 50%, 10% to 45%, or 10%to 40%).

In some cases, one or more of the nucleotides of a nucleic acid (e.g., aguide RNA, etc.) have a phosphorothioate linkage (e.g., 2 or more, 3 ormore, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more,10 or more, 11 or more, 12 or more, 13 or more, 14 or more, 15 or more,16 or more, 17 or more, 18 or more, 19 or more, 20 or more, 21 or more,22 or more, or all of the nucleotides of a subject nucleic acid have aphosphorothioate linkage). In some cases, one or more of the nucleotidesof a subject guide RNA have a phosphorothioate linkage (e.g., 2 or more,3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 ormore, 10 or more, 11 or more, 12 or more, 13 or more, 14 or more, 15 ormore, 16 or more, 17 or more, 18 or more, 19 or more, 20 or more, 21 ormore, 22 or more, or all of the nucleotides of a subject guide RNA havea phosphorothioate linkage). In some cases, one or more of thenucleotides of a guide RNA have a phosphorothioate linkage (e.g., 2 ormore, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more,9 or more, 10 or more, 11 or more, 12 or more, 13 or more, 14 or more,15 or more, 16 or more, 17 or more, 18 or more, 19 or more, 20 or more,21 or more, 22 or more, or all of the nucleotides of a guide RNA have aphosphorothioate linkage).

In some cases, 99% or less of the nucleotides of a nucleic acid (e.g., aguide RNA, etc.) have a phosphorothioate linkage (e.g., 99% or less, 95%or less, 90% or less, 85% or less, 80% or less, 75% or less, 70% orless, 65% or less, 60% or less, 55% or less, 50% or less, or 45% or lessof the nucleotides of a subject nucleic acid have a phosphorothioatelinkage). In some cases, 99% or less of the nucleotides of a subjectguide RNA have a phosphorothioate linkage (e.g., e.g., 99% or less, 95%or less, 90% or less, 85% or less, 80% or less, 75% or less, 70% orless, 65% or less, 60% or less, 55% or less, 50% or less, or 45% or lessof the nucleotides of a guide RNA have a phosphorothioate linkage). Insome cases, 99% or less of the nucleotides of a guide RNA have aphosphorothioate linkage (e.g., 99% or less, 95% or less, 90% or less,85% or less, 80% or less, 75% or less, 70% or less, 65% or less, 60% orless, 55% or less, 50% or less, or 45% or less of the nucleotides of aguide RNA have a phosphorothioate linkage).

In some cases, the number of nucleotides of a nucleic acid nucleic acid(e.g., a guide RNA, etc.) that have a phosphorothioate linkage is in arange of from 1 to 30 (e.g., 1 to 25, 1 to 20, 1 to 18, ito 15, 1 to 10,2 to 25, 2 to 20, 2 to 18, 2 to 15, 2 to 10, 3 to 25, 3 to 20, 3 to 18,3 to 15, or 3 to 10). In some cases, the number of nucleotides of aguide RNA that have a phosphorothioate linkage is in a range of from 1to 30 (e.g., 1 to 25, 1 to 20, 1 to 18, 1 to 15, 1 to 10, 2 to 25, 2 to20, 2 to 18, 2 to 15, 2 to 10, 3 to 25, 3 to 20, 3 to 18, 3 to 15, or 3to 10). In some cases, the number of nucleotides of a guide RNA thathave a phosphorothioate linkage is in a range of from 1 to 30 (e.g., 1to 25, 1 to 20, 1 to 18, 1 to 15, 1 to 10, 2 to 25, 2 to 20, 2 to 18, 2to 15, 2 to 10, 3 to 25, 3 to 20, 3 to 18, 3 to 15, or 3 to 10).

In some cases, 20 or fewer of the nucleotides of a nucleic acid (e.g., aguide RNA, etc.) have a phosphorothioate linkage (e.g., 19 or fewer, 18or fewer, 17 or fewer, 16 or fewer, 15 or fewer, 14 or fewer, 13 orfewer, 12 or fewer, 11 or fewer, 10 or fewer, 9 or fewer, 8 or fewer, 7or fewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 or fewer, 2 or fewer, orone, of the nucleotides of a subject nucleic acid have aphosphorothioate linkage). In some cases, 20 or fewer of the nucleotidesof a guide RNA have a phosphorothioate linkage (e.g., 19 or fewer, 18 orfewer, 17 or fewer, 16 or fewer, 15 or fewer, 14 or fewer, 13 or fewer,12 or fewer, 11 or fewer, 10 or fewer, 9 or fewer, 8 or fewer, 7 orfewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 or fewer, 2 or fewer, orone, of the nucleotides of a subject guide RNA have a phosphorothioatelinkage). In some cases, 20 or fewer of the nucleotides of a guide RNAhave a phosphorothioate linkage (e.g., 19 or fewer, 18 or fewer, 17 orfewer, 16 or fewer, 15 or fewer, 14 or fewer, 13 or fewer, 12 or fewer,11 or fewer, 10 or fewer, 9 or fewer, 8 or fewer, 7 or fewer, 6 orfewer, 5 or fewer, 4 or fewer, 3 or fewer, 2 or fewer, or one, of thenucleotides of a guide RNA have a phosphorothioate linkage).

In some cases, a nucleic acid (e.g., a guide RNA, etc.) has one or morenucleotides that are 2′-O-Methyl modified nucleotides. In someembodiments, a subject nucleic acid (e.g., a guide RNA, etc.) has one ormore 2′ Fluoro modified nucleotides. In some cases, a subject nucleicacid (e.g., a guide RNA, etc.) has one or more LNA bases. In some cases,a subject nucleic acid (e.g., a guide RNA, etc.) has one or morenucleotides that are linked by a phosphorothioate bond (i.e., thesubject nucleic acid has one or more phosphorothioate linkages). In someembodiments, a subject nucleic acid (e.g., a guide RNA, etc.) has a 5′cap (e.g., a 7-methylguanylate cap (m7G)).

In some cases, a nucleic acid (e.g., a DNA or RNA encoding an RNA guidedendonuclease, a guide RNA, etc.) has a combination of modifiednucleotides. For example, a nucleic acid can have a 5′ cap (e.g., a7-methylguanylate cap (m7G)) in addition to having one or morenucleotides with other modifications (e.g., a 2′-O-Methyl nucleotideand/or a 2′ Fluoro modified nucleotide and/or a LNA base and/or aphosphorothioate linkage). A nucleic acid can have any combination ofmodifications. For example, a subject nucleic acid can have anycombination of the above described modifications.

In some cases, a guide RNA has one or more nucleotides that are2′-O-Methyl modified nucleotides. In some embodiments, a guide RNA hasone or more 2′ Fluoro modified nucleotides. In some embodiments, a guideRNA has one or more LNA bases. In some embodiments, a guide RNA has oneor more nucleotides that are linked by a phosphorothioate bond (i.e.,the subject nucleic acid has one or more phosphorothioate linkages). Insome embodiments, a guide RNA has a 5′ cap (e.g., a 7-methylguanylatecap (m7G)).

In some cases, a guide RNA has a combination of modified nucleotides.For example, a guide RNA can have a 5′ cap (e.g., a 7-methylguanylatecap (m7G)) in addition to having one or more nucleotides with othermodifications (e.g., a 2′-O-Methyl nucleotide and/or a 2′ Fluoromodified nucleotide and/or a LNA base and/or a phosphorothioatelinkage). A guide RNA can have any combination of modifications. Forexample, a guide RNA can have any combination of the above describedmodifications.

Modified Backbones and Modified Internucleoside Linkages

Examples of suitable nucleic acids containing modifications includenucleic acids containing modified backbones or non-naturalinternucleoside linkages. Nucleic acids having modified backbonesinclude those that retain a phosphorus atom in the backbone and thosethat do not have a phosphorus atom in the backbone.

Suitable modified oligonucleotide backbones containing a phosphorus atomtherein include, for example, phosphorothioates, chiralphosphorothioates, phosphorodithioates, phosphotriesters,aminoalkylphosphotriesters, methyl and other alkyl phosphonatesincluding 3′-alkylene phosphonates, 5′-alkylene phosphonates and chiralphosphonates, phosphinates, phosphoramidates including 3′-aminophosphoramidate and aminoalkylphosphoramidates, phosphorodiamidates,thionophosphoramidates, thionoalkylphosphonates,thionoalkylphosphotriesters, selenophosphates and boranophosphateshaving normal 3′-5′ linkages, 2′-5′ linked analogs of these, and thosehaving inverted polarity wherein one or more internucleotide linkages isa 3′ to 3′, 5′ to 5′ or 2′ to 2′ linkage. Suitable oligonucleotideshaving inverted polarity comprise a single 3′ to 3′ linkage at the3′-most internucleotide linkage i.e. a single inverted nucleosideresidue which may be a basic (the nucleobase is missing or has ahydroxyl group in place thereof). Various salts (such as, for example,potassium or sodium), mixed salts and free acid forms are also included.

In some cases, a nucleic acid comprises one or more phosphorothioateand/or heteroatom internucleoside linkages, in particular—CH₂—NH—O—CH₂—, —CH₂—N(CH₃)—O—CH₂— (known as a methylene (methylimino)or MMI backbone), —CH₂—O—N(CH₃)—CH₂—, —CH₂—N(CH₃)—N(CH₃)—CH₂— and—O—N(CH₃)—CH₂—CH₂— (wherein the native phosphodiester internucleotidelinkage is represented as —O—P(═O)(OH)—O—CH₂—). MMI type internucleosidelinkages are disclosed in the above referenced U.S. Pat. No. 5,489,677.Suitable amide internucleoside linkages are disclosed in t U.S. Pat. No.5,602,240.

Also suitable are nucleic acids having morpholino backbone structures asdescribed in, e.g., U.S. Pat. No. 5,034,506. For example, in someembodiments, a subject nucleic acid comprises a 6-membered morpholinoring in place of a ribose ring. In some of these embodiments, aphosphorodiamidate or other non-phosphodiester internucleoside linkagereplaces a phosphodiester linkage.

Suitable modified polynucleotide backbones that do not include aphosphorus atom therein have backbones that are formed by short chainalkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkylor cycloalkyl internucleoside linkages, or one or more short chainheteroatomic or heterocyclic internucleoside linkages. These includethose having morpholino linkages (formed in part from the sugar portionof a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfonebackbones; formacetyl and thioformacetyl backbones; methylene formacetyland thioformacetyl backbones; riboacetyl backbones; alkene containingbackbones; sulfamate backbones; methyleneimino and methylenehydrazinobackbones; sulfonate and sulfonamide backbones; amide backbones; andothers having mixed N, O, S and CH₂ component parts.

Mimetics

A nucleic acid can be a nucleic acid mimetic. The term “mimetic” as itis applied to polynucleotides is intended to include polynucleotideswherein only the furanose ring or both the furanose ring and theinternucleotide linkage are replaced with non-furanose groups,replacement of only the furanose ring is also referred to in the art asbeing a sugar surrogate. The heterocyclic base moiety or a modifiedheterocyclic base moiety is maintained for hybridization with anappropriate target nucleic acid. One such nucleic acid, a polynucleotidemimetic that has been shown to have excellent hybridization properties,is referred to as a peptide nucleic acid (PNA). In PNA, thesugar-backbone of a polynucleotide is replaced with an amide containingbackbone, in particular an aminoethylglycine backbone. The nucleotidesare retained and are bound directly or indirectly to aza nitrogen atomsof the amide portion of the backbone.

One polynucleotide mimetic that has been reported to have excellenthybridization properties is a peptide nucleic acid (PNA). The backbonein PNA compounds is two or more linked aminoethylglycine units whichgives PNA an amide containing backbone. The heterocyclic base moietiesare bound directly or indirectly to aza nitrogen atoms of the amideportion of the backbone. Representative U.S. patents that describe thepreparation of PNA compounds include, but are not limited to: U.S. Pat.Nos. 5,539,082; 5,714,331; and 5,719,262.

Another class of polynucleotide mimetic that has been studied is basedon linked morpholino units (morpholino nucleic acid) having heterocyclicbases attached to the morpholino ring. A number of linking groups havebeen reported that link the morpholino monomeric units in a morpholinonucleic acid. One class of linking groups has been selected to give anon-ionic oligomeric compound. The non-ionic morpholino-based oligomericcompounds are less likely to have undesired interactions with cellularproteins. Morpholino-based polynucleotides are non-ionic mimics ofoligonucleotides which are less likely to form undesired interactionswith cellular proteins (Dwaine A. Braasch and David R. Corey,Biochemistry, 2002, 41(14), 4503-4510). Morpholino-based polynucleotidesare disclosed in U.S. Pat. No. 5,034,506. A variety of compounds withinthe morpholino class of polynucleotides have been prepared, having avariety of different linking groups joining the monomeric subunits.

A further class of polynucleotide mimetic is referred to as cyclohexenylnucleic acids (CeNA). The furanose ring normally present in a DNA/RNAmolecule is replaced with a cyclohexenyl ring. CeNA DMT protectedphosphoramidite monomers have been prepared and used for oligomericcompound synthesis following classical phosphoramidite chemistry. Fullymodified CeNA oligomeric compounds and oligonucleotides having specificpositions modified with CeNA have been prepared and studied (see Wang etal., J. Am. Chem. Soc., 2000, 122, 8595-8602). In general theincorporation of CeNA monomers into a DNA chain increases its stabilityof a DNA/RNA hybrid. CeNA oligoadenylates formed complexes with RNA andDNA complements with similar stability to the native complexes. Thestudy of incorporating CeNA structures into natural nucleic acidstructures was shown by NMR and circular dichroism to proceed with easyconformational adaptation.

A further modification includes Locked Nucleic Acids (LNAs) in which the2′-hydroxyl group is linked to the 4′ carbon atom of the sugar ringthereby forming a 2′-C,4′-C-oxymethylene linkage thereby forming abicyclic sugar moiety. The linkage can be a methylene (—CH₂—), groupbridging the 2′ oxygen atom and the 4′ carbon atom wherein n is 1 or 2(Singh et al., Chem. Commun., 1998, 4, 455-456). LNA and LNA analogsdisplay very high duplex thermal stabilities with complementary DNA andRNA (Tm=+3 to +10° C.), stability towards 3′-exonucleolytic degradationand good solubility properties. Potent and nontoxic antisenseoligonucleotides containing LNAs have been described (e.g., Wahlestedtet al., Proc. Natl. Acad. Sci. U.S.A., 2000, 97, 5633-5638).

The synthesis and preparation of the LNA monomers adenine, cytosine,guanine, 5-methylcytosine, thymine and uracil, along with theiroligomerization, and nucleic acid recognition properties have beendescribed (e.g., Koshkin et al., Tetrahedron, 1998, 54, 3607-3630). LNAsand preparation thereof are also described in WO 98/39352 and WO99/14226, as well as U.S. applications 20120165514, 20100216983,20090041809, 20060117410, 20040014959, 20020094555, and 20020086998.

Modified Sugar Moieties

A nucleic acid can also include one or more substituted sugar moieties.Suitable polynucleotides comprise a sugar substituent group selectedfrom: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- orN-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynylmay be substituted or unsubstituted C₁ to C₁₀ alkyl or C₂ to C₁₀ alkenyland alkynyl. Particularly suitable are O((CH₂)_(n)O)_(m)CH₃,O(CH₂)_(n)OCH₃, O(CH₂)_(n)NH₂, O(CH₂)_(n)CH₃, O(CH₂)_(n)ONH₂, andO(CH₂)_(n)ON((CH₂)_(n)CH₃)₂, where n and m are from 1 to about 10. Othersuitable polynucleotides comprise a sugar substituent group selectedfrom: C₁ to C₁₀ lower alkyl, substituted lower alkyl, alkenyl, alkynyl,alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH₃, OCN, Cl, Br, CN,CF₃, OCF₃, SOCH₃, SO₂CH₃, ONO₂, NO₂, N₃, NH₂, heterocycloalkyl,heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl,an RNA cleaving group, a reporter group, an intercalator, a group forimproving the pharmacokinetic properties of an oligonucleotide, or agroup for improving the pharmacodynamic properties of anoligonucleotide, and other substituents having similar properties. Asuitable modification includes 2′-methoxyethoxy (2′-O—CH₂CH₂OCH₃, alsoknown as 2′-O-(2-methoxyethyl) or 2′-MOE) (Martin et al., Helv. Chim.Acta, 1995, 78, 486-504) i.e., an alkoxyalkoxy group. A further suitablemodification includes 2′-dimethylaminooxyethoxy, i.e., a O(CH₂)₂ON(CH₃)₂group, also known as 2′-DMAOE, as described in examples herein below,and 2′-dimethylaminoethoxyethoxy (also known in the art as2′-O-dimethyl-amino-ethoxy-ethyl or 2′-DMAEOE), i.e.,2′-O—CH₂—O—CH₂—N(CH₃)₂.

Other suitable sugar substituent groups include methoxy (—O—CH₃),aminopropoxy (—OCH₂CH₂CH₂NH₂), allyl (—CH₂—CH═CH₂), —O-allyl(—O—CH₂—CH═CH₂) and fluoro (F). 2′-sugar substituent groups may be inthe arabino (up) position or ribo (down) position. A suitable 2′-arabinomodification is 2′-F. Similar modifications may also be made at otherpositions on the oligomeric compound, particularly the 3′ position ofthe sugar on the 3′ terminal nucleoside or in 2′-5′ linkedoligonucleotides and the 5′ position of 5′ terminal nucleotide.Oligomeric compounds may also have sugar mimetics such as cyclobutylmoieties in place of the pentofuranosyl sugar.

Base Modifications and Substitutions

A nucleic acid may also include nucleobase (often referred to in the artsimply as “base”) modifications or substitutions. As used herein,“unmodified” or “natural” nucleobases include the purine bases adenine(A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C)and uracil (U). Modified nucleobases include other synthetic and naturalnucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine,xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkylderivatives of adenine and guanine, 2-propyl and other alkyl derivativesof adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine,5-halouracil and cytosine, 5-propynyl (—C═C—CH₃) uracil and cytosine andother alkynyl derivatives of pyrimidine bases, 6-azo uracil, cytosineand thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino,8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines andguanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other5-substituted uracils and cytosines, 7-methylguanine and7-methyladenine, 2-F-adenine, 2-amino-adenine, 8-azaguanine and8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and3-deazaadenine. Further modified nucleobases include tricyclicpyrimidines such as phenoxazine cytidine(1H-pyrimido(5,4-b)(1,4)benzoxazin-2(3H)-one), phenothiazine cytidine(1H-pyrimido(5,4-b)(1,4)benzothiazin-2(3H)-one), G-clamps such as asubstituted phenoxazine cytidine (e.g.9-(2-aminoethoxy)-H-pyrimido(5,4-(b)(1,4)benzoxazin-2(3H)-one),carbazole cytidine (2H-pyrimido(4,5-b)indol-2-one), pyridoindolecytidine (H-pyrido(3′,2′:4,5)pyrrolo(2,3-d)pyrimidin-2-one).

Heterocyclic base moieties may also include those in which the purine orpyrimidine base is replaced with other heterocycles, for example7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine and 2-pyridone.Further nucleobases include those disclosed in U.S. Pat. No. 3,687,808,those disclosed in The Concise Encyclopedia Of Polymer Science AndEngineering, pages 858-859, Kroschwitz, J. I., ed. John Wiley & Sons,1990, those disclosed by Englisch et al., Angewandte Chemie,International Edition, 1991, 30, 613, and those disclosed by Sanghvi, Y.S., Chapter 15, Antisense Research and Applications, pages 289-302,Crooke, S. T. and Lebleu, B., ed., CRC Press, 1993. Certain of thesenucleobases are useful for increasing the binding affinity of anoligomeric compound. These include 5-substituted pyrimidines,6-azapyrimidines and N-2, N-6 and 0-6 substituted purines, including2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine.5-methylcytosine substitutions have been shown to increase nucleic acidduplex stability by 0.6-1.2° C. (Sanghvi et al., eds., AntisenseResearch and Applications, CRC Press, Boca Raton, 1993, pp. 276-278) andare suitable base substitutions, e.g., when combined with2′-O-methoxyethyl sugar modifications.

Error-Prone DNA Polymerases

A number of error-prone DNA polymerases are known in the art, and anyknown error-prone DNA polymerase is suitable for use in a fusionpolypeptide of the present disclosure. A suitable error-prone DNApolymerase possesses nick translating activity.

Suitable error-prone DNA polymerases include, but are not limited to,Taq polymerase, Thermus flavus DNA polymerase I, Thermus thermophilusHB-8 DNA polymerase I, Thermophilus ruber DNA polymerase I, Thermophilusbrokianus DNA polymerase I, Thermophilus caldophilus GK14 DNA polymeraseI, Thermophilus filoformis DNA polymerase I, Bacillus stearothermophilusDNA polymerase I, Bacillus caldotonex YT-G DNA polymerase I, andBacillus caldovelox YT-F DNA polymerase I. Suitable error-prone DNApolymerases include, but are not limited to, a Niastella koreensiserror-prone DNA polymerase, a Mucilaginibacter paludis error-prone DNApolymerase, a Methylobacterium extorquens error-prone DNA polymerase,and a Stenotrophomonas maltophilia error-prone DNA polymerase.

In some cases, a suitable error-prone DNA polymerase is Escherichia coliDNA polymerase I, with three fidelity-reducing mutations; thiserror-prone DNA polymerase is referred to as PolI3M. PolI3M comprisesD424A, I709N, and A759R substitutions relative to wild-type E. coli DNApolymerase I. In some cases, a suitable error-prone DNA polymerasecomprises an amino acid sequence having at least 85%, at least 90%, atleast 95%, at least 98%, at least 99%, or 100%, amino acid sequenceidentity to the DNA polymerase I amino acid sequence depicted in FIG. 8; where the DNA polymerase has an Ala at amino acid position 424, an Asnat amino acid position 709, and an Arg at amino acid position 759 of theamino acid sequence depicted in FIG. 8 , or a corresponding amino acidin another DNA polymerase.

In some cases, a suitable error-prone DNA polymerase is Escherichia coliDNA polymerase I, with five fidelity-reducing mutations: D242A, 1709N,A759R, F742Y, and P796H. In some cases, a suitable error-prone DNApolymerase comprises an amino acid sequence having at least 85%, atleast 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acidsequence identity to the DNA polymerase I amino acid sequence depictedin FIG. 8 ; where the DNA polymerase has an Ala at amino acid position242, an Asn at amino acid position 709, an Arg at amino acid position759, a Tyr at amino acid position 742, and a His at amino acid position796; or corresponding amino acids in another DNA polymerase.

In some cases, a suitable error-prone DNA polymerase comprises an aminoacid sequence having at least 85%, at least 90%, at least 95%, at least98%, or at least 99%, amino acid sequence identity to the DNA polymeraseI amino acid sequence depicted in FIG. 8 ; where the DNA polymerase hasan Ala at amino acid position 424, and an Asn at amino acid position709.

In some cases, a suitable error-prone DNA polymerase comprises an aminoacid sequence having at least 85%, at least 90%, at least 95%, at least98%, at least 99%, or 100%, amino acid sequence identity to the DNApolymerase I amino acid sequence depicted in FIG. 9 .

In some cases, a suitable error-prone DNA polymerase comprises an aminoacid sequence having at least 85%, at least 90%, at least 95%, at least98%, at least 99%, or 100%, amino acid sequence identity to the DNApolymerase I amino acid sequence depicted in FIG. 10 .

In some cases, a suitable error-prone DNA polymerase comprises an aminoacid sequence having at least 85%, at least 90%, at least 95%, at least98%, at least 99%, or 100%, amino acid sequence identity to the DNApolymerase I amino acid sequence depicted in FIG. 11 .

In some cases, a suitable error-prone DNA polymerase comprises an aminoacid sequence having at least 85%, at least 90%, at least 95%, at least98%, at least 99%, or 100%, amino acid sequence identity to the DNApolymerase iota amino acid sequence depicted in FIG. 13 .

In some cases, a suitable error-prone DNA polymerase comprises an aminoacid sequence having at least 85%, at least 90%, at least 95%, at least98%, at least 99%, or 100%, amino acid sequence identity to the DNApolymerase η amino acid sequence depicted in FIGS. 14A-14B.

In some cases, a suitable error-prone DNA polymerase comprises an aminoacid sequence having at least 85%, at least 90%, at least 95%, at least98%, at least 99%, or 100%, amino acid sequence identity to the DNApolymerase κ amino acid sequence depicted in FIGS. 15A-15B.

In some cases, a suitable error-prone DNA polymerase comprises an aminoacid sequence having at least 85%, at least 90%, at least 95%, at least98%, at least 99%, or 100%, amino acid sequence identity to the DNApolymerase θ amino acid sequence depicted in FIGS. 16A-16D.

In some cases, a suitable error-prone DNA polymerase comprises an aminoacid sequence having at least 85%, at least 90%, at least 95%, at least98%, at least 99%, or 100%, amino acid sequence identity to the DNApolymerase ν (nu) amino acid sequence depicted in FIGS. 17A-17B.

In some cases, a suitable error-prone DNA polymerase comprises an aminoacid sequence having at least 85%, at least 90%, at least 95%, at least98%, at least 99%, or 100%, amino acid sequence identity to the E. coliDNA polymerase IV amino acid sequence depicted in FIG. 18 .

In some cases, a suitable error-prone DNA polymerase comprises an aminoacid sequence having at least 85%, at least 90%, at least 95%, at least98%, at least 99%, or 100%, amino acid sequence identity to a DNApolymerase R having the following amino acid sequence:

(SEQ ID NO: 1163) MSKRKAPQETLNGGITDMLTELANFEKNVSQAIHKYNAYRKAASVIAKYPHKIKSGAEAKKLPGVGTKIAEKIDEFLATGKLRKLEKIRQDDTSSSINFLTRVSGIGPSAARKFVDEGIKTLEDLRKNEDKLNHHQRIGLKYFGDFEKRIPREEMLQMQDIVLNEVKKVDSEYIATVCGSFRRGAESSGDMDVLLTHPSFTSESTKQPKLLHQVVEQLQKVHFITDTLSKGETKFMGVCQLPSKNDEKEYPHRRIDIRLIPKDQYYCGVLYFTGSDIFNKNMRAHALEKGFTINEYTIRPLGVTGVAGEPLPVDSEKDIFDYIQWKYREPKDRSE.

In some cases, a suitable error-prone DNA polymerase comprises an aminoacid sequence having at least 85%, at least 90%, at least 95%, at least98%, at least 99%, or 100%, amino acid sequence identity to a DNApolymerase iota having the following amino acid sequence:

(SEQ ID NO: 1164) MEKLGVEPEEEGGGDDDEEDAEAWAMELADVGAAASSQGVHDQVLPTPNASSRVIVHVDLDCFYAQVEMISNPELKDKPLGVQQKYLVVTCNYEARKLGVKKLMNVRDAKEKCPQLVLVNGEDLTRYREMSYKVTELLEEFSPVVERLGFDENFVDLTEMVEKRLQQLQSDELSAVTVSGHVYNNQSINLLDVLHIRLLVGSQIAAEMREAMYNQLGLTGCAGVASNKLLAKLVSGVFKPNQQTVLLPESCQHLIHSLNHIKEIPGIGYKTAKCLEALGINSVRDLQTFSPKILEKELGISVAQRIQKLSFGEDNSPVILSGPPQSFSEEDSFKKCSSEVEAKNKIEELLASLLNRVCQDGRKPHTVRLIIRRYSSEKHYGRESRQCPIPSHVIQKLGTGNYDVMTPMVDILMKLFRNMVNVKMPFHLTLLSVCFCNLKALNTAKKGLIDYYLMPSLSTTSRSGKHSFKMKDTHMEDFPKDKETNRDFLPSGRIESTRTRESPLDTTNFSKEKDINEFPLCSLPEGVDQEVFKQLPVDIQEEILSGKSREKFQGKGSVSCPLHASRGVLSFFSKKQMQDIPINPRDHLSSSKQVSSVSPCEPGTSGFNSSSSSYMSSQKDYSYYLDNRLKDERISQGPKEPQGFHFTNSNPAVSAFHSFPNLQSEQLFSRNHTTDSHKQTVATDSHEGLTENREPDSVDEKITFPSDIDPQVFYELPEAVQKELLAEWKRAGSDFHIGHK.In some cases, such a DNA polymerase generates T→G substitutions.

In some cases, a suitable error-prone DNA polymerase comprises an aminoacid sequence having at least 85%, at least 90%, at least 95%, at least98%, at least 99%, or 100%, amino acid sequence identity to a DNApolymerase iota having the following amino acid sequence (amino acids1-445 of DNA polymerase iota):

(SEQ ID NO: 1165) MEKLGVEPEEEGGGDDDEEDAEAWAMELADVGAAASSQGVHDQVLPTPNASSRVIVHVDLDCFYAQVEMISNPELKDKPLGVQQKYLVVTCNYEARKLGVKKLMNVRDAKEKCPQLVLVNGEDLTRYREMSYKVTELLEEFSPVVERLGFDENFVDLTEMVEKRLQQLQSDELSAVTVSGHVYNNQSINLLDVLHIRLLVGSQIAAEMREAMYNQLGLTGCAGVASNKLLAKLVSGVFKPNQQTVLLPESCQHLIHSLNHIKEIPGIGYKTAKCLEALGINSVRDLQTFSPKILEKELGISVAQRIQKLSFGEDNSPVILSGPPQSFSEEDSFKKCSSEVEAKNKIEELLASLLNRVCQDGRKPHTVRLIIRRYSSEKHYGRESRQCPIPSHVIQKLGTGNYDVMTPMVDILMKLFRNMVNVKMPFHLTLLSVCFCNLKALNTAK;and having a length of 445 amino acids. In some cases, such a DNApolymerase generates T→G substitutions. In some cases, such a DNApolymerase has a T→G error rate approaching 1.

In some cases, a suitable error-prone DNA polymerase comprises an aminoacid sequence having at least 85%, at least 90%, at least 95%, at least98%, at least 99%, or 100%, amino acid sequence identity to a DNApolymerase iota having the following amino acid sequence (amino acids26-445 of DNA polymerase iota):

(SEQ ID NO: 1166) ELADVGAAASSQGVHDQVLPTPNASSRVIVHVDLDCFYAQVEMISNPELKDKPLGVQQKYLVVTCNYEARKLGVKKLMNVRDAKEKCPQLVLVNGEDLTRYREMSYKVTELLEEFSPVVERLGFDENFVDLTEMVEKRLQQLQSDELSAVTVSGHVYNNQSINLLDVLHIRLLVGSQIAAEMREAMYNQLGLTGCAGVASNKLLAKLVSGVFKPNQQTVLLPESCQHLIHSLNHIKEIPGIGYKTAKCLEALGINSVRDLQTFSPKILEKELGISVAQRIQKLSFGEDNSPVILSGPPQSFSEEDSFKKCSSEVEAKNKIEELLASLLNRVCQDGRKPHTVRLIIRRYSSEKHYGRESRQCPIPSHVIQKLGTGNYDVMTPMVDILMKLFRNMVNVKMPFHLTLLSVC FCNLKALNTAK;and having a length of 419 amino acids. In some cases, such a DNApolymerase generates T→G substitutions. In some cases, such a DNApolymerase has a T→G error rate approaching 1.

In some cases, a suitable error-prone DNA polymerase comprises an aminoacid sequence having at least 85%, at least 90%, at least 95%, at least98%, at least 99%, or 100%, amino acid sequence identity to a DNApolymerase nu (ν) having the following amino acid sequence:

(SEQ ID NO: 1167) ENYEALVGFDLCNTPLSSVAQKIMSAMHSGDLVDSKTWGKSTETMEVINKSSVKYSVQLEDRKTQSPEKKDLKSLRSQTSRGSAKLSPQSFSVRLTDQLSADQKQKSISSLTLSSCLIPQYNQEASVLQKKGHKRKHFLMENINNENKGSINLKRKHITYNNLSEKTSKQMALEEDTDDAEGYLNSGNSGALKKHFCDIRHLDDWAKSQLIEMLKQAAALVITVMYTDGSTQLGADQTPVSSVRGIVVLVKRQAEGGHGCPDAPACGPVLEGFVSDDPCIYIQIEHSAIWDQEQEAHQQFARNVLFQTMKCKCPVICFNAKDFVRIVLQFFGNDGSWKHVADFIGLDPRIAAWLIDPSDATPSFEDLVEKYCEKSITVKVNSTYGNSSRNIVNQNVRENLKTLYRLTMDLCSKLKDYGLWQLFRTLELPLIPILAVMESHAIQVNKEEMEKTSALLGARLKELEQEAHFVAGERFLITSNNQLREILFGKLKLHLLSQRNSLPRTGLQKYPSTSEAVLNALRDLHPLPKIILEYRQVHKIKSTFVDGLLACMKKGSISSTWNQTGTVTGRLSAKHPNIQGISKHPIQITTPKNFKGKEDKILTISPRAMFVSSKGHTFLAADFSQIELRILTHLSGDPELLKLFQESERDDVFSTLTSQWKDVPVEQVTHADREQTKKVVYAVVYGAGKERLAACLGVPIQEAAQFLESFLQKYKKIKDFARAAIAQCHQTGCVVSIMGRRRPLPRIHAHDQQLRAQAERQAVNFVVQGSAADLCKLAMIHVFTAVAASHTLTARLVAQIHDELLFEVEDPQIPECAALVRRTMESLEQVQALELQLQVPLKVSLSAGRSWGHLVPLQEAWGPPPGPCRTESPSNSLAAPGSPASTQPPPLHFSPSFCL.In some cases, such a DNA polymerase generates G→T substitutions.

In some cases, a suitable error-prone DNA polymerase comprises an aminoacid sequence having at least 85%, at least 90%, at least 95%, at least98%, at least 99%, or 100%, amino acid sequence identity to a DNApolymerase eta (q) having the following amino acid sequence:

(SEQ ID NO: 1168) MATGQDRVVALVDMDCFFVQVEQRQNPHLRNKPCAVVQYKSWKGGGIIAVSYEARAFGVTRSMWADDAKKLCPDLLLAQVRESRGKANLTKYREASVEVMEIMSRFAVIERASIDEAYVDLTSAVQERLQKLQGQPISADLLPSTYIEGLPQGPTTAEETVQKEGMRKQGLFQWLDSLQIDNLTSPDLQLTVGAVIVEEMRAAIERETGFQCSAGISHNKVLAKLACGLNKPNRQTLVSHGSVPQLFSQMPIRKIRSLGGKLGASVIEILGIEYMGELTQFTESQLQSHFGEKNGSWLYAMCRGIEHDPVKPRQLPKTIGCSKNFPGKTALATREQVQWWLLQLAQELEERLTKDRNDNDRVATQLVVSIRVQGDKRLSSLRRCCALTRYDAHKMSHDAFTVIKNCNTSGIQTEWSPPLTMLFLCATKFSASAPSSSTDITSFLSSDPSSLPKVPVTSSEAKTQGSGPAVTATKKATTSLESFFQKAAERQKVKEASLSSLTAPTQAPMSNSPSKPSLPFQTSQSTGTEPFFKQKSLLLKQKQLNNSSVSSPQQNPWSNCKALPNSLPTEYPGCVPVCEGVSKLEESSKATPAEMDLAHNSQSMHASSASKSVLEVTQKATPNPSLLAAEDQVPCEKCGSLVPVWDMPEHMDYHFALELQKSFLQPHSSNPQVVSAVSHQGKRNPKSPLACTNKRPRPEGMQTLESFFKPLTH.

In some cases, a suitable error-prone DNA polymerase comprises an aminoacid sequence having at least 85%, at least 90%, at least 95%, at least98%, at least 99%, or 100%, amino acid sequence identity to a DNApolymerase eta (q) having the following amino acid sequence:

(SEQ ID NO: 1169) MATGQDRVVALVDMDCFFVQVEQRQNPHLRNKPCAVVQYKSWKGGGIIAVSYEARAFGVTRSMWADDAKKLCPDLLLAQVRESRGKANLTKYREASVEVMEIMSRFAVIERASIDEAYVDLTSAVQERLQKLQGQPISADLLPSTYIEGLPQGPTTAEETVQKEGMRKQGLFQWLDSLQIDNLTSPDLQLTVGAVIVEEMRAAIERETGFQCSAGISHNKVLAKLACGLNKPNRQTLVSHGSVPQLFSQMPIRKIRSLGGKLGASVIEILGIEYMGELTQFTESQLQSHFGEKNGSWLYAMCRGIEHDPVKPRQLPKTIGCSKNFPGKTALATREQVQWWLLQLAQELEERLTKDRNDNDRVATQLVVSIRVQGDKRLSSLRRCCALTRYDAHKMSHDAFTVIKNCNTSGIQTEWSPPLTMLFLCATKFSASAPSSSTDITSFLSSDPSSLPKVPVTSSEAKTQGSGPAVTATKKATTSLESFFQKAAERQKVKEASLSSLTAPTQAPMS N;and has a length of 511 amino acids.

In some cases, a suitable error-prone DNA polymerase comprises an aminoacid sequence having at least 85%, at least 90%, at least 95%, at least98%, at least 99%, or 100%, amino acid sequence identity to a DNApolymerase kappa (κ) having the following amino acid sequence:

(SEQ ID NO: 1170) MDSTKEKCDSYKDDLLLRMGLNDNKAGMEGLDKEKINKIIMEATKGSRFYGNELKKEKQVNQRIENMMQQKAQITSQQLRKAQLQVDRFAMELEQSRNLSNTIVHIDMDAFYAAVEMRDNPELKDKPIAVGSMSMLSTSNYHARRFGVRAAMPGFIAKRLCPQLIIVPPNFDKYRAVSKEVKEILADYDPNFMAMSLDEAYLNITKHLEERQNWPEDKRRYFIKMGSSVENDNPGKEVNKLSEHERSISPLLFEESPSDVQPPGDPFQVNFEEQNNPQILQNSVVFGTSAQEVVKEIRFRIEQKTTLTASAGIAPNTMLAKVCSDKNKPNGQYQILPNRQAVMDFIKDLPIRKVSGIGKVTEKMLKALGIITCTELYQQRALLSLLFSETSWHYFLHISLGLGSTHLTRDGERKSMSVERTFSEINKAEEQYSLCQELCSELAQDLQKERLKGRTVTIKLKNVNFEVKTRASTVSSVVSTAEEIFAIAKELLKTEIDADFPHPLRLRLMGVRISSFPNEEDRKHQQRSIIGFLQAGNQALSATECTLEKTDKDKFVKPLEMSHKKSFFDKKRSERKWSHQDTFKCEAVNKQSFQTSQPFQVLKKKMNENLEISENSDDCQILTCPVCFRAQGCISLEALNKHVDECLDGPSISENFKMFSCSHVSATKVNKKENVPASSLCEKQDYEAHPKIKEISSVDCIALVDTIDNSSKAESIDALSNKHSKEECSSLPSKSFNIEHCHQNSSSTVSLENEDVGSFRQEYRQPYLCEVKTGQALVCPVCNVEQKTSDLTLFNVHVDVCLNKSFIQELRKDKFNPVNQPKESSRSTGSSSGVQKAVTRTKRPGLMTKYSTSKKIKPNNPKHTLDI FFK.

In some cases, a suitable error-prone DNA polymerase comprises an aminoacid sequence having at least 85%, at least 90%, at least 95%, at least98%, at least 99%, or 100%, amino acid sequence identity to a DNApolymerase kappa (κ) having the following amino acid sequence:

(SEQ ID NO: 1171) MDSTKEKCDSYKDDLLLRMGLNDNKAGMEGLDKEKINKIIMEATKGSRFYGNELKKEKQVNQRIENMMQQKAQITSQQLRKAQLQVDRFAMELEQSRNLSNTIVHIDMDAFYAAVEMRDNPELKDKPIAVGSMSMLSTSNYHARRFGVRAAMPGFIAKRLCPQLIIVPPNFDKYRAVSKEVKEILADYDPNFMAMSLDEAYLNITKHLEERQNWPEDKRRYFIKMGSSVENDNPGKEVNKLSEHERSISPLLFEESPSDVQPPGDPFQVNFEEQNNPQILQNSVVFGTSAQEVVKEIRFRIEQKTTLTASAGIAPNTMLAKVCSDKNKPNGQYQILPNRQAVMDFIKDLPIRKVSGIGKVTEKMLKALGIITCTELYQQRALLSLLFSETSWHYFLHISLGLGSTHLTRDGERKSMSVERTFSEINKAEEQYSLCQELCSELAQDLQKERLKGRTVTIKLKNVNFEVKTRASTVSSVVSTAEEIFAIAKELLKTEIDADFPHPLRLRLMGVRISSFPNEEDRKHQQRSIIGFLQAGNQALSATECTLEKTDKDKFVKPLE;and has a length of 560 amino acids.

Linkers

In some cases, a fusion polypeptide of the present disclosure comprisesa linker positioned between the DNA polymerase and the RNA-guidedendonuclease.

In some embodiments, a subject fusion polypeptide can be fused to afusion partner via a linker polypeptide (e.g., one or more linkerpolypeptides). The linker polypeptide may have any of a variety of aminoacid sequences. Proteins can be joined by a spacer peptide, generally ofa flexible nature, although other chemical linkages are not excluded.Suitable linkers include polypeptides of between 4 amino acids and 40amino acids in length, or between 4 amino acids and 25 amino acids inlength. These linkers can be produced by using synthetic,linker-encoding oligonucleotides to couple the proteins, or can beencoded by a nucleic acid sequence encoding the fusion protein. Peptidelinkers with a degree of flexibility can be used. The linking peptidesmay have virtually any amino acid sequence, bearing in mind that thepreferred linkers will have a sequence that results in a generallyflexible peptide. The use of small amino acids, such as glycine andalanine, are of use in creating a flexible peptide. The creation of suchsequences is routine to those of skill in the art. A variety ofdifferent linkers are commercially available and are considered suitablefor use.

Examples of linker polypeptides include glycine polymers (G)_(n),glycine-serine polymers (including, for example, (GS)_(n), (GSGGS)_(n)(SEQ ID NO:1154), (GGSGGS)_(n) (SEQ ID NO:1155), and (GGGS)_(n) (SEQ IDNO:1156), where n is an integer of at least one), glycine-alaninepolymers, alanine-serine polymers. Exemplary linkers can comprise aminoacid sequences including, but not limited to, GGSG (SEQ ID NO:1157),GGSGG (SEQ ID NO:1158), GSGSG (SEQ ID NO:1159), GSGGG (SEQ ID NO:1160),GGGSG (SEQ ID NO:1161), GSSSG (SEQ ID NO:1162), and the like. Theordinarily skilled artisan will recognize that design of a peptideconjugated to any desired element can include linkers that are all orpartially flexible, such that the linker can include a flexible linkeras well as one or more portions that confer less flexible structure.

Additional Polypeptides

A fusion polypeptide of the present disclosure can comprise one or moreadditional polypeptides. Suitable additional polypeptides include, butare not limited to, a nuclear localization signal (NLS); a DNA-bindingpolypeptide that increases the processivity of the DNA polymerase; a tagfor ease of tracking and/or purification (e.g., a fluorescent protein,e.g., green fluorescent protein (GFP), yellow fluorescent protein (YFP),red fluorescent protein (RFP), cyan fluorescent protein (CFP), mCherry,tdTomato, and the like; a histidine tag, e.g., a 6×His tag; ahemagglutinin (HA) tag; a FLAG tag; a Myc tag; a flap endonuclease; aDNA ligase; etc.

In some cases, e.g., in the context of a base editor, the additionalpolypeptide promotes or provides for efficient ligation of the nickgenerated by the RNA-guided endonuclease after the polymerase makes amis-incorporation. For example, in some cases, a fusion polypeptide ofthe present disclosure comprises a flap endonuclease and/or a DNAligase.

A suitable flap endonuclease comprises an amino acid sequence having atleast 85%, at least 90%, at least 95%, at least 98%, at least 99%, or100%, amino acid sequence identity to the FEN1 amino acid sequencedepicted in FIG. 20 .

A suitable DNA ligase comprises an amino acid sequence having at least85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100%,amino acid sequence identity to the T4 DNA ligase amino acid sequencedepicted in FIG. 21 .

In some cases, a fusion polypeptide of the present disclosure comprises,in order from N-terminus to C-terminus: a) an error-prone DNApolymerase; b) a flap endonuclease; and c) an enzymatically activeRNA-guided endonuclease that introduces a single-stranded break in atarget DNA. In some cases, a fusion polypeptide of the presentdisclosure comprises, in order from N-terminus to C-terminus: a) anerror-prone DNA polymerase; b) an enzymatically active RNA-guidedendonuclease that introduces a single-stranded break in a target DNA;and c) a DNA ligase.

Localization Signals

In some cases, a fusion polypeptide of the present disclosure comprisesone or more localization signal peptides. Suitable localization signals(“subcellular localization signals”) include, e.g., a nuclearlocalization signal (NLS) for targeting to the nucleus; a sequence tokeep the fusion protein out of the nucleus, e.g., a nuclear exportsequence (NES); a sequence to keep the fusion protein retained in thecytoplasm; a mitochondrial localization signal for targeting to themitochondria; a chloroplast localization signal for targeting to achloroplast; an endoplasmic reticulum (ER) retention signal; and ERexport signal; and the like. In some cases, a fusion polypeptide doesnot include a NLS so that the protein is not targeted to the nucleus(which can be advantageous, e.g., when the target nucleic acid is an RNAthat is present in the cytosol).

In some cases, a fusion polypeptide includes (is fused to) a nuclearlocalization signal (NLS) (e.g., in some cases 2 or more, 3 or more, 4or more, or 5 or more NLSs). Thus, in some cases, a fusion polypeptideincludes one or more NLSs (e.g., 2 or more, 3 or more, 4 or more, or 5or more NLSs). In some cases, one or more NLSs (2 or more, 3 or more, 4or more, or 5 or more NLSs) are positioned at or near (e.g., within 50amino acids of) the N-terminus and/or the C-terminus. In some cases, oneor more NLSs (2 or more, 3 or more, 4 or more, or 5 or more NLSs) arepositioned at or near (e.g., within 50 amino acids of) the N-terminus.In some cases, one or more NLSs (2 or more, 3 or more, 4 or more, or 5or more NLSs) are positioned at or near (e.g., within 50 amino acids of)the C-terminus. In some cases, one or more NLSs (3 or more, 4 or more,or 5 or more NLSs) are positioned at or near (e.g., within 50 aminoacids of) both the N-terminus and the C-terminus. In some cases, an NLSis positioned at the N-terminus and an NLS is positioned at theC-terminus.

In some cases, a fusion polypeptide includes (is fused to) between 1 and10 NLSs (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 2-10, 2-9, 2-8, 2-7, 2-6, or 2-5NLSs). In some cases, a fusion polypeptide includes (is fused to)between 2 and 5 NLSs (e.g., 2-4, or 2-3 NLSs).

Non-limiting examples of NLSs include an NLS sequence derived from: theNLS of the SV40 virus large T-antigen, having the amino acid sequencePKKKRKV (SEQ ID NO:1172); the NLS from nucleoplasmin (e.g., thenucleoplasmin bipartite NLS with the sequence KRPAATKKAGQAKKKK (SEQ IDNO:1173)); the c-myc NLS having the amino acid sequence PAAKRVKLD (SEQID NO:1174) or RQRRNELKRSP (SEQ ID NO:1175); the hRNPA1 M9 NLS havingthe sequence NQSSNFGPMKGGNFGGRSSGPYGGGGQYFAKPRNQGGY (SEQ ID NO:1176);the sequence RMRIZFKNKGKDTAELRRRRVEVSVELRKAKKDEQILKRRNV (SEQ ID NO:1177)of the IBB domain from importin-alpha; the sequences VSRKRPRP (SEQ IDNO:1178) and PPKKARED (SEQ ID NO:1179) of the myoma T protein; thesequence PQPKKKPL (SEQ ID NO:1180) of human p53; the sequenceSALIKKKKKMAP (SEQ ID NO:1181) of mouse c-abl IV; the sequences DRLRR(SEQ ID NO:1182) and PKQKKRK (SEQ ID NO:1183) of the influenza virusNS1; the sequence RKLKKKIKKL (SEQ ID NO:1184) of the Hepatitis virusdelta antigen; the sequence REKKKFLKRR (SEQ ID NO:1185) of the mouse Mx1protein; the sequence KRKGDEVDGVDEVAKKKSKK (SEQ ID NO:1186) of the humanpoly(ADP-ribose) polymerase; and the sequence RKCLQAGMNLEARKTKK (SEQ IDNO:1187) of the steroid hormone receptors (human) glucocorticoid. Insome cases, an NLS comprises the amino acid sequenceMDSLLMNRRKFLYQFKNVRWAKGRRETYLC (SEQ ID NO:1188). In general, NLS (ormultiple NLSs) are of sufficient strength to drive accumulation of thefusion polypeptide in a detectable amount in the nucleus of a eukaryoticcell. Detection of accumulation in the nucleus may be performed by anysuitable technique. For example, a detectable marker may be fused to thefusion polypeptide such that location within a cell may be visualized.Cell nuclei may also be isolated from cells, the contents of which maythen be analyzed by any suitable process for detecting protein, such asimmunohistochemistry, Western blot, or enzyme activity assay.Accumulation in the nucleus may also be determined indirectly.

In some cases, the NLS is located N-terminal of the RNA-guidedendonuclease present in a fusion polypeptide of the present disclosure.In some cases, the NLS is located between the DNA polymerase and theRNA-guided endonuclease present in a fusion polypeptide of the presentdisclosure. In some cases, the NLS is located N-terminal of the DNApolymerase present in a fusion polypeptide of the present disclosure. Insome cases, the NLS is located C-terminal of the DNA polymerase presentin a fusion polypeptide of the present disclosure.

In some cases, a fusion polypeptide includes a “Protein TransductionDomain” or PTD (also known as a CPP—cell penetrating peptide), whichrefers to a polypeptide, polynucleotide, carbohydrate, or organic orinorganic compound that facilitates traversing a lipid bilayer, micelle,cell membrane, organelle membrane, or vesicle membrane. A PTD attachedto another molecule, which can range from a small polar molecule to alarge macromolecule and/or a nanoparticle, facilitates the moleculetraversing a membrane, for example going from extracellular space tointracellular space, or cytosol to within an organelle. In someembodiments, a PTD is covalently linked to the amino terminus of apolypeptide. In some embodiments, a PTD is covalently linked to thecarboxyl terminus of a polypeptide. In some cases, the PTD is insertedinternally in the fusion polypeptide (i.e., is not at the N- orC-terminus of the fusion polypeptide) at a suitable insertion site. Insome cases, a subject fusion polypeptide includes (is conjugated to, isfused to) one or more PTDs (e.g., two or more, three or more, four ormore PTDs). In some cases, a PTD includes a nuclear localization signal(NLS) (e.g., in some cases 2 or more, 3 or more, 4 or more, or 5 or moreNLSs). Thus, in some cases, a fusion polypeptide includes one or moreNLSs (e.g., 2 or more, 3 or more, 4 or more, or 5 or more NLSs). In someembodiments, a PTD is covalently linked to a nucleic acid (e.g., a guidenucleic acid, a polynucleotide encoding a guide nucleic acid, apolynucleotide encoding a fusion polypeptide, a donor polynucleotide,etc.). Examples of PTDs include but are not limited to a minimalundecapeptide protein transduction domain (corresponding to residues47-57 of HIV-1 TAT comprising YGRKKRRQRRR; SEQ ID NO:1189); apolyarginine sequence comprising a number of arginines sufficient todirect entry into a cell (e.g., 3, 4, 5, 6, 7, 8, 9, 10, or 10-50arginines); a VP22 domain (Zender et al. (2002) Cancer Gene Ther.9(6):489-96); an Drosophila Antennapedia protein transduction domain(Noguchi et al. (2003) Diabetes 52(7):1732-1737); a truncated humancalcitonin peptide (Trehin et al. (2004) Pharm. Research 21:1248-1256);polylysine (Wender et al. (2000) Proc. Natl. Acad. Sci. USA97:13003-13008); RRQRRTSKLMKR (SEQ ID NO:1190); TransportanGWTLNSAGYLLGKINLKALAALAKKIL (SEQ ID NO:1191);KALAWEAKLAKALAKALAKHLAKALAKALKCEA (SEQ ID NO:1192); and RQIKIWFQNRRMKWKK(SEQ ID NO:1193). Exemplary PTDs include but are not limited to,YGRKKRRQRRR (SEQ ID NO:1189), RKKRRQRRR (SEQ ID NO:1194); an argininehomopolymer of from 3 arginine residues to 50 arginine residues;Exemplary PTD domain amino acid sequences include, but are not limitedto, any of the following: YGRKKRRQRRR (SEQ ID NO:1189); RKKRRQRR (SEQ IDNO:1195); YARAAARQARA (SEQ ID NO:1196); THRLPRRRRRR (SEQ ID NO:1197);and GGRRARRRRRR (SEQ ID NO:1198). In some embodiments, the PTD is anactivatable CPP (ACPP) (Aguilera et al. (2009) Integr Biol (Camb) June;1(5-6): 371-381). ACPPs comprise a polycationic CPP (e.g., Arg9 or “R9”)connected via a cleavable linker to a matching polyanion (e.g., Glu9 or“E9”), which reduces the net charge to nearly zero and thereby inhibitsadhesion and uptake into cells. Upon cleavage of the linker, thepolyanion is released, locally unmasking the polyarginine and itsinherent adhesiveness, thus “activating” the ACPP to traverse themembrane.

DNA-Binding Polypeptides that Increase the Processivity of the DNAPolymerase

In some cases, a fusion polypeptide of the present disclosure comprisesa DNA-binding polypeptide that increases the processivity of the DNApolymerase. Suitable DNA-binding polypeptides that increase theprocessivity of the DNA polymerase include, but are not limited to, anSso7d polypeptide, a helix-hairpin-helix domain of topoisomerase I, athioredoxin binding domain of a T7 DNA polymerase, or a thioredoxinbinding domain of a T3 polymerase.

Suitable Sso7d polypeptides comprise an amino acid sequence having atleast 30%, at least 35%, at least 40%, at least 45%, at least 50%, atleast 55%, at least 60%, at least 65%, at least 70%, at least 75%, atleast 80%, at least 85%, at least 90%, at least 95%, at least 90%, or100%, amino acid sequence identity to the Sso7d amino acid sequencedepicted in FIG. 12 .

Suitable thioredoxin binding domains comprise an amino acid sequencehaving at least 30%, at least 35%, at least 40%, at least 45%, at least50%, at least 55%, at least 60%, at least 65%, at least 70%, at least75%, at least 80%, at least 85%, at least 90%, at least 95%, at least90%, or 100%, amino acid sequence identity to the following amino acidsequence:

(SEQ ID NO: 1199) TETFGSWYQPKGGTEMFCHPRTGKPLPKYPRIKTPKVGGIFKKPKNKAQREGREPCELDTREYVAGAPYTPVEHV.

Systems

The present disclosure provides a system comprising: a) a fusionpolypeptide of the present disclosure; and b) a guide RNA thatcomprises: i) a protein-binding segment comprising a nucleotide sequencethat binds to the RNA-guided endonuclease; and ii) a target-bindingsegment comprising a nucleotide sequence that is complementary to atarget nucleotide sequence in a target nucleic acid. Fusion polypeptidesof the present disclosure are described above. Suitable guide RNAs aredescribed above. A system of the present disclosure (e.g., a systemcomprising: a) a fusion protein comprising: i) an enzymatically activeRNA-guided endonuclease that introduces a single-stranded break in atarget DNA; and ii) an error-prone DNA polymerase; and b) a guide RNA)is also referred to herein as “EvolvR.”

In some cases, the guide RNA is a single-molecule guide RNA. In somecases, the guide RNA is a dual-molecule guide RNA. In some cases, theguide RNA comprises one or more of: a) a modified base; b) a modifiedbackbone; c) a modified sugar moiety; and d) a non-naturalinternucleoside linkage. Such modifications are described above.

Nucleic Acids; Recombinant Expression Vectors

The present disclosure provides a nucleic acid comprising a nucleotidesequence encoding a fusion polypeptide of the present disclosure.

In some cases, a nucleic acid comprising a nucleotide sequence encodinga fusion polypeptide of the present disclosure is contained within anexpression vector. Thus, the present disclosure provides a recombinantexpression vector comprising a nucleic acid comprising a nucleotidesequence encoding a fusion polypeptide of the present disclosure. Insome cases, the nucleotide sequence encoding a fusion polypeptide of thepresent disclosure is operably linked to a transcriptional controlelement (e.g., a promoter; an enhancer; etc.). In some cases, thetranscriptional control element is inducible. In some cases, thetranscriptional control element is constitutive. In some cases, thepromoters are functional in eukaryotic cells. In some cases, thepromoters are cell type-specific promoters. In some cases, the promotersare tissue-specific promoters.

Depending on the host/vector system utilized, any of a number ofsuitable transcription and translation control elements, includingconstitutive and inducible promoters, transcription enhancer elements,transcription terminators, etc. may be used in the expression vector(see e.g., Bitter et al. (1987) Methods in Enzymology, 153:516-544).

A promoter can be a constitutively active promoter (i.e., a promoterthat is constitutively in an active/“ON” state), it may be an induciblepromoter (i.e., a promoter whose state, active/“ON” or inactive/“OFF”,is controlled by an external stimulus, e.g., the presence of aparticular temperature, compound, or protein), it may be a spatiallyrestricted promoter (i.e., transcriptional control element, enhancer,etc.)(e.g., tissue specific promoter, cell type specific promoter,etc.), and it may be a temporally restricted promoter (i.e., thepromoter is in the “ON” state or “OFF” state during specific stages ofembryonic development or during specific stages of a biologicalprocess).

Suitable promoter and enhancer elements are known in the art. Forexpression in a bacterial cell, suitable promoters include, but are notlimited to, lacI, lacZ, T3, T7, gpt, lambda P and trc. For expression ina eukaryotic cell, suitable promoters include, but are not limited to,light and/or heavy chain immunoglobulin gene promoter and enhancerelements; cytomegalovirus immediate early promoter; herpes simplex virusthymidine kinase promoter; early and late SV40 promoters; promoterpresent in long terminal repeats from a retrovirus; mousemetallothionein-I promoter; and various art-known tissue specificpromoters.

Suitable reversible promoters, including reversible inducible promotersare known in the art. Such reversible promoters may be isolated andderived from many organisms, e.g., eukaryotes and prokaryotes. Suchreversible promoters, and systems based on such reversible promoters butalso comprising additional control proteins, include, but are notlimited to, alcohol regulated promoters (e.g., alcohol dehydrogenase I(alcA) gene promoter, promoters responsive to alcohol transactivatorproteins (AlcR), etc.), tetracycline regulated promoters, (e.g.,promoter systems including TetActivators, TetON, TetOFF, etc.), steroidregulated promoters (e.g., rat glucocorticoid receptor promoter systems,human estrogen receptor promoter systems, retinoid promoter systems,thyroid promoter systems, ecdysone promoter systems, mifepristonepromoter systems, etc.), metal regulated promoters (e.g.,metallothionein promoter systems, etc.), pathogenesis-related regulatedpromoters (e.g., salicylic acid regulated promoters, ethylene regulatedpromoters, benzothiadiazole regulated promoters, etc.), temperatureregulated promoters (e.g., heat shock inducible promoters (e.g., HSP-70,HSP-90, soybean heat shock promoter, etc.), light regulated promoters,synthetic inducible promoters, and the like.

Inducible promoters suitable for use include any inducible promoterdescribed herein or known to one of ordinary skill in the art. Examplesof inducible promoters include, without limitation,chemically/biochemically-regulated and physically-regulated promoterssuch as alcohol-regulated promoters, tetracycline-regulated promoters(e.g., anhydrotetracycline (aTc)-responsive promoters and othertetracycline-responsive promoter systems, which include a tetracyclinerepressor protein (tetR), a tetracycline operator sequence (tetO) and atetracycline transactivator fusion protein (tTA)), steroid-regulatedpromoters (e.g., promoters based on the rat glucocorticoid receptor,human estrogen receptor, moth ecdysone receptors, and promoters from thesteroid/retinoid/thyroid receptor superfamily), metal-regulatedpromoters (e.g., promoters derived from metallothionein (proteins thatbind and sequester metal ions) genes from yeast, mouse and human),pathogenesis-regulated promoters (e.g., induced by salicylic acid,ethylene or benzothiadiazole (BTH)), temperature/heat-induciblepromoters (e.g., heat shock promoters), and light-regulated promoters(e.g., light responsive promoters from plant cells).

Examples of constitutive plant promoters include the cauliflower mosaicvirus (CaMV) 35S promoter, which confers constitutive, high-levelexpression in most plant tissues (see, e.g., Odell et al. (1985) Nature313: 810-812); the nopaline synthase promoter (An et al. (1988) PlantPhysiol. 88: 547-552); and the octopine synthase promoter (Fromm et al.(1989) Plant Cell 1: 977-984).

A variety of plant gene promoters that regulate gene expression inresponse to environmental, hormonal, chemical, developmental signals,and in a tissue-active manner can be used for expression of a nucleotidesequence (e.g., a nucleotide sequence encoding a fusion polypeptide ofthe present disclosure) in plants. The choice of a promoter can bedetermined by such factors as tissue (e.g., seed, fruit, root, pollen,vascular tissue, flower, carpel, etc.), inducibility (e.g., in responseto wounding, heat, cold, drought, light, pathogens, etc.), timing,developmental stage, and the like. Numerous known promoters have beencharacterized and can be employed to promote expression of apolynucleotide of the invention in a transgenic plant or cell ofinterest. For example, tissue specific promoters include: seed-specificpromoters (such as the napin, phaseolin or DC3 promoter described inU.S. Pat. No. 5,773,697), fruit-specific promoters that are activeduring fruit ripening (such as the dru 1 promoter (U.S. Pat. No.5,783,393), or the 2A11 promoter (U.S. Pat. No. 4,943,674) and thetomato polygalacturonase promoter (Bird et al. (1988) Plant Mol. Biol.11: 651-662), root-specific promoters, such as those disclosed in U.S.Pat. Nos. 5,618,988, 5,837,848 and 5,905,186, pollen-active promoterssuch as PTA29, PTA26 and PTA13 (U.S. Pat. No. 5,792,929), promotersactive in vascular tissue (Ringli and Keller (1998) Plant Mol. Biol. 37:977-988), flower-specific (Kaiser et al. (1995) Plant Mol. Biol. 28:231-243), pollen (Baerson et al. (1994) Plant Mol. Biol. 26: 1947-1959),carpels (Ohl et al. (1990) Plant Cell 2: 837-848), pollen and ovules(Baerson et al. (1993) Plant Mol. Biol. 22: 255-267), auxin-induciblepromoters (such as that described in van der Kop et al. (1999) PlantMol. Biol. 39: 979-990 or Baumann et al. (1999) Plant Cell 11: 323-334),cytokinin-inducible promoter (Guevara-Garcia (1998) Plant Mol. Biol. 38:743-753), promoters responsive to gibberellin (Shi et al. (1998) PlantMol. Biol. 38: 1053-1060, Willmott et al. (1998) 38: 817-825) and thelike. Additional promoters are those that elicit expression in responseto heat (Ainley et al. (1993) Plant Mol. Biol. 22: 13-23), light (e.g.,the pea rbcS-3A promoter, Kuhlemeier et al. (1989) Plant Cell 1:471-478, and the maize rbcS promoter, Schaffner and Sheen (1991) PlantCell 3: 997-1012); wounding (e.g., wunI, Siebertz et al. (1989) PlantCell 1: 961-968); pathogens (such as the PR-1 promoter described inBuchel et al. (1999) Plant Mol. Biol. 40: 387-396, and the PDF1.2promoter described in Manners et al. (1998) Plant Mol. Biol. 38:1071-1080), and chemicals such as methyl jasmonate or salicylic acid(Gatz (1997) Annu. Rev. Plant Physiol. Plant Mol. Biol. 48: 89-108). Inaddition, the timing of the expression can be controlled by usingpromoters such as those acting at senescence (Gan and Amasino (1995)Science 270: 1986-1988); or late seed development (Odell et al. (1994)Plant Physiol. 106: 447-458).

In some cases, a nucleic acid comprising a nucleotide sequence encodinga fusion polypeptide of the present disclosure is a recombinantexpression vector. In some embodiments, the recombinant expressionvector is a viral construct, e.g., a recombinant adeno-associated virus(AAV) construct, a recombinant adenoviral construct, a recombinantlentiviral construct, a recombinant retroviral construct, etc. In somecases, a nucleic acid comprising a nucleotide sequence encoding a fusionpolypeptide of the present disclosure is a recombinant lentivirusvector. In some cases, a nucleic acid comprising a nucleotide sequenceencoding a fusion polypeptide of the present disclosure is a recombinantAAV vector.

Suitable expression vectors include, but are not limited to, viralvectors (e.g. viral vectors based on vaccinia virus; poliovirus;adenovirus (see, e.g., Li et al., Invest Opthalmol Vis Sci 35:2543 2549,1994; Borras et al., Gene Ther 6:515 524, 1999; Li and Davidson, PNAS92:7700 7704, 1995; Sakamoto et al., Hum Gene Ther 5:1088 1097, 1999; WO94/12649, WO 93/03769; WO 93/19191; WO 94/28938; WO 95/11984 and WO95/00655); adeno-associated virus (see, e.g., Ali et al., Hum Gene Ther9:81 86, 1998, Flannery et al., PNAS 94:6916 6921, 1997; Bennett et al.,Invest Opthalmol Vis Sci 38:2857 2863, 1997; Jomary et al., Gene Ther4:683 690, 1997, Rolling et al., Hum Gene Ther 10:641 648, 1999; Ali etal., Hum Mol Genet 5:591 594, 1996; Srivastava in WO 93/09239, Samulskiet al., J. Vir. (1989) 63:3822-3828; Mendelson et al., Virol. (1988)166:154-165; and Flotte et al., PNAS (1993) 90:10613-10617); SV40;herpes simplex virus; human immunodeficiency virus (see, e.g., Miyoshiet al., PNAS 94:10319 23, 1997; Takahashi et al., J Virol 73:7812 7816,1999); a retroviral vector (e.g., Murine Leukemia Virus, spleen necrosisvirus, and vectors derived from retroviruses such as Rous Sarcoma Virus,Harvey Sarcoma Virus, avian leukosis virus, a lentivirus, humanimmunodeficiency virus, myeloproliferative sarcoma virus, and mammarytumor virus); and the like. In some cases, the vector is a lentivirusvector. Also suitable are transposon-mediated vectors, such as piggybackand sleeping beauty vectors.

A number of expression vectors suitable for stable transformation ofplant cells or for the establishment of transgenic plants have beendescribed including those described in Weissbach and Weissbach (1989)Methods for Plant Molecular Biology, Academic Press, and Gelvin et al.(1990) Plant Molecular Biology Manual, Kluwer Academic Publishers.Specific examples include those derived from a Ti plasmid ofAgrobacterium tumefaciens, as well as those disclosed byHerrera-Estrella et al. (1983) Nature 303: 209, Bevan (1984) NucleicAcids Res. 12: 8711-8721, Klee (1985) Bio/Technology 3: 637-642, fordicotyledonous plants.

Alternatively, non-Ti vectors can be used to transfer a nucleic acidinto monocotyledonous plants and cells by using free DNA deliverytechniques. Such methods can involve, for example, the use of liposomes,electroporation, microprojectile bombardment, silicon carbide whiskers,and viruses. By using these methods transgenic plants such as wheat,rice (Christou (1991) Bio/Technology 9: 957-962) and corn (Gordon-Kamm(1990) Plant Cell 2: 603-618) can be produced. An immature embryo canalso be a good target tissue for monocots for direct DNA deliverytechniques by using the particle gun (Weeks et al. (1993) Plant Physiol.102: 1077-1084; Vasil (1993) Bio/Technology 10: 667-674; Wan and Lemeaux(1994) Plant Physiol. 104: 37-48, and for Agrobacterium-mediated DNAtransfer (Ishida et al. (1996) Nature Biotechnol. 14: 745-750).

Cells

The present disclosure provides a cell comprising a fusion polypeptideof the present disclosure. The present disclosure provides a cellcomprising a system of the present disclosure. The present disclosureprovides a cell comprising a nucleic acid (e.g., a recombinantexpression vector) of the present disclosure.

Suitable host cells include, e.g. a bacterial cell; an archaeal cell; acell of a single-cell eukaryotic organism; a plant cell; an algal cell,e.g., Botryococcus braunii, Chlamydomonas reinhardtii, Nannochloropsisgaditana, Chlorella pyrenoidosa, Sargassum patens, C. agardh, and thelike; a fungal cell (e.g., a yeast cell); an animal cell; a cell from aninvertebrate animal (e.g. fruit fly, cnidarian, echinoderm, nematode,etc.); a cell from a vertebrate animal (e.g., fish, amphibian, reptile,bird, mammal); a cell from a mammal (e.g., a cell from a rodent, a cellfrom a human, etc.); and the like.

A suitable host cell can be a stem cell (e.g. an embryonic stem (ES)cell, an induced pluripotent stem (iPS) cell); a germ cell; a somaticcell, e.g. a fibroblast, a hematopoietic cell, a neuron, a muscle cell,a bone cell, a hepatocyte, a pancreatic cell; an in vitro or in vivoembryonic cell of an embryo at any stage, e.g., a 1-cell, 2-cell,4-cell, 8-cell, etc. stage zebrafish embryo; etc.). Cells may be fromestablished cell lines or they may be primary cells, where “primarycells”, “primary cell lines”, and “primary cultures” are usedinterchangeably herein to refer to cells and cells cultures that havebeen derived from a subject and allowed to grow in vitro for a limitednumber of passages of the culture. For example, primary cultures includecultures that may have been passaged 0 times, 1 time, 2 times, 4 times,5 times, 10 times, or 15 times, but not enough times go through thecrisis stage. Primary cell lines can be maintained for fewer than 10passages in vitro. Host cells are in some cases unicellular organisms,or are grown in culture.

If the cells are primary cells, they may be harvest from an organism(e.g., an individual) by any convenient method. For example, leukocytesmay be conveniently harvested by apheresis, leukocytapheresis, densitygradient separation, etc., while cells from tissues such as skin,muscle, bone marrow, spleen, liver, pancreas, lung, intestine, stomach,etc. are most conveniently harvested by biopsy. An appropriate solutionmay be used for dispersion or suspension of the harvested cells. Suchsolution will generally be a balanced salt solution, e.g. normal saline,phosphate-buffered saline (PBS), Hank's balanced salt solution, etc.,conveniently supplemented with fetal calf serum or other naturallyoccurring factors, in conjunction with an acceptable buffer at lowconcentration, e.g., from 5-25 mM. Convenient buffers include HEPES,phosphate buffers, lactate buffers, etc. The cells may be usedimmediately, or they may be stored, frozen, for long periods of time,being thawed and capable of being reused. In such cases, the cells canbe frozen in 10% dimethyl sulfoxide (DMSO), 50% serum, 40% bufferedmedium, or some other such solution as is commonly used in the art topreserve cells at such freezing temperatures, and thawed in a manner ascommonly known in the art for thawing frozen cultured cells.

In some cases, a subject genetically modified host cell is in vitro. Insome embodiments, a subject genetically modified host cell is in vivo.In some embodiments, a subject genetically modified host cell is aprokaryotic cell or is derived from a prokaryotic cell. In someembodiments, a subject genetically modified host cell is a bacterialcell or is derived from a bacterial cell. In some cases, a subjectgenetically modified host cell is an archaeal cell or is derived from anarchaeal cell. In some embodiments, a subject genetically modified hostcell is a eukaryotic cell or is derived from a eukaryotic cell. In somecases, a subject genetically modified host cell is a plant cell or isderived from a plant cell. In some cases, a subject genetically modifiedhost cell is an animal cell or is derived from an animal cell. In someembodiments, a subject genetically modified host cell is an invertebratecell or is derived from an invertebrate cell. In some cases, a subjectgenetically modified host cell is a vertebrate cell or is derived from avertebrate cell. In some cases, a subject genetically modified host cellis a mammalian cell or is derived from a mammalian cell. In some cases,a subject genetically modified host cell is a rodent cell or is derivedfrom a rodent cell. In cases embodiments, a subject genetically modifiedhost cell is a human cell or is derived from a human cell.

The present disclosure provides a genetically modified plant cell, wherethe genetically modified plant cell is genetically modified with anucleic acid (e.g., a recombinant expression vector) comprising anucleotide sequence encoding a fusion polypeptide of the presentdisclosure. In some cases, the plant cell is a cell of a monocot (amonocotyledon). In some cases, the plant cell is a cell of a dicot (adicotyledon). A plant cell can be a cell of the xylem, the phloem, thecambium layer, a leaf, a root, etc.

Suitable plants include, e.g., soybean, wheat, corn, potato, cotton,rice, oilseed rape, sunflower, alfalfa, clover, sugarcane, turf, banana,blackberry, blueberry, strawberry, raspberry, cantaloupe, carrot,cauliflower, coffee, cucumber, eggplant, grapes, honeydew, lettuce,mango, melon, onion, papaya, peas, peppers, pineapple, pumpkin, spinach,squash, sweet corn, tobacco, tomato, watermelon, mint and otherlabiates, rosaceous fruits, and vegetable brassicas.

Plant protoplasts are also suitable for some applications. For example,a nucleic acid is introduced into plant tissues, cultured plant cells orplant protoplasts by standard methods including electroporation (Frommet al. (1985) Proc. Natl. Acad. Sci. 82: 5824-5828), infection by viralvectors such as cauliflower mosaic virus (CaMV) (Hohn et al. (1982)Molecular Biology of Plant Tumors Academic Press, New York, N.Y., pp.549-560; U.S. Pat. No. 4,407,956), high velocity ballistic penetrationby small particles with the nucleic acid either within the matrix ofsmall beads or particles, or on the surface (Klein et al. (1987) Nature327: 70-73), use of pollen as vector (WO 85/01856), or use ofAgrobacterium tumefaciens or A. rhizogenes carrying a T-DNA plasmid inwhich a nucleic acid encoding a fusion polypeptide of the presentdisclosure is cloned. The T-DNA plasmid is transmitted to plant cellsupon infection by Agrobacterium tumefaciens, and a portion is stablyintegrated into the plant genome (Horsch et al. (1984) Science 233:496-498; Fraley et al. (1983) Proc. Natl. Acad. Sci. 80: 4803-4807).

The present disclosure further provides progeny of a subject geneticallymodified cell, where the progeny can comprise the same exogenous nucleicacid or polypeptide as the subject genetically modified cell from whichit was derived. The present disclosure further provides a compositioncomprising a subject genetically modified host cell.

Methods

A fusion polypeptide of the present disclosure is useful for introducingmutations into a target region of a target nucleic acid; i.e., in somecases, a fusion polypeptide of the present disclosure functions as amutator. Thus, the present disclosure provides methods of introducingmutations into a target region of a target nucleic acid. A fusionpolypeptide of the present disclosure is useful for correcting amutation in a target nucleic acid; i.e., in some cases, a fusionpolypeptide of the present disclosure functions as a base editor. Thus,the present disclosure provides methods correcting a mutation in atarget nucleic acid.

Method of Introducing Mutations into a Target Region of a Target NucleicAcid

The present disclosure provides a method of mutagenizing a targetnucleic, e.g., introducing mutations into a target nucleic acid. Themethod comprises contacting the target nucleic acid with a system of thepresent disclosure (e.g., EvolvR); i.e., the method comprises contactingthe target nucleic acid with a complex comprising: a) a fusionpolypeptide of the present disclosure; and b) a guide RNA. In somecases, the target nucleic acid is present in a cell; and the methodcomprises introducing a system of the present disclosure into the cell.In some cases, the cell is a prokaryotic cell. In some cases, the cellis a eukaryotic cell. In some cases, the cell is a plant cell. In somecases, the plant cell is a cell of a dicotyledonous plant. In somecases, the plant cell is a cell of a monocotyledonous plant. In somecases, the cell is in vitro. In some cases, the cell is in vivo.

A method of the present disclosure finds use in a variety ofapplications. Non-limiting examples of applications involving use of anEvolvR system of the present disclosure include: a) diversifyingantibody-encoding genes; b) diversifying protein-coding nucleotidesequences; c) diversifying regulatory elements; d) optimizing antibodyaffinity; e) diversifying T cells; f) engineering T-cell activity; g)discovering disease-causing genotypes; h) engineering desirable traitsinto plants.

In some cases, contacting a target nucleic acid with a complexcomprising: a) a fusion polypeptide of the present disclosure; and b) aguide RNA results in introduction of from 1 mutation to 10³ mutationswithin a target region of a target nucleic acid. For example, in somecases, contacting a target nucleic acid with a complex comprising: a) afusion polypeptide of the present disclosure; and b) a guide RNA resultsin introduction of from 1 mutation to 5 mutations, from 5 mutations to10 mutations, from 10 mutations to 50 mutations, from 50 mutations to10² mutations, from 10² mutations to 5×10² mutations, or from to 5×10²mutations to 10³ mutations within a target region of a target nucleicacid. As noted above, in some cases, the target region of a targetnucleic acid is from 1 nucleotide (nt) to 10 nucleotides (nt), from 10nt to 50 nt, from 50 nt to 100 nt, from 100 nt to 500 nt, from 500 nt to103 nt, from 103 nt to 5×10³ nt, or from 5×10³ nt to 10⁴ nt from a nickin a target DNA introduced by the RNA-guided endonuclease.

Introducing mutations into a target region of a target nucleic acidprovides for generation of a plurality of mutants, which can then beselected for a particular desired trait. Alternatively, an undesirabletrait can be selected against. A desired trait can be selected forsimultaneously with selecting against an undesired trait.

In some cases, a method of the present disclosure comprises: a)mutagenizing a target nucleic acid, generating a plurality of mutatednucleic acids; and b) applying a selection to the mutated nucleic acids.Applying a selection to the mutated nucleic acids can comprise: i)selecting a mutated nucleic acid(s) that confers a desirable trait(phenotype) on a genetically modified host cell comprising the mutatednucleic acid; or ii) selecting a mutated nucleic acid(s) that confers adesirable trait (phenotype) on a transgenic non-human organism that isgenetically modified to comprise the mutated nucleic acid. Selectionmethods are well known in the art, and any known method can be applied.

For example, in some cases, a mutated nucleic acid may confer increaseddrought resistance to a plant; and the mutated nucleic acid isidentified by subjecting a plurality of plants (or a plurality of plantseeds), each of which is genetically modified with a single member ofthe plurality of mutated nucleic acids, to drought conditions, andselecting plants that exhibit increased resistance to the droughtconditions. Drought assays can be applied to identify a mutated nucleicacid that confers better plant survival after short-term, severe waterdeprivation. Ion leakage can be measured in the context of a droughtassay.

As another example, in some cases, a mutated nucleic acid may conferincreased resistance of a plant to a pathogen (e.g., a fungus; aninsect; etc.); and the mutated nucleic acid is identified by subjectinga plurality of plants (or a plurality of plant seeds), each of which isgenetically modified with a single member of the plurality of mutatednucleic acids, to the pathogen, and selecting plants that exhibitincreased resistance to the pathogen.

As another example, in some cases, a mutated nucleic acid may conferincreased resistance of a plant to salt stress (e.g., high saltconditions; e.g., high NaCl concentrations); and the mutated nucleicacid is identified by subjecting a plurality of plants (or a pluralityof plant seeds), each of which is genetically modified with a singlemember of the plurality of mutated nucleic acids, to high saltconditions, and selecting plants that exhibit increased resistance tothe high salt conditions. Plants differ in their tolerance to NaCldepending on their stage of development; therefore seed germination,seedling vigor, and plant growth responses can be evaluated to determineresistance to high salt conditions.

As another example, in some cases, a mutated nucleic acid may conferincreased resistance of a plant to freezing; and the mutated nucleicacid is identified by subjecting a plurality of plants (or a pluralityof plant seeds), each of which is genetically modified with a singlemember of the plurality of mutated nucleic acids, to low temperature(e.g., freezing) conditions, and selecting plants that exhibit increasedresistance to the low temperature conditions.

As another example, in some cases, a mutated nucleic acid may conferincreased ability to germinate under high temperature conditions; andthe mutated nucleic acid is identified by subjecting a plurality ofplants (or a plurality of plant seeds), each of which is geneticallymodified with a single member of the plurality of mutated nucleic acids,to high temperature conditions, and selecting plants that exhibitincreased resistance to the high temperature conditions. Parameters thatcan be tested include seed germination, seedling vigor, and plantgrowth.

As another example, in some cases, a mutated nucleic acid may conferincreased resistance to hyperosmotic stress; and the mutated nucleicacid is identified by subjecting a plurality of plants (or a pluralityof plant seeds), each of which is genetically modified with a singlemember of the plurality of mutated nucleic acids, to hyperosmotic stressconditions, and selecting plants that exhibit increased resistance tothe hyperosmotic stress conditions. Plants that are resistant tohyperosmotic stress may be more tolerant to drought or freezing.

Sugar sensing assays can be conducted to identify mutated nucleic acidsthat provide for sugar sensing by germinating seeds on highconcentrations of sucrose and glucose and looking for degrees ofhypocotyl elongation. The germination assay on mannitol controls forresponses related to hyperosmotic stress. Sugars are key regulatorymolecules that affect diverse processes in higher plants includinggermination, growth, flowering, senescence, sugar metabolism andphotosynthesis. Sucrose is the major transport form of photosynthate andits flux through cells has been shown to affect gene expression andalter storage compound accumulation in seeds (source-sinkrelationships). Glucose-specific hexose-sensing has also been describedin plants and is implicated in cell division and repression of “famine”genes (photosynthetic or glyoxylate cycles).

Crop productivity is in part limited by its rate of CO₂ fixation by theRuBisCo enzyme. In some cases, all RuBisCo catalytic subunits aresimultaneously targeted within cyanobacteria using a system of thepresent disclosure; growing this microbe under high temperature and/orlow CO₂ conditions will enrich for RuBisco variants with improvedcatalytic efficiency and specificity.

Base Editor

In some cases, a system of the present disclosure (a fusion polypeptideof the present disclosure and a guide RNA) is a base editor system thatcomprises a non-processive DNA polymerase that is biased in whichmismatches it generates. Such as system provides for targeted basesubstitutions.

In some cases, a base editor system of the present disclosure providesfor generation of a G→T substitution. In some cases, a base editorsystem of the present disclosure provides for generation of a G→Csubstitution. In some cases, a base editor system of the presentdisclosure provides for generation of a C→A substitution. In some cases,a base editor system of the present disclosure provides for generationof a C→G substitution. In some cases, a base editor system of thepresent disclosure provides for generation of an A→T substitution. Insome cases, a base editor system of the present disclosure provides forgeneration of an A→G substitution. In some cases, a base editor systemof the present disclosure provides for generation of an A→Csubstitution. In some cases, a base editor system of the presentdisclosure provides for generation of a T→A substitution. In some cases,a base editor system of the present disclosure provides for generationof a T→G substitution. In some cases, a base editor system of thepresent disclosure provides for generation of a T→C substitution. Insome cases, a base editor system of the present disclosure provides forgeneration of a G→A substitution. In some cases, a base editor system ofthe present disclosure provides for generation of a C→T substitution.

A base-editor system of the present disclosure provides for generationof targeted substitutions that can reverse pathogenic single nucleotidepolymorphisms. A base-editor system of the present disclosure providesfor creation of crop plants with new alleles.

In some cases, the substitution rate is 1 mutation per nucleotide pergeneration.

A base editor system of the present disclosure comprises a DNApolymerase such as DNA polymerase beta, DNA polymerase iota, DNApolymerase nu, DNA polymerase eta, or DNA polymerase kappa. Variants ofthese polymerases that place the wrong nucleotide three times more oftenacross from the template base than the correct complementary base can beused.

In some cases, a fusion polypeptide of the present disclosure comprises:a) an enzymatically active RNA-guided endonuclease; and b) a DNApolymerase selected from a DNA polymerase-beta, a DNA polymerase-iota, aDNA polymerase nu, a DNA polymerase eta, and a DNA polymerase kappa.

In some cases, a DNA polymerase beta suitable for inclusion in a fusionpolypeptide of the present disclosure comprises an amino acid sequencehaving at least 85%, at least 90%, at least 95%, at least 98%, at least99%, or 100%, amino acid sequence identity to a DNA polymerase R havingthe following amino acid sequence:

(SEQ ID NO: 1163) MSKRKAPQETLNGGITDMLTELANFEKNVSQAIHKYNAYRKAASVIAKYPHKIKSGAEAKKLPGVGTKIAEKIDEFLATGKLRKLEKIRQDDTSSSINFLTRVSGIGPSAARKFVDEGIKTLEDLRKNEDKLNHHQRIGLKYFGDFEKRIPREEMLQMQDIVLNEVKKVDSEYIATVCGSFRRGAESSGDMDVLLTHPSFTSESTKQPKLLHQVVEQLQKVHFITDTLSKGETKFMGVCQLPSKNDEKEYPHRRIDIRLIPKDQYYCGVLYFTGSDIFNKNMRAHALEKGFTINEYTIRPLGVTGVAGEPLPVDSEKDIFDYIQWKYREPKDRSE.

In some cases, a DNA polymerase iota suitable for inclusion in a fusionpolypeptide of the present disclosure comprises an amino acid sequencehaving at least 85%, at least 90%, at least 95%, at least 98%, at least99%, or 100%, amino acid sequence identity to a DNA polymerase iotahaving the following amino acid sequence:

(SEQ ID NO: 1164) MEKLGVEPEEEGGGDDDEEDAEAWAMELADVGAAASSQGVHDQVLPTPNASSRVIVHVDLDCFYAQVEMISNPELKDKPLGVQQKYLVVTCNYEARKLGVKKLMNVRDAKEKCPQLVLVNGEDLTRYREMSYKVTELLEEFSPVVERLGFDENFVDLTEMVEKRLQQLQSDELSAVTVSGHVYNNQSINLLDVLHIRLLVGSQIAAEMREAMYNQLGLTGCAGVASNKLLAKLVSGVFKPNQQTVLLPESCQHLIHSLNHIKEIPGIGYKTAKCLEALGINSVRDLQTFSPKILEKELGISVAQRIQKLSFGEDNSPVILSGPPQSFSEEDSFKKCSSEVEAKNKIEELLASLLNRVCQDGRKPHTVRLIIRRYSSEKHYGRESRQCPIPSHVIQKLGTGNYDVMTPMVDILMKLFRNMVNVKMPFHLTLLSVCFCNLKALNTAKKGLIDYYLMPSLSTTSRSGKHSFKMKDTHMEDFPKDKETNRDFLPSGRIESTRTRESPLDTTNFSKEKDINEFPLCSLPEGVDQEVFKQLPVDIQEEILSGKSREKFQGKGSVSCPLHASRGVLSFFSKKQMQDIPINPRDHLSSSKQVSSVSPCEPGTSGFNSSSSSYMSSQKDYSYYLDNRLKDERISQGPKEPQGFHFTNSNPAVSAFHSFPNLQSEQLFSRNHTTDSHKQTVATDSHEGLTENREPDSVDEKITFPSDIDPQVFYELPEAVQKELLAEWKRAGSDFHIGHK.In some cases, such a DNA polymerase generates T→G substitutions.

In some cases, a DNA polymerase iota suitable for inclusion in a fusionpolypeptide of the present disclosure comprises an amino acid sequencehaving at least 85%, at least 90%, at least 95%, at least 98%, at least99%, or 100%, amino acid sequence identity to a DNA polymerase iotahaving the following amino acid sequence (amino acids 1-445 of DNApolymerase iota):

(SEQ ID NO: 1165) MEKLGVEPEEEGGGDDDEEDAEAWAMELADVGAAASSQGVHDQVLPTPNASSRVIVHVDLDCFYAQVEMISNPELKDKPLGVQQKYLVVTCNYEARKLGVKKLMNVRDAKEKCPQLVLVNGEDLTRYREMSYKVTELLEEFSPVVERLGFDENFVDLTEMVEKRLQQLQSDELSAVTVSGHVYNNQSINLLDVLHIRLLVGSQIAAEMREAMYNQLGLTGCAGVASNKLLAKLVSGVFKPNQQTVLLPESCQHLIHSLNHIKEIPGIGYKTAKCLEALGINSVRDLQTFSPKILEKELGISVAQRIQKLSFGEDNSPVILSGPPQSFSEEDSFKKCSSEVEAKNKIEELLASLLNRVCQDGRKPHTVRLIIRRYSSEKHYGRESRQCPIPSHVIQKLGTGNYDVMTPMVDILMKLFRNMVNVKMPFHLTLLSVCFCNLKALNTAK;and having a length of 445 amino acids. In some cases, such a DNApolymerase generates T→G substitutions. In some cases, such a DNApolymerase has a T→G error rate approaching 1.

In some cases, a DNA polymerase iota suitable for inclusion in a fusionpolypeptide of the present disclosure comprises an amino acid sequencehaving at least 85%, at least 90%, at least 95%, at least 98%, at least99%, or 100%, amino acid sequence identity to a DNA polymerase iotahaving the following amino acid sequence (amino acids 26-445 of DNApolymerase iota):

(SEQ ID NO: 1166) ELADVGAAASSQGVHDQVLPTPNASSRVIVHVDLDCFYAQVEMISNPELKDKPLGVQQKYLVVTCNYEARKLGVKKLMNVRDAKEKCPQLVLVNGEDLTRYREMSYKVTELLEEFSPVVERLGFDENFVDLTEMVEKRLQQLQSDELSAVTVSGHVYNNQSINLLDVLHIRLLVGSQIAAEMREAMYNQLGLTGCAGVASNKLLAKLVSGVFKPNQQTVLLPESCQHLIHSLNHIKEIPGIGYKTAKCLEALGINSVRDLQTFSPKILEKELGISVAQRIQKLSFGEDNSPVILSGPPQSFSEEDSFKKCSSEVEAKNKIEELLASLLNRVCQDGRKPHTVRLIIRRYSSEKHYGRESRQCPIPSHVIQKLGTGNYDVMTPMVDILMKLFRNMVNVKMPFHLTLLSVC FCNLKALNTAK;and having a length of 419 amino acids. In some cases, such a DNApolymerase generates T→G substitutions. In some cases, such a DNApolymerase has a T→G error rate approaching 1.

In some cases, a DNA polymerase iota suitable for inclusion in a fusionpolypeptide of the present disclosure comprises an amino acid sequencehaving at least 85%, at least 90%, at least 95%, at least 98%, at least99%, or 100%, amino acid sequence identity to a DNA polymerase nu (ν)having the following amino acid sequence:

(SEQ ID NO: 1167) ENYEALVGFDLCNTPLSSVAQKIMSAMHSGDLVDSKTWGKSTETMEVINKSSVKYSVQLEDRKTQSPEKKDLKSLRSQTSRGSAKLSPQSFSVRLTDQLSADQKQKSISSLTLSSCLIPQYNQEASVLQKKGHKRKHFLMENINNENKGSINLKRKHITYNNLSEKTSKQMALEEDTDDAEGYLNSGNSGALKKHFCDIRHLDDWAKSQLIEMLKQAAALVITVMYTDGSTQLGADQTPVSSVRGIVVLVKRQAEGGHGCPDAPACGPVLEGFVSDDPCIYIQIEHSAIWDQEQEAHQQFARNVLFQTMKCKCPVICFNAKDFVRIVLQFFGNDGSWKHVADFIGLDPRIAAWLIDPSDATPSFEDLVEKYCEKSITVKVNSTYGNSSRNIVNQNVRENLKTLYRLTMDLCSKLKDYGLWQLFRTLELPLIPILAVMESHAIQVNKEEMEKTSALLGARLKELEQEAHFVAGERFLITSNNQLREILFGKLKLHLLSQRNSLPRTGLQKYPSTSEAVLNALRDLHPLPKIILEYRQVHKIKSTFVDGLLACMKKGSISSTWNQTGTVTGRLSAKHPNIQGISKHPIQITTPKNFKGKEDKILTISPRAMFVSSKGHTFLAADFSQIELRILTHLSGDPELLKLFQESERDDVFSTLTSQWKDVPVEQVTHADREQTKKVVYAVVYGAGKERLAACLGVPIQEAAQFLESFLQKYKKIKDFARAAIAQCHQTGCVVSIMGRRRPLPRIHAHDQQLRAQAERQAVNFVVQGSAADLCKLAMIHVFTAVAASHTLTARLVAQIHDELLFEVEDPQIPECAALVRRTMESLEQVQALELQLQVPLKVSLSAGRSWGHLVPLQEAWGPPPGPCRTESPSNSLAAPGSPASTQPPPLHFSPSFCL.In some cases, such a DNA polymerase generates G→T substitutions.

In some cases, a DNA polymerase eta suitable for inclusion in a fusionpolypeptide of the present disclosure comprises an amino acid sequencehaving at least 85%, at least 90%, at least 95%, at least 98%, at least99%, or 100%, amino acid sequence identity to a DNA polymerase eta (η)having the following amino acid sequence:

(SEQ ID NO: 1168) MATGQDRVVALVDMDCFFVQVEQRQNPHLRNKPCAVVQYKSWKGGGIIAVSYEARAFGVTRSMWADDAKKLCPDLLLAQVRESRGKANLTKYREASVEVMEIMSRFAVIERASIDEAYVDLTSAVQERLQKLQGQPISADLLPSTYIEGLPQGPTTAEETVQKEGMRKQGLFQWLDSLQIDNLTSPDLQLTVGAVIVEEMRAAIERETGFQCSAGISHNKVLAKLACGLNKPNRQTLVSHGSVPQLFSQMPIRKIRSLGGKLGASVIEILGIEYMGELTQFTESQLQSHFGEKNGSWLYAMCRGIEHDPVKPRQLPKTIGCSKNFPGKTALATREQVQWWLLQLAQELEERLTKDRNDNDRVATQLVVSIRVQGDKRLSSLRRCCALTRYDAHKMSHDAFTVIKNCNTSGIQTEWSPPLTMLFLCATKFSASAPSSSTDITSFLSSDPSSLPKVPVTSSEAKTQGSGPAVTATKKATTSLESFFQKAAERQKVKEASLSSLTAPTQAPMSNSPSKPSLPFQTSQSTGTEPFFKQKSLLLKQKQLNNSSVSSPQQNPWSNCKALPNSLPTEYPGCVPVCEGVSKLEESSKATPAEMDLAHNSQSMHASSASKSVLEVTQKATPNPSLLAAEDQVPCEKCGSLVPVWDMPEHMDYHFALELQKSFLQPHSSNPQVVSAVSHQGKRNPKSPLACTNKRPRPEGMQTLESFFKPLTH.

In some cases, a DNA polymerase eta suitable for inclusion in a fusionpolypeptide of the present disclosure comprises an amino acid sequencehaving at least 85%, at least 90%, at least 95%, at least 98%, at least99%, or 100%, amino acid sequence identity to a DNA polymerase eta (η)having the following amino acid sequence:

(SEQ ID NO: 1169) MATGQDRVVALVDMDCFFVQVEQRQNPHLRNKPCAVVQYKSWKGGGIIAVSYEARAFGVTRSMWADDAKKLCPDLLLAQVRESRGKANLTKYREASVEVMEIMSRFAVIERASIDEAYVDLTSAVQERLQKLQGQPISADLLPSTYIEGLPQGPTTAEETVQKEGMRKQGLFQWLDSLQIDNLTSPDLQLTVGAVIVEEMRAAIERETGFQCSAGISHNKVLAKLACGLNKPNRQTLVSHGSVPQLFSQMPIRKIRSLGGKLGASVIEILGIEYMGELTQFTESQLQSHFGEKNGSWLYAMCRGIEHDPVKPRQLPKTIGCSKNFPGKTALATREQVQWWLLQLAQELEERLTKDRNDNDRVATQLVVSIRVQGDKRLSSLRRCCALTRYDAHKMSHDAFTVIKNCNTSGIQTEWSPPLTMLFLCATKFSASAPSSSTDITSFLSSDPSSLPKVPVTSSEAKTQGSGPAVTATKKATTSLESFFQKAAERQKVKEASLSSLTAPTQAPMS N;and has a length of 511 amino acids.

In some cases, a DNA polymerase kappa suitable for inclusion in a fusionpolypeptide of the present disclosure comprises an amino acid sequencehaving at least 85%, at least 90%, at least 95%, at least 98%, at least99%, or 100%, amino acid sequence identity to a DNA polymerase kappa (κ)having the following amino acid sequence:

(SEQ ID NO: 1170) MDSTKEKCDSYKDDLLLRMGLNDNKAGMEGLDKEKINKIIMEATKGSRFYGNELKKEKQVNQRIENMMQQKAQITSQQLRKAQLQVDRFAMELEQSRNLSNTIVHIDMDAFYAAVEMRDNPELKDKPIAVGSMSMLSTSNYHARRFGVRAAMPGFIAKRLCPQLIIVPPNFDKYRAVSKEVKEILADYDPNFMAMSLDEAYLNITKHLEERQNWPEDKRRYFIKMGSSVENDNPGKEVNKLSEHERSISPLLFEESPSDVQPPGDPFQVNFEEQNNPQILQNSVVFGTSAQEVVKEIRFRIEQKTTLTASAGIAPNTMLAKVCSDKNKPNGQYQILPNRQAVMDFIKDLPIRKVSGIGKVTEKMLKALGIITCTELYQQRALLSLLFSETSWHYFLHISLGLGSTHLTRDGERKSMSVERTFSEINKAEEQYSLCQELCSELAQDLQKERLKGRTVTIKLKNVNFEVKTRASTVSSVVSTAEEIFAIAKELLKTEIDADFPHPLRLRLMGVRISSFPNEEDRKHQQRSIIGFLQAGNQALSATECTLEKTDKDKFVKPLEMSHKKSFFDKKRSERKWSHQDTFKCEAVNKQSFQTSQPFQVLKKKMNENLEISENSDDCQILTCPVCFRAQGCISLEALNKHVDECLDGPSISENFKMFSCSHVSATKVNKKENVPASSLCEKQDYEAHPKIKEISSVDCIALVDTIDNSSKAESIDALSNKHSKEECSSLPSKSFNIEHCHQNSSSTVSLENEDVGSFRQEYRQPYLCEVKTGQALVCPVCNVEQKTSDLTLFNVHVDVCLNKSFIQELRKDKFNPVNQPKESSRSTGSSSGVQKAVTRTKRPGLMTKYSTSKKIKPNNPKHTLDI FFK.

In some cases, a DNA polymerase kappa suitable for inclusion in a fusionpolypeptide of the present disclosure comprises an amino acid sequencehaving at least 85%, at least 90%, at least 95%, at least 98%, at least99%, or 100%, amino acid sequence identity to a DNA polymerase kappa (κ)having the following amino acid sequence:

(SEQ ID NO: 1171) MDSTKEKCDSYKDDLLLRMGLNDNKAGMEGLDKEKINKIIMEATKGSRFYGNELKKEKQVNQRIENMMQQKAQITSQQLRKAQLQVDRFAMELEQSRNLSNTIVHIDMDAFYAAVEMRDNPELKDKPIAVGSMSMLSTSNYHARRFGVRAAMPGFIAKRLCPQLIIVPPNFDKYRAVSKEVKEILADYDPNFMAMSLDEAYLNITKHLEERQNWPEDKRRYFIKMGSSVENDNPGKEVNKLSEHERSISPLLFEESPSDVQPPGDPFQVNFEEQNNPQILQNSVVFGTSAQEVVKEIRFRIEQKTTLTASAGIAPNTMLAKVCSDKNKPNGQYQILPNRQAVMDFIKDLPIRKVSGIGKVTEKMLKALGIITCTELYQQRALLSLLFSETSWHYFLHISLGLGSTHLTRDGERKSMSVERTFSEINKAEEQYSLCQELCSELAQDLQKERLKGRTVTIKLKNVNFEVKTRASTVSSVVSTAEEIFAIAKELLKTEIDADFPHPLRLRLMGVRISSFPNEEDRKHQQRSIIGFLQAGNQALSATECTLEKTDKDKFVKPLE;and has a length of 560 amino acids.

In some cases, a base editor system of the present disclosure comprises:a) a fusion polypeptide of the present disclosure (e.g., a fusionpolypeptide comprising: i) an enzymatically active RNA-guidedendonuclease; and ii) a DNA polymerase selected from a DNApolymerase-beta, a DNA polymerase-iota, a DNA polymerase nu, a DNApolymerase eta, and a DNA polymerase kappa); and b) a guide RNA thatcomprises a nucleotide sequence that comprises: i) a protein-bindingsegment comprising a nucleotide sequence that binds to the RNA-guidedendonuclease; and ii) a target-binding segment comprising a nucleotidesequence that is complementary to a target nucleotide sequence in atarget nucleic acid.

In some cases, a base editor system of the present disclosure comprises:a) a nucleic acid (e.g., a recombinant expression vector) comprising anucleotide sequence encoding a fusion polypeptide of the presentdisclosure (e.g., a fusion polypeptide comprising: i) an enzymaticallyactive RNA-guided endonuclease; and ii) a DNA polymerase selected from aDNA polymerase-beta, a DNA polymerase-iota, a DNA polymerase nu, a DNApolymerase eta, and a DNA polymerase kappa); and b) a guide RNA thatcomprises a nucleotide sequence that comprises: i) a protein-bindingsegment comprising a nucleotide sequence that binds to the RNA-guidedendonuclease; and ii) a target-binding segment comprising a nucleotidesequence that is complementary to a target nucleotide sequence in atarget nucleic acid.

A fusion polypeptide of the present disclosure is useful for correctinga mutation in a target nucleic acid; i.e., in some cases, a fusionpolypeptide of the present disclosure functions as a base editor. Thus,the present disclosure provides methods correcting a mutation in atarget nucleic acid.

In some cases, the target nucleic acid comprises a target nucleotidesequence associated with a disease or disorder. In some cases, thetarget nucleotide sequence comprises a point mutation associated with adisease or disorder. In some cases, a base editor system of the presentdisclosure introduces a single nucleotide mutation; i.e., changes asingle nucleotide in a target nucleotide sequence.

In some cases, the disease or disorder is cystic fibrosis;phenylketonuria; epidermolytic hyperkeratosis (EHK); Charcot-Marie-Tootdisease type 4J; neuroblastoma (NB); von Willebrand disease (vWD);myotonia congenital; hereditary renal amyloidosis; dilatedcardiomyopathy (DCM); hereditary lymphedema; familial Alzheimer'sdisease; Prion disease; chronic infantile neurologic cutaneousparticular syndrome (CINCA); desmin-related myopathy (DRM); or aneoplastic disease associated with a mutant PI3KCA protein, a mutantCTNNB1 protein, a mutant HRAS protein, or a mutant p53 protein.

A base editor system of the present disclosure is introduced into a cell(in vivo or in vitro), where the cell comprises a target nucleic acidcomprising a target nucleotide sequence having a single nucleotidemutation that gives rise to a disease or disorder. For example, aeukaryotic cell comprising a mutation to be corrected, e.g., a cellcarrying a point mutation, is contacted with a base editor system of thepresent disclosure. Suitable cells include mammalian cells, including,e.g., non-human primate cells, human cells, canine cells, feline cells,ungulate cells, etc. Suitable cells include plant cells. Suitable cellsinclude insect cells. Suitable cells include arachnid cells.

A base editor system of the present disclosure is capable of modifying aspecific nucleotide base without generating a significant proportion ofindels. An “indel”, as used herein, refers to the insertion or deletionof a nucleotide base within a nucleic acid. Such insertions or deletionscan lead to frame shift mutations within a coding region of a gene. Insome cases, it is desirable to generate base editors that efficientlysubstitute a specific nucleotide within a nucleic acid, withoutgenerating a large number of insertions or deletions (i.e., indels) inthe nucleic acid. In cases, a base editor system of the presentdisclosure is capable of generating a greater proportion of intendedmodifications (e.g., nucleotide substitutions) versus indels. In somecases, a base editor system of the present disclosure is capable ofgenerating a ratio of intended point mutations to indels that is greaterthan 1:1. In some cases, a base editor system of the present disclosureis capable of generating a ratio of intended point mutations to indelsthat is at least 1.5:1, at least 2:1, at least 2.5:1, at least 3:1, atleast 3.5:1, at least 4:1, at least 4.5:1, at least 5:1, at least 5.5:1,at least 6:1, at least 6.5:1, at least 7:1, at least 7.5:1, at least8:1, at least 10:1, at least 12:1, at least 15:1, at least 20:1, atleast 25:1, at least 30:1, at least 40:1, at least 50:1, at least 100:1,at least 200:1, at least 300:1, at least 400:1, at least 500:1, at least600:1, at least 700:1, at least 800:1, at least 900:1, or at least1000:1, or more than 1000:1.

Fusion Polypeptide Comprising a Modifying Enzyme, an RNA-Guided Nickase,and a DNA Polymerase

The present disclosure provides a fusion polypeptide comprising: a) anRNA-guided enzyme that exhibits nickase activity; b) a modifying enzyme(e.g., a DNA-modifying enzyme or a protein-modifying enzyme); and c) aDNA polymerase. The RNA-guided enzyme that exhibits nickase activity,together with a guide RNA, guides the fusion polypeptide to a targetnucleotide sequence in a target nucleic acid (e.g., a genome).

In some cases, a fusion polypeptide of the present disclosure (e.g., afusion polypeptide comprising: a) an RNA-guided enzyme that exhibitsnickase activity; b) a DNA- or protein-modifying enzyme; and c) a DNApolymerase) is a base editor. Thus, in some cases, a base editor of thepresent disclosure is a fusion polypeptide comprising: a) an RNA-guidedenzyme that exhibits nickase activity; b) a DNA- or protein-modifyingenzyme; and c) a DNA polymerase. In some cases, a base editor fusionpolypeptide of the present disclosure comprises, in order fromN-terminus to C-terminus: a) an RNA-guided enzyme that exhibits nickaseactivity; b) a DNA- or protein-modifying enzyme; and c) a DNApolymerase. In some cases, a base editor fusion polypeptide of thepresent disclosure comprises, in order from N-terminus to C-terminus: a)a DNA polymerase; b) an RNA-guided enzyme that exhibits nickaseactivity; and c) a DNA-modifying enzyme. In some cases, a base editorfusion polypeptide of the present disclosure comprises, in order fromN-terminus to C-terminus: a) a DNA- or protein-modifying enzyme; b) anRNA-guided enzyme that exhibits nickase activity; and c) a DNApolymerase. In these embodiments, the DNA polymerase can be ahigh-fidelity DNA polymerase, or a DNA polymerase that lacks substantialproofreading activity. In some cases, the DNA polymerase comprises aD424A substitution.

Suitable DNA- and protein-modifying enzymes are known in the art. Insome cases, the modifying enzyme is a nucleic acid-modifying enzyme.Examples of suitable nucleic acid-modifying enzymes include DNA editingenzymes; deaminases, such as activation induced deaminase and APOBECproteins; nucleases; recombinases; glycosylases; methyltransferases; andthe like. In other cases, the modifying enzyme is a protein-modifyingenzyme. For example, the modifying enzyme may be one that modifies aprotein associated with a nucleic acid. Examples of suitableprotein-modifying enzymes include histone-modifying enzymes, acetylases,kinases, methyltransferases, ubiquitin ligases, SUMO ligases,demethylases, deacetylases, phosphatases, and the like.

In some cases, a base editor fusion polypeptide of the presentdisclosure comprises, in order from N-terminus to C-terminus: a) adeaminase; b) a DNA polymerase; and c) an RNA-guided enzyme thatexhibits nickase activity. Suitable deaminases include a cytidinedeaminase and an adenosine deaminase. In some cases, a base editorfusion polypeptide of the present disclosure comprises, in order fromN-terminus to C-terminus: a) a cytidine deaminase; b) an RNA-guidedenzyme that exhibits nickase activity; and c) a DNA polymerase. In somecases, a base editor fusion polypeptide of the present disclosurecomprises, in order from N-terminus to C-terminus: a) an adeninedeaminase; b) an RNA-guided enzyme that exhibits nickase activity; andc) a DNA polymerase. In these embodiments, the DNA polymerase can be ahigh-fidelity DNA polymerase, or a DNA polymerase that lacks substantialproofreading activity. In some cases, the DNA polymerase comprises aD424A substitution. In some cases, the fusion polypeptide comprises alinker between the deaminase and the DNA polymerase, between thedeaminase and the gene-editing enzyme, or between the gene-editingenzyme and the DNA polymerase.

In some cases, a deaminase-containing base editor system of the presentdisclosure provides for generation of a G→T substitution. In some cases,a deaminase-containing base editor system of the present disclosureprovides for generation of a G→C substitution. In some cases, adeaminase-containing base editor system of the present disclosureprovides for generation of a C→A substitution. In some cases, adeaminase-containing base editor system of the present disclosureprovides for generation of a C→G substitution. In some cases, adeaminase-containing base editor system of the present disclosureprovides for generation of an A→T substitution. In some cases, adeaminase-containing base editor system of the present disclosureprovides for generation of an A→G substitution. In some cases, adeaminase-containing base editor system of the present disclosureprovides for generation of an A→C substitution. In some cases, adeaminase-containing base editor system of the present disclosureprovides for generation of a T→A substitution. In some cases, adeaminase-containing base editor system of the present disclosureprovides for generation of a T→G substitution. In some cases, adeaminase-containing base editor system of the present disclosureprovides for generation of a T→C substitution. In some cases, adeaminase-containing base editor system of the present disclosureprovides for generation of a G→A substitution. In some cases, adeaminase-containing base editor system of the present disclosureprovides for generation of a C→T substitution.

DNA Polymerase

A DNA- or protein-modifying enzyme-containing fusion polypeptide of thepresent disclosure (e.g., a deaminase-containing base editor of thepresent disclosure) comprises a DNA polymerase that is a high-fidelityDNA polymerase. In some cases, a DNA- or protein-modifyingenzyme-containing fusion polypeptide of the present disclosure comprisesa DNA polymerase lacks proof-reading activity. In some cases, a DNA- orprotein-modifying enzyme-containing fusion polypeptide of the presentdisclosure comprises a DNA polymerase comprises a D424A substitutionthat exhibits increase nick translation activity. In some cases, a DNA-or protein-modifying enzyme-containing fusion polypeptide of the presentdisclosure comprises a DNA polymerase is not an error-prone DNApolymerase.

Previous base-editors fused a DNA-editing enzyme to a programmablenuclease; such a fusion protein will chemically modify a targetnucleotide in such a way that DNA polymerases will incorporate acrossfrom the chemically modified nucleotide a nucleotide that is not thesame nucleotide type originally at this position. However, theseprevious base-editors rely on replication or repair machinery to performthis DNA polymerase-mediated new nucleotide insertion. A base editorfusion polypeptide of the present disclosure fuses a nick translatingDNA polymerase to a deaminase and an RNA-guided enzyme that providesnickase activity, such that the chemically altered nucleotide will beused as a template for the fused DNA polymerase-mediated nicktranslation. This removes the dependence on replication and repair toachieve base-editing.

In some cases, a deaminase-containing base editor of the presentdisclosure comprises a DNA polymerase lacks proof-reading activity. Insome cases, a deaminase-containing base editor of the present disclosurecomprises a DNA polymerase comprises a D424A substitution that exhibitsincrease nick translation activity. In some cases, adeaminase-containing base editor of the present disclosure comprises aDNA polymerase is not an error-prone DNA polymerase.

In some cases, DNA- or protein-modifying enzyme-containing fusionpolypeptide of the present disclosure (e.g., a deaminase-containing baseeditor of the present disclosure) comprises a DNA polymerase thatcomprises an amino acid sequence having at least 80%, at least 85%, atleast 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acidsequence identity to the following E. coli DNA polymerase I amino acidsequence:

(SEQ ID NO: 1246) VQIPQNPLILVDGSSYLYRAYHAFPPLTNSAGEPTGAMYGVLNMLRSLIMQYKPTHAAVVFDAKGKTFRDELFEHYKSHRPPMPDDLRAQIEPLHAMVKAMGLPLLAVSGVEADDVIGTLAREAEKAGRPVLISTGDKDMAQLVTPNITLINTMTNTILGPEEVVNKYGVPPELIIDFLALMGDSSDNIPGVPGVGEKTAQALLQGLGGLDTLYAEPEKIAGLSFRGAKTMAAKLEQNKEVAYLSYQLATIKTDVELELTCEQLEVQQPAAEELLGLFKKYEFKRWTADVEAGKWLQAKGAKPAAKPQETSVADEAPEVTATVISYDNYVTILDEETLKAWIAKLEKAPVFAFDTETDSLDNISANLVGLSFAIEPGVAAYIPVAHDYLDAPDQISRERALELLKPLLEDEKALKVGQNLKYDRGILANYGIELRGIAFDTMLESYILNSVAGRHDMDSLAERWLKHKTITFEEIAGKGKNQLTFNQIALEEAGRYAAEDADVTLQLHLKMWPDLQKHKGPLNVFENIEMPLVPVLSRIERNGVKIDPKVLHNHSEELTLRLAELEKKAHEIAGEEFNLSSTKQLQTILFEKQGIKPLKKTPGGAPSTSEEVLEELALDYPLPKVILEYRGLAKLKSTYTDKLPLMINPKTGRVHTSYHQAVTATGRLSSTDPNLQNIPVRNEEGRRIRQAFIAPEDYVIVSADYSQIELRIMAHLSRDKGLLTAFAEGKDIHRATAAEVFGLPLETVTSEQRRSAKAINFGLIYGMSAFGLARQLNIPRKEAQKYMDLYFERYPGVLEYMERTRAQAKEQGYVETLDGRRLYLPDIKSSNGARRAAAERAAINAPMQGTAADIIKRAMIAVDAWLQAEQPRVRMIMQVHDELVFEVHKDDVDAVAKQIHQLMENCTRLDVPLLVEVG SGENWDQAH.

In some cases, a DNA- or protein-modifying enzyme-containing fusionpolypeptide of the present disclosure (e.g., a deaminase-containing baseeditor of the present disclosure) comprises a DNA polymerase thatcomprises an amino acid sequence having at least 80%, at least 85%, atleast 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acidsequence identity to the following exonuclease-deficient E. coli DNApolymerase I amino acid sequence:

(SEQ ID NO: 1144) VQIPQNPLILVDGSSYLYRAYHAFPPLTNSAGEPTGAMYGVLNMLRSLIMQYKPTHAAVVFDAKGKTFRDELFEHYKSHRPPMPDDLRAQIEPLHAMVKAMGLPLLAVSGVEADDVIGTLAREAEKAGRPVLISTGDKDMAQLVTPNITLINTMTNTILGPEEVVNKYGVPPELIIDFLALMGDSSDNIPGVPGVGEKTAQALLQGLGGLDTLYAEPEKIAGLSFRGAKTMAAKLEQNKEVAYLSYQLATIKTDVELELTCEQLEVQQPAAEELLGLFKKYEFKRWTADVEAGKWLQAKGAKPAAKPQETSVADEAPEVTATVISYDNYVTILDEETLKAWIAKLEKAPVFAFDTETDSLDNISANLVGLSFAIEPGVAAYIPVAHDYLDAPDQISRERALELLKPLLEDEKALKVGQNLKYARGILANYGIELRGIAFDTMLESYILNSVAGRHDMDSLAERWLKHKTITFEEIAGKGKNQLTFNQIALEEAGRYAAEDADVTLQLHLKMWPDLQKHKGPLNVFENIEMPLVPVLSRIERNGVKIDPKVLHNHSEELTLRLAELEKKAHEIAGEEFNLSSTKQLQTILFEKQGIKPLKKTPGGAPSTSEEVLEELALDYPLPKVILEYRGLAKLKSTYTDKLPLMINPKTGRVHTSYHQAVTATGRLSSTDPNLQNIPVRNEEGRRIRQAFIAPEDYVIVSADYSQIELRIMAHLSRDKGLLTAFAEGKDIHRATAAEVFGLPLETVTSEQRRSAKAINFGLIYGMSAFGLARQLNIPRKEAQKYMDLYFERYPGVLEYMERTRAQAKEQGYVETLDGRRLYLPDIKSSNGARRAAAERAAINAPMQGTAADIIKRAMIAVDAWLQAEQPRVRMIMQVHDELVFEVHKDDVDAVAKQIHQLMENCTRLDVPLLVEVG SGENWDQAH

Modifying Enzymes

As noted above, suitable DNA- and protein-modifying enzymes are known inthe art. In some cases, the modifying enzyme is a nucleic acid-modifyingenzyme. Examples of suitable nucleic acid-modifying enzymes include DNAediting enzymes; deaminases, such as activation induced deaminase andAPOBEC proteins; nucleases; recombinases; glycosylases;methyltransferases; and the like. In other cases, the modifying enzymeis a protein-modifying enzyme. For example, the modifying enzyme may beone that modifies a protein associated with a nucleic acid. Examples ofsuitable protein-modifying enzymes include histone-modifying enzymes,acetylases, kinases, methyltransferases, ubiquitin ligases, SUMOligases, demethylases, deacetylases, phosphatases, and the like.

Adenosine Deaminases

Adenosine deaminases suitable for inclusion in a deaminase-containingbase editor of the present disclosure include any enzyme that is capableof deaminating adenosine in DNA. In some cases, the deaminase is a TadAdeaminase.

In some cases, a suitable adenosine deaminase comprises an amino acidsequence having at least 80%, at least 85%, at least 90%, at least 95%,at least 98%, at least 99%, or 100%, amino acid sequence identity to thefollowing amino acid sequence:

(SEQ ID NO: 1247) MSEVEFSHEYWMRHALTLAKRAWDEREVPVGAVLVHNNRVIGEGWNRPIGRHDPTAHAEIMALRQGGLVMQNYRLIDATLYVTLEPCVMCAGAMIHSRIGRVVFGARDAKTGAAGSLMDVLHHPGMNHRVEITEGILADECAALLSDFFRMRR QEIKAQKKAQSSTD

In some cases, a suitable adenosine deaminase comprises an amino acidsequence having at least 80%, at least 85%, at least 90%, at least 95%,at least 98%, at least 99%, or 100%, amino acid sequence identity to thefollowing amino acid sequence:

(SEQ ID NO: 1248) MRRAFITGVFFLSEVEFSHEYWMRHALTLAKRAWDEREVPVGAVLVHNNRVIGEGWNRPIGRHDPTAHAEIMALRQGGLVMQNYRLIDATLYVTLEPCVMCAGAMIHSRIGRVVFGARDAKTGAAGSLMDVLHHPGMNHRVEITEGILADECAALLSDFFRMRRQEIKAQKKAQSSTD.

In some cases, a suitable adenosine deaminase comprises an amino acidsequence having at least 80%, at least 85%, at least 90%, at least 95%,at least 98%, at least 99%, or 100%, amino acid sequence identity to thefollowing Staphylococcus aureus TadA amino acid sequence:

(SEQ ID NO: 1200) MGSHMTNDIYFMTLAIEEAKKAAQLGEVPIGAIITKDDEVIARAHNLRETLQQPTAHAEHIAIERAAKVLGSWRLEGCTLYVTLEPCVMCAGTIVMSRIPRVVYGADDPKGGCSGSLMNLLQQSNFNHRAIVDKGVLKEACSTLLTTFFK NLRANKKSTN:

In some cases, a suitable adenosine deaminase comprises an amino acidsequence having at least 80%, at least 85%, at least 90%, at least 95%,at least 98%, at least 99%, or 100%, amino acid sequence identity to thefollowing Bacillus subtilis TadA amino acid sequence:

(SEQ ID NO: 1201) MTQDELYMKEAIKEAKKAEEKGEVPIGAVLVINGEIIARAHNLRETEQRSIAHAEMLVIDEACKALGTWRLEGATLYVTLEPCPMCAGAVVLSRVEKVVFGAFDPKGGCSGTLMNLLQEERFNHQAEVVSGVLEEECGGMLSAFFRELRK KKKAARKNLSE

In some cases, a suitable adenosine deaminase comprises an amino acidsequence having at least 80%, at least 85%, at least 90%, at least 95%,at least 98%, at least 99%, or 100%, amino acid sequence identity to thefollowing Salmonella typhimurium TadA:

(SEQ ID NO: 1202) MPPAFITGVTSLSDVELDHEYWMRHALTLAKRAWDEREVPVGAVLVHNHRVIGEGWNRPIGRHDPTAHAEIMALRQGGLVLQNYRLLDTTLYVTLEPCVMCAGAMVHSRIGRVVFGARDAKTGAAGSLIDVLHHPGMNHRVEIIEGVLRDECATLLSDFFRMRRQEIKALKKADRAEGAGPAV

In some cases, a suitable adenosine deaminase comprises an amino acidsequence having at least 80%, at least 85%, at least 90%, at least 95%,at least 98%, at least 99%, or 100%, amino acid sequence identity to thefollowing Shewanella putrefaciens TadA amino acid sequence:

(SEQ ID NO: 1203) MDEYWMQVAMQMAEKAEAAGEVPVGAVLVKDGQQIATGYNLSISQHDPTAHAEILCLRSAGKKLENYRLLDATLYITLEPCAMCAGAMVHSRIARVVYGARDEKTGAAGTVVNLLQHPAFNHQVEVTSGVLAEACSAQLSRFFKRRRDEK KALKLAQRAQQGIE

In some cases, a suitable adenosine deaminase comprises an amino acidsequence having at least 80%, at least 85%, at least 90%, at least 95%,at least 98%, at least 99%, or 100%, amino acid sequence identity to thefollowing Haemophilus influenzae F3031 TadA amino acid sequence:

(SEQ ID NO: 1204) MDAAKVRSEFDEKMMRYALELADKAEALGEIPVGAVLVDDARNIIGEGWNLSIVQSDPTAHAEIIALRNGAKNIQNYRLLNSTLYVTLEPCTMCAGAILHSRIKRLVFGASDYKTGAIGSRFHFFDDYKMNHTLEITSGVLAEECSQKLSTFFQKRREEKKIEKALLKSLSDK

In some cases, a suitable adenosine deaminase comprises an amino acidsequence having at least 80%, at least 85%, at least 90%, at least 95%,at least 98%, at least 99%, or 100%, amino acid sequence identity to thefollowing Caulobacter crescentus TadA amino acid sequence:

(SEQ ID NO: 1205) MRTDESEDQDHRMMRLALDAARAAAEAGETPVGAVILDPSTGEVIATAGNGPIAAHDPTAHAEIAAMRAAAAKLGNYRLTDLTLVVTLEPCAMCAGAISHARIGRVVFGADDPKGGAVVHGPKFFAQPTCHWRPEVTGGVLADESADLLR GFFRARRKAKI

In some cases, a suitable adenosine deaminase comprises an amino acidsequence having at least 80%, at least 85%, at least 90%, at least 95%,at least 98%, at least 99%, or 100%, amino acid sequence identity to thefollowing Geobacter sulfurreducens TadA amino acid sequence:

(SEQ ID NO: 1206) MSSLKKTPIRDDAYWMGKAIREAAKAAARDEVPIGAVIVRDGAVIGRGHNLREGSNDPSAHAEMIAIRQAARRSANWRLTGATLYVTLEPCLMCMGAIILARLERVVFGCYDPKGGAAGSLYDLSADPRLNHQVRLSPGVCQEECGTMLSDFFRDLRRRKKAKATPALFIDERKVPPEP

Cytidine Deaminases

Cytidine deaminases suitable for inclusion in a deaminase-containingbase editor of the present disclosure include any enzyme that is capableof deaminating cytidine in DNA.

In some cases, the cytidine deaminase is a deaminase from theapolipoprotein B mRNA-editing complex (APOBEC) family of deaminases. Insome cases, the APOBEC family deaminase is selected from the groupconsisting of APOBEC1 deaminase, APOBEC2 deaminase, APOBEC3A deaminase,APOBEC3B deaminase, APOBEC3C deaminase, APOBEC3D deaminase, APOBEC3Fdeaminase, APOBEC3G deaminase, and APOBEC3H deaminase. In some cases,the cytidine deaminase is an activation induced deaminase (AID).

In some cases, a suitable cytidine deaminase comprises an amino acidsequence having at least 80%, at least 85%, at least 90%, at least 95%,at least 98%, at least 99%, or 100%, amino acid sequence identity to thefollowing amino acid sequence:

(SEQ ID NO: 1207) MDSLLMNRRKFLYQFKNVRWAKGRRETYLCYVVKRRDSATSFSLDFGYLRNKNGCHVELLFLRYISDWDLDPGRCYRVTWFTSWSPCYDCARHVADFLRGNPNLSLRIFTARLYFCEDRKAEPEGLRRLHRAGVQIAIMTFKDYFYCWNTFVENHERTFKAWEGLHENSVRLSRQLRRILLPLYEVDDLRDAFRTLGL

In some cases, a suitable cytidine deaminase is an AID and comprises anamino acid sequence having at least 80%, at least 85%, at least 90%, atleast 95%, at least 98%, at least 99%, or 100%, amino acid sequenceidentity to the following amino acid sequence:

(SEQ ID NO: 1208) MDSLLMNRRK FLYQFKNVRW AKGRRETYLC YVVKRRDSATSFSLDFGYLR NKNGCHVELL FLRYISDWDL DPGRCYRVTWFTSWSPCYDC ARHVADFLRG NPNLSLRIFT ARLYFCEDRKAEPEGLRRLH RAGVQIAIMT FKENHERTFK AWEGLHENSVRLSRQLRRIL LPLYEVDDLR DAFRTLGL.

In some cases, a suitable cytidine deaminase is an AID and comprises anamino acid sequence having at least 80%, at least 85%, at least 90%, atleast 95%, at least 98%, at least 99%, or 100%, amino acid sequenceidentity to the following amino acid sequence:

(SEQ ID NO: 1209) MDSLLMNRRK FLYQFKNVRW AKGRRETYLC YVVKRRDSATSFSLDFGYLR NKNGCHVELL FLRYISDWDL DPGRCYRVTWFTSWSPCYDC ARHVADFLRG NPNLSLRIFT ARLYFCEDRKAEPEGLRRLH RAGVQIAIMT FKDYFYCWNT FVENHERTFKAWEGLHENSV RLSRQLRRIL LPLYEVDDLR DAFRTLGL.

RNA-Guided Enzyme Exhibiting Nickase Activity

As noted above, a DNA- or protein-modifying enzyme-containing fusionpolypeptide of the present disclosure (e.g., a deaminase-containing baseeditor of the present disclosure) comprises an RNA-guided enzyme thatexhibits nickase activity. Suitable nickases are described elsewhereherein.

In some cases, a suitable RNA-guided enzyme that exhibits nickaseactivity comprises an amino acid sequence having at least 80%, at least85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100%,amino acid sequence identity to the following “nicking high fidelity”Cas9 amino acid sequence:

(SEQ ID NO: 1210) DKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTAFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGALSRKLINGIRDKQSGKTILDFLKSDGFANRNFMALIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRAITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQS ITGLYETRIDLSQLGGD.

In some cases, a suitable RNA-guided enzyme that exhibits nickaseactivity comprises an amino acid sequence having at least 80%, at least85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100%,amino acid sequence identity to the following “nicking enhanced” Cas9amino acid sequence:

(SEQ ID NO: 1211) DKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLADDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKYPALESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITLANGEIRKAPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQS ITGLYETRIDLSQLGGD.

In some cases, a suitable RNA-guided enzyme that exhibits nickaseactivity comprises an amino acid sequence having at least 80%, at least85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100%,amino acid sequence identity to the following “nicking” Cas9 amino acidsequence:

(SEQ ID NO: 1212) DKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQS ITGLYETRIDLSQLGGD.

UGI

In some cases, a DNA- or protein-modifying enzyme-containing fusionpolypeptide of the present disclosure (e.g., a deaminase-containing baseeditor of the present disclosure) further includes a uracil glycosylaseinhibitor (UGI) polypeptide. The UGI polypeptide can be positioned atthe N-terminus, at the C-terminus, or internally within the fusionpolypeptide.

In some cases, a suitable UGI polypeptide comprises an amino acidsequence having at least 80%, at least 85%, at least 90%, at least 95%,at least 98%, at least 99%, or 100%, amino acid sequence identity to thefollowing amino acid sequence:

(SEQ ID NO: 1213) TNLSDIIEKETGKQLVIQESILMLPEEVEEVIGNKPESDILVHTAYDESTDENVMLLTSDAPEYKPWALVIQDSNGENKIKML.

NLS

In some cases, a DNA- or protein-modifying enzyme-containing fusionpolypeptide of the present disclosure (e.g., a deaminase-containing baseeditor of the present disclosure) includes a nuclear localization signal(NLS). In some cases, a DNA- or protein-modifying enzyme-containingfusion polypeptide of the present disclosure (e.g., adeaminase-containing base editor of the present disclosure) comprises asingle NLS at the N-terminus of the fusion polypeptide. In some cases, aDNA- or protein-modifying enzyme-containing fusion polypeptide of thepresent disclosure (e.g., a deaminase-containing base editor of thepresent disclosure) comprises 2, 3, or 4 NLSs at the N-terminus of thefusion polypeptide. In other instances, a DNA- or protein-modifyingenzyme-containing fusion polypeptide of the present disclosure (e.g., adeaminase-containing base editor of the present disclosure) comprises asingle NLS at the C-terminus of the fusion polypeptide. In some cases, aDNA- or protein-modifying enzyme-containing fusion polypeptide of thepresent disclosure (e.g., a deaminase-containing base editor of thepresent disclosure) comprises 2, 3, or 4 NLSs at the C-terminus of thefusion polypeptide.

Non-limiting examples of suitable NLSs include an NLS sequence derivedfrom: the NLS of the SV40 virus large T-antigen, having the amino acidsequence PKKKRKV (SEQ ID NO:1172); the NLS from nucleoplasmin (e.g., thenucleoplasmin bipartite NLS with the sequence KRPAATKKAGQAKKKK (SEQ IDNO:1173)); the c-myc NLS having the amino acid sequence PAAKRVKLD (SEQID NO:1174) or RQRRNELKRSP (SEQ ID NO:1175); the hRNPA1 M9 NLS havingthe sequence NQSSNFGPMKGGNFGGRSSGPYGGGGQYFAKPRNQGGY (SEQ ID NO:1176);the sequence RMRIZFKNKGKDTAELRRRRVEVSVELRKAKKDEQILKRRNV (SEQ ID NO:1177)of the IBB domain from importin-alpha; the sequences VSRKRPRP (SEQ IDNO:1178) and PPKKARED (SEQ ID NO:1179) of the myoma T protein; thesequence PQPKKKPL (SEQ ID NO:1180) of human p53; the sequenceSALIKKKKKMAP (SEQ ID NO:1181) of mouse c-abl IV; the sequences DRLRR(SEQ ID NO:1182) and PKQKKRK (SEQ ID NO:1183) of the influenza virusNS1; the sequence RKLKKKIKKL (SEQ ID NO:1185) of the Hepatitis virusdelta antigen; the sequence REKKKFLKRR (SEQ ID NO:1185) of the mouse Mx1protein; the sequence KRKGDEVDGVDEVAKKKSKK (SEQ ID NO:1186) of the humanpoly(ADP-ribose) polymerase; and the sequence RKCLQAGMNLEARKTKK (SEQ IDNO:1187) of the steroid hormone receptors (human) glucocorticoid. Insome cases, an NLS comprises the amino acid sequenceMDSLLMNRRKFLYQFKNVRWAKGRRETYLC (SEQ ID NO:1188). In general, NLS (ormultiple NLSs) are of sufficient strength to drive accumulation of thefusion polypeptide in a detectable amount in the nucleus of a eukaryoticcell. Detection of accumulation in the nucleus may be performed by anysuitable technique. For example, a detectable marker may be fused to thefusion polypeptide such that location within a cell may be visualized.Cell nuclei may also be isolated from cells, the contents of which maythen be analyzed by any suitable process for detecting protein, such asimmunohistochemistry, Western blot, or enzyme activity assay.Accumulation in the nucleus may also be determined indirectly.

System Comprising a Modifying Enzyme-Containing Fusion Protein

The present disclosure provides a system comprising a DNA- orprotein-modifying enzyme-containing fusion polypeptide of the presentdisclosure (e.g., a deaminase-containing base editor of the presentdisclosure). The system comprises: a) the DNA- or protein-modifyingenzyme-containing fusion polypeptide; and b) a guide RNA.

The present disclosure provides a base-editing system comprising adeaminase-containing base editor of the present disclosure. The systemcomprises: a) a base-editing system comprising a deaminase-containingbase editor of the present disclosure; and b) a guide RNA. In somecases, the guide RNA is a single-molecule guide RNA. In some cases, theguide RNA is a dual-molecule guide RNA. In some cases, the guide RNAcomprises a modified base and/or a modified sugar and/or a non-naturallyoccurring internucleoside linkage, as described above.

Examples of Non-Limiting Aspects of the Disclosure

Aspects, including embodiments, of the present subject matter describedabove may be beneficial alone or in combination, with one or more otheraspects or embodiments. Without limiting the foregoing description,certain non-limiting aspects of the disclosure numbered 1-84 areprovided below. As will be apparent to those of skill in the art uponreading this disclosure, each of the individually numbered aspects maybe used or combined with any of the preceding or following individuallynumbered aspects. This is intended to provide support for all suchcombinations of aspects and is not limited to combinations of aspectsexplicitly provided below:

Aspect 1. A fusion polypeptide comprising: a) an enzymatically activeRNA-guided endonuclease that introduces a single-stranded break in atarget DNA; and b) an error-prone DNA polymerase.

Aspect 2. The fusion polypeptide of aspect 1, wherein the RNA-guidedendonuclease is a class 2 CRISPR/Cas endonuclease.

Aspect 3. The fusion polypeptide of aspect 2, wherein the class 2CRISPR/Cas endonuclease is a type V or type VI CRISPR/Cas endonuclease.

Aspect 4. The fusion polypeptide of aspect 2, wherein the class 2CRISPR/Cas endonuclease is a Cas9 polypeptide.

Aspect 5. The fusion polypeptide of aspect 4, wherein the Cas9polypeptide comprises a mutation that reduces off-target binding.

Aspect 6. The fusion polypeptide of aspect 3, wherein the RNA-guidedendonuclease is a Cpf1 polypeptide.

Aspect 7. The fusion polypeptide of any one of aspects 1-6, furthercomprising a nuclear localization signal.

Aspect 8. The fusion polypeptide of any one of aspects 1-7, comprising alinker interposed between the RNA-guided endonuclease and theerror-prone DNA polymerase.

Aspect 9. The fusion polypeptide of any one of aspects 1-8, furthercomprising a DNA-binding polypeptide that increases the processivity ofthe DNA polymerase.

Aspect 10. The fusion polypeptide of aspect 9, wherein the DNA-bindingpolypeptide that increases the processivity of the DNA polymerase is anSso7d polypeptide.

Aspect 11. The fusion polypeptide of aspect 9, wherein the DNA-bindingpolypeptide that increases the processivity of the DNA polymerase is ahelix-hairpin-helix domain of topoisomerase I.

Aspect 12. The fusion polypeptide of aspect 9, wherein the DNA-bindingpolypeptide that increases the processivity of the DNA polymerase is athioredoxin binding domain of a T7 DNA polymerase or T3 polymerase.

Aspect 13. The fusion polypeptide of any one of aspects 1-12, whereinthe fusion polypeptide, when complexed with a guide RNA, exhibits atarget mutation rate of from 10⁻⁸ to 10⁻² mutations per nucleotide pergenome replication event.

Aspect 14. The fusion polypeptide of any one of aspects 1-12, whereinthe fusion polypeptide, when complexed with a guide RNA, exhibits atarget mutation rate of from 10⁻⁶ to 10⁻⁵ mutations per nucleotide pergenome replication event.

Aspect 15. The fusion polypeptide of any one of aspects 1-12, whereinthe fusion polypeptide, when complexed with a guide RNA, exhibits atarget mutation rate of from 10⁻⁵ to 10⁻³ mutations per nucleotide pergenome replication event.

Aspect 16. The fusion polypeptide of any one of aspects 1-12, whereinthe fusion polypeptide, when complexed with a guide RNA, exhibits atarget mutation rate of from 10⁻³ to 10⁻² mutations per nucleotide pergenome replication event.

Aspect 17. The fusion polypeptide of any one of aspects 1-12, whereinthe fusion polypeptide, when complexed with a guide RNA, exhibits atarget mutation rate that is at least 5-fold higher than the globalmutation rate exhibited by the error-prone DNA polymerase not fused tothe RNA-guided endonuclease.

Aspect 18. The fusion polypeptide of any one of aspects 1-12, whereinthe fusion polypeptide, when complexed with a guide RNA, exhibits atarget mutation rate that is at least 10-fold higher than the globalmutation rate exhibited by the error-prone DNA polymerase not fused tothe RNA-guided endonuclease.

Aspect 19. The fusion polypeptide of any one of aspects 1-12, whereinthe fusion polypeptide, when complexed with a guide RNA, exhibits atarget mutation rate that is at least 10²-fold higher than the globalmutation rate exhibited by the error-prone DNA polymerase not fused tothe RNA-guided endonuclease.

Aspect 20. The fusion polypeptide of any one of aspects 1-19, whereinthe fusion polypeptide, when complexed with a guide RNA, introducesmutations at a distance of from 1 nucleotide to 10⁴ nucleotides from anick in a target DNA introduced by the RNA-guided endonuclease.

Aspect 21. The fusion polypeptide of any one of aspects 1-19, whereinthe fusion polypeptide, when complexed with a guide RNA, introducesmutations at a distance of from 1 nucleotide to 100 nucleotides from anick in a target DNA introduced by the RNA-guided endonuclease.

Aspect 22. The fusion polypeptide of any one of aspects 1-19, whereinthe fusion polypeptide, when complexed with a guide RNA, introducesmutations at a distance of from 1 nucleotide to 50 nucleotides from anick in a target DNA introduced by the RNA-guided endonuclease.

Aspect 23. The fusion polypeptide of any one of aspects 1-22, whereinthe fusion polypeptide comprises, in order from N-terminus toC-terminus: a) the enzymatically active RNA-guided endonuclease; and b)the error-prone DNA polymerase.

Aspect 24. The fusion polypeptide of any one of aspects 1-22, whereinthe fusion polypeptide comprises, in order from N-terminus toC-terminus: a) the enzymatically active RNA-guided endonuclease; b) alinker; and c) the error-prone DNA polymerase.

Aspect 25. The fusion polypeptide of any one of aspects 1-22, whereinthe fusion polypeptide comprises, in order from N-terminus toC-terminus: a) the error-prone DNA polymerase; and b) the enzymaticallyactive RNA-guided endonuclease.

Aspect 26. The fusion polypeptide of any one of aspects 1-22, whereinthe fusion polypeptide comprises, in order from N-terminus toC-terminus: a) the error-prone DNA polymerase; b) a linker; and c) theenzymatically active RNA-guided endonuclease.

Aspect 27. The fusion polypeptide of any one of aspects 1-26, whereinthe fusion polypeptide comprises, in order from N-terminus to C-terminusa) a nuclear localization signal; b) an enzymatically inactiveRNA-guided endonuclease; and c) an error-prone DNA polymerase.

Aspect 28. The fusion polypeptide of any one of aspects 1-26, whereinthe fusion polypeptide comprises, in order from N-terminus toC-terminus: a) a nuclear localization signal; b) an error-prone DNApolymerase; and c) an enzymatically inactive RNA-guided endonuclease.

Aspect 29. The fusion polypeptide of any one of aspects 28, wherein theDNA polymerase comprises an amino acid sequence having at least 85%amino acid sequence to the DNA polymerase I amino acid sequence depictedin FIG. 8 , wherein the DNA polymerase has one or more of the following:an Ala at amino acid position 242, an Asn at amino acid position 709, anArg at amino acid position 759, a Tyr at amino acid position 742, and aHis at amino acid position 796.

Aspect 30. The fusion polypeptide of any one of aspects 28, wherein theDNA polymerase is a DNA polymerase beta, a DNA polymerase iota, a DNApolymerase nu, a DNA polymerase eta, or a DNA polymerase kappa.

Aspect 31. The fusion polypeptide of aspect 30, wherein the fusionpolypeptide, when complexed with a guide RNA, exhibits a target mutationrate of 1 mutation per nucleotide per genome replication event.

Aspect 32. A system comprising: a) the fusion polypeptide of any one ofaspects 1-31; and b) a guide RNA that comprises: i) a protein-bindingsegment comprising a nucleotide sequence that binds to the RNA-guidedendonuclease; and ii) a target-binding segment comprising a nucleotidesequence that is complementary to a target nucleotide sequence in atarget nucleic acid.

Aspect 33. The system of aspect 32, wherein the guide RNA is asingle-molecule guide RNA.

Aspect 34. The system of aspect 32, wherein the guide RNA is adual-molecule guide RNA.

Aspect 35. The system of any one of aspects 32-34, wherein the guide RNAcomprises one or more of: a) a modified base; b) a modified backbone; c)a modified sugar moiety; and d) a non-natural internucleoside linkage.

Aspect 36. A cell comprising the fusion polypeptide of any one ofaspects 1-31.

Aspect 37. The cell of aspect 36, wherein the cell is a prokaryoticcell.

Aspect 38. The cell of aspect 36, wherein the cell is a eukaryotic cell.

Aspect 39. The cell of any one of aspects 36-38, wherein the cell is invitro.

Aspect 40. A cell comprising the system of any one of aspects 36-39.

Aspect 41. The cell of aspect 40, wherein the cell is a prokaryoticcell.

Aspect 42. The cell of aspect 40, wherein the cell is a eukaryotic cell.

Aspect 43. The cell of any one of aspects 40-42, wherein the cell is invitro.

Aspect 44. A method of mutagenizing a target DNA, the method comprisingcontacting the target DNA with the system of any one of aspects 32-35.

Aspect 45. The method of aspect 44, wherein the target DNA is present ina cell.

Aspect 46. The method of aspect 44, wherein the cell is a prokaryoticcell.

Aspect 47. The method of aspect 45, wherein the cell is a eukaryoticcell.

Aspect 48. The method of aspect 47, wherein the cell is an animal cell.

Aspect 49. The method of aspect 47, wherein the cell is a plant cell.

Aspect 50. The method of aspect 49, wherein the plant cell is a cell ofa dicotyledon.

Aspect 51. The method of aspect 49, wherein the plant cell is a cell ofa monocotyledon.

Aspect 52. The method of any one of aspects 44-51, wherein the cell isin vitro.

Aspect 53. The method of any one of aspects 44-51, wherein the cell isin vivo.

Aspect 54. The method of any one of aspects 44-53, wherein mutations areintroduced into the target DNA at a mutation rate of from 10⁻⁸ to 10⁻²mutations per nucleotide per genome replication event.

Aspect 55. The method of any one of aspects 44-53, wherein mutations areintroduced into the target DNA at a mutation rate of from 10⁻⁶ to 10⁻⁵mutations per nucleotide per genome replication event.

Aspect 56. The method of any one of aspects 44-53, wherein mutations areintroduced into the target DNA at a mutation rate of from 10⁻⁵ to 10⁻³mutations per nucleotide per genome replication event.

Aspect 57. The method of any one of aspects 44-53, wherein mutations areintroduced into the target DNA at a mutation rate of from 10⁻³ to 10⁻²mutations per nucleotide per genome replication event.

Aspect 58. A base editor system comprising: a) the fusion polypeptide ofany one of aspects 29-31; and b) a guide RNA that comprises: i) aprotein-binding segment comprising a nucleotide sequence that binds tothe RNA-guided endonuclease; and ii) a target-binding segment comprisinga nucleotide sequence that is complementary to a target nucleotidesequence in a target nucleic acid.

Aspect 59. The system of aspect 58, wherein the guide RNA is asingle-molecule guide RNA.

Aspect 60. The system of aspect 58, wherein the guide RNA is adual-molecule guide RNA.

Aspect 61. The system of any one of aspects 58-60, wherein the guide RNAcomprises one or more of: a) a modified base; b) a modified backbone; c)a modified sugar moiety; and d) a non-natural internucleoside linkage.

Aspect 62. A method of editing a target nucleotide sequence in a targetnucleic acid, the method comprising contacting the target nucleotidesequence with the base editor system of any one of aspects 58-61.

Aspect 63. The method of aspect 62, wherein the target nucleotidesequence comprises a single nucleotide mutation that results in adisease or disorder in an organism.

Aspect 64. A fusion polypeptide comprising: a) an enzymatically activeRNA-guided endonuclease that introduces a single-stranded break in atarget DNA; b) a DNA polymerase; and c) modifying enzyme.

Aspect 65. The fusion polypeptide of aspect 64, wherein the modifyingenzyme is a protein-modifying enzyme.

Aspect 66. The fusion polypeptide of aspect 64, wherein the modifyingenzyme is a DNA-modifying enzyme.

Aspect 67. The fusion polypeptide of aspect 66, wherein theDNA-modifying enzyme is a cytidine deaminase or an adenosine deaminase.

Aspect 68. The fusion polypeptide of aspect 64, wherein the RNA-guidedendonuclease is a class 2 CRISPR/Cas endonuclease.

Aspect 69. The fusion polypeptide of aspect 68, wherein the class 2CRISPR/Cas endonuclease is a type V or type VI CRISPR/Cas endonuclease.

Aspect 70. The fusion polypeptide of aspect 68, wherein the class 2CRISPR/Cas endonuclease is a Cas9 polypeptide.

Aspect 71. The fusion polypeptide of aspect 70, wherein the Cas9polypeptide comprises a mutation that reduces off-target binding.

Aspect 72. The fusion polypeptide of aspect 64, wherein the RNA-guidedendonuclease is a Cpf1 polypeptide.

Aspect 73. The fusion polypeptide of any one of aspects 64-72, furthercomprising a nuclear localization signal.

Aspect 74. The fusion polypeptide of any one of aspects 64-73,comprising a linker between the RNA-guided endonuclease and the DNApolymerase.

Aspect 75. The fusion polypeptide of any one of aspects 64-74, whereinthe DNA polymerase is a high-fidelity DNA polymerase.

Aspect 76. The fusion polypeptide of any one of aspects 64-75, whereinthe fusion polypeptide further comprises a uracil glycosylase inhibitor(UGI).

Aspect 77. A system comprising: a) the fusion polypeptide of any one ofaspects 64-76; and b) a guide RNA that comprises: i) a protein-bindingsegment comprising a nucleotide sequence that binds to the RNA-guidedendonuclease; and ii) a target-binding segment comprising a nucleotidesequence that is complementary to a target nucleotide sequence in atarget nucleic acid.

Aspect 78. The system of aspect 77, wherein the guide RNA is asingle-molecule guide RNA.

Aspect 79. The system of aspect 77, wherein the guide RNA is adual-molecule guide RNA.

Aspect 80. The system of any one of aspects 77-79, wherein the guide RNAcomprises one or more of: a) a modified base; b) a modified backbone; c)a modified sugar moiety; and d) a non-natural internucleoside linkage.

Aspect 81. A method of editing a target nucleotide sequence in a targetnucleic acid, the method comprising contacting the target nucleotidesequence with the system of any one of aspects 77-80.

Aspect 82. A nucleic acid comprising a nucleotide sequence encoding thefusion polypeptide of any one of aspects 64-76.

Aspect 83. A recombinant expression vector comprising the nucleic acidof aspect 82.

Aspect 84. A cell comprising the nucleic acid of aspect 82 or therecombinant expression vector of aspect 83.

EXAMPLES

The following examples are put forth so as to provide those of ordinaryskill in the art with a complete disclosure and description of how tomake and use the present invention, and are not intended to limit thescope of what the inventors regard as their invention nor are theyintended to represent that the experiments below are all or the onlyexperiments performed. Efforts have been made to ensure accuracy withrespect to numbers used (e.g. amounts, temperature, etc.) but someexperimental errors and deviations should be accounted for. Unlessindicated otherwise, parts are parts by weight, molecular weight isweight average molecular weight, temperature is in degrees Celsius, andpressure is at or near atmospheric. Standard abbreviations may be used,e.g., bp, base pair(s); kb, kilobase(s); pl, picoliter(s); s or sec,second(s); min, minute(s); h or hr, hour(s); aa, amino acid(s); kb,kilobase(s); bp, base pair(s); nt, nucleotide(s); i.m.,intramuscular(ly); i.p., intraperitoneal(ly); s.c., subcutaneous(ly);and the like.

Example 1

A schematic depiction of a mutagenesis tool of the present disclosure isprovided in FIG. 1 . A fusion polypeptide comprising an error-pronenick-translating DNApol and a variant of Cas9 that nicks its targetsequence (nCas9) is depicted in FIG. 1 . The specificity of thepolymerase initiation site created by the nCas9 offers single-baseresolution for the start site of the editing window while themutagenesis window length, mutation rate, and substitution bias arecontrolled by the polymerase processivity, fidelity, andmisincorporation bias, characteristics chosen through polymerase variantselection. Because this genetic device will not rely on host machineryfor the mutagenesis, it is readily adaptable to anytransformation-competent organism. This mutagenesis tool is termed“EvolvR”, reflecting how evolution often begins with replicative errors.

FIG. 1 . Fusion of DNApol to nCas9 for targeted mutagenesis. A nickingCas9 (nCas9) fused to an error prone DNA polymerase is targeted to theregion to be mutated with an sgRNA. After the nCas9 makes a singlestranded break, the polymerase binds to the nick, and synthesizes a newstrand with low fidelity while displacing and degrading the originalstrand.

Mutator designs are tested for their ability to mutagenize target locithrough fluctuation analysis, which determines mutation rates from therate of reversing a nonsense mutation in an antibiotic resistance gene.In this assay, depicted schematically in FIG. 2A, a plasmid expressingthe EvolvR components (pMut) is cotransformed into E. coli with aplasmid containing a nonfunctional antibiotic resistance gene (pNARG)containing a disabling nonsense mutation. After sixteen hours of growthwithout the antibiotic, the cultures are plated on the antibiotic andthe mutation rates are determined by applying the Ma-Sandri-Sarkarstatistical analysis to the colony counts.

Preliminary fluctuation analysis estimated the mutation rate ofwild-type E. coli to be approximately 10⁻¹⁰ mutations per nucleotide pergeneration, which is similar to a previously reported 5.4×10⁻¹⁰. Thefirst mutator architecture tested was a translational fusion of nCas9and the most well characterized nick-translating DNA polymerase, E. coliDNA polymerase I, with three fidelity-reducing mutations (PolI3M). Thesemutations include D424A, which inactivates proofreading activity, I709N,which is thought to enlarge the substrate-binding pocket by disruptingthe hydrophobic pocket, and A759R, which is thought to stabilize thepolymerase's closed conformation promoting translocation after amisincorporation. Combining these mutations results in a polymerase thathas a reported mutation rate of approximately 8.1×10⁻⁴ mutations pernucleotide.

To control for changes in global mutation rate that occur as a result ofexpressing an error-prone polymerase in the cell, the rate ofnon-specific mutation accumulation will be determined by measuring theantibiotic-resistance reversion rate of cells carrying a pMut plasmidtargeting the (fitness-neutral) dbpA gene in the E. coli genome. Thetargeted mutation rate will be determined with an sgRNA nicking 11 bases5′ of the nonsense mutation. FIG. 2B shows that nCas9 alone has nodifference in global and targeted mutation rate. Expressing nCas9 andPolI3M as separate proteins elevated the global mutation rate ˜100 foldand the targeted mutation rate ˜1,000 fold. An N-terminally fused PolI3Mmaintains the ˜100 fold increase in global mutation rate but provides agreater than 10,000 fold increase of mutation rate over wild-type at thetargeted locus.

To promote the unbinding of the nuclease after cleavage, it washypothesized that DNA residence time could be reduced by introducing aset of mutations into the fused nCas9 that are suggested to lower Cas9'snon-specific DNA affinity, Using this mutant nCas9 (enCas9) increasedthe global mutation rate 1.9 fold while the targeted mutation rateincreased 8.6 fold compared to nCas9.

FIG. 2C shows that the fidelity of the DNApol confers the targeted andglobal mutation rate. PolI with a D424A mutation (PolI1M) was lessmutagenic than PolI with both D424A and T709N mutations (PolI3M). PolI3Mwas the most mutagenic.

FIG. 2A-2C. A fluctuation analysis using different mutator architectureswill determine targetability of mutagenesis. a) A fluctuation analysiswill determine mutation rates by cotransforming E. coli with a plasmidcoding the mutator architecture (pMut) and a plasmid containing anantibiotic resistance gene with a nonsense mutation (pNARG) and countingresistant colonies after 16 hours of growth. b) A fluctuation analysisshowed that nCas9 and PolI3M-nCas9 do not increase the global ortargeted mutation rate, as determined by an off target sgRNA and sgRNAnicking 11 nucleotides 5′ of the nonsense mutation, respectively.nCas9-PolI3M increased the global mutation rate 100 fold and increasedthe targeted mutation rate 10,000 fold. Replacing nCas9 with a variantproposed to have lower affinity for DNA (enCas9) increased the targetedmutation rate 8.6 fold while the global mutation rate increased 1.9fold, c) enCas9 fused to PolI with a D424A mutation (PolI1M) was lessmutagenic that enCas9 fused to PolI with D424A and 1709 mutations(PolI2M). enCas9 fused to PolI3M was that most mutagenic.

The mutagenesis window length can be determined with a fluctuationanalysis using sgRNAs targeting different distances from the antibioticresistance gene's nonsense mutation. To test whether the mutagenesiswindow length is determined by the processivity of the polymerase, PolIwith T7 DNA polymerase's thioredoxin binding domain (PolI-TBD) wastested. This chimera has previously been shown to have higherprocessivity than PolI, Indeed, FIG. 3 shows that while PolI does notshow any increase in mutagenesis over background when targeted 56nucleotides from the nonsense mutation, PolI-TBD does. This suggeststhat the mutagenesis window length can be tuned by modifying thepolymerase's processivity. It was found that a mutation that abolishesthe flap endonuclease activity only slightly decreases the mutationrate. This suggests that DNA polymerases without flap endonucleaseactivity can be used, likely relying on endogenous single strandedexonucleases for degrading the displaced strand.

FIG. 3 . Mutagenesis window length can be tuned by changing polymeraseprocessivity. enCas9-PolI3M has a mutagenesis window length between 11and 56 nucleotides. enCas9-PolI3M-TBD has a mutagenesis window lengthbetween 56 and 197 nucleotides. Inactivating flap endonuclease activityslightly decreases targeted mutation rate.

As shown in FIG. 4A, cells are transformed with EvolvR constructstargeted to a neutral genomic locus. The number of cell generations isestimated by quantifying the viable cell count before and after thegrowth period. The genomic target is amplified from purified genomesusing polymerase chain reaction (PCR) primers that simultaneously addIllumina adapters. A second round of PCR add indexes to de-multiplexpooled sequence runs. The samples are then analyzed with 300-base pairpaired-end sequencing on an Illumina MiSeq.

FIG. 4A. Targeted amplification of genomic loci targeted with a mutatorfor a certain number of generations is sequenced with 300-bp completelyoverlapping paired-end sequencing with an Illumina MiSeq. Unmatchingpaired reads and low frequency variants are discarded. The variants areused to determine the distribution of types of substitution as well asthe mutagenesis window length.

High throughput sequencing is used to characterize the mutation rate,frequency of each type of nucleotide substitution and mutagenesis windowlength of the optimal architecture and polymerase combinations. Thetarget region is amplified from purified genomes using PCR primers thatsimultaneously add Illumina adapters. A second round of PCR adds indexesto de-multiplex pooled sequencing runs. The samples are then analyzedwith 300 base pair paired-end sequencing on an Illumina MiSeq. Toprevent sequencing errors contributing false positive mutational eventsto the analysis, the paired-end reads is compared to each other and anyunidentical pairs are discarded. After aligning to a reference, VarScan2is used to call the variants. Any variant represented by more than 0.4%of the total reads is considered a true mutational event. The mutationsidentified are used to quantify the relative frequency of the 12 typesof substitutions and will determine a 5 bp window rolling averagemutation rate. FIG. 4B shows that variants can be captured at afrequency greater than 0.4% within a window of twenty nucleotides 3′ ofthe nick using the enCas9-PolI3M construct and that all four nucleotideswere substituted,

FIG. 4B. (left panel) Frequency of single nucleotide variants after 24hours of growth (“on”=sgRNA causing nicking at position 0; “off”=sgRNAtargeting dbpA, a safespot in the genome; “vector”=empty plasmid withoutenCas9-PolI™ construct). (right panel) Distribution of point mutants'original nucleotide identity.

Example 2

EvolvR, a system that can continuously diversify all nucleotides withina tunable window length at user-defined loci was developed. This wasachieved by directly generating mutations using engineered DNApolymerases targeted to desired loci via CRISPR-guided nickases. Nickaseand polymerase variants that offer a range of targeted mutation rates upto 7,770,000-fold greater than wild type cells, and editing windowlengths up to 350 nucleotides were identified. EvolvR was then used toidentify novel ribosomal mutations that confer resistance to theantibiotic spectinomycin. The results demonstrate that CRISPR-guided DNApolymerases enable multiplexed and continuous diversification ofuser-defined genomic loci that will be useful for a broad range of basicand biotechnological applications.

It was hypothesized-that recruiting an error-prone, nick-translating DNApolymerase with a nicking variant of Cas9 (nCas9) could offer an idealHDR-independent targeted mutagenesis tool, termed EvolvR (FIG. 22A). Thespecificity of the polymerase initiation site created by the nCas9specifies the start site of the editing window, while the mutagenesiswindow length, mutation rate, and substitution bias are controlled bythe polymerase variant's processivity, fidelity, and misincorporationbias, respectively.

FIG. 22A-22E|EvolvR (error-prone DNA polymerase fused to nicking Cas9)enables targeted mutagenesis. a, The EvolvR system consists of aCRISPR-guided nickase that nicks the target locus and a fused DNApolymerase which performs error-prone nick translation. b,High-throughput sequencing shows that fusing nicking Cas9 (nCas9) to E.coli DNA polymerase I with the fidelity-reducing mutations D424A, I709N,and A759R (PolI3M) resulted in substitutions in a ˜17 nucleotide window3′ from the nick. Only data points above 0.04% frequency were consideredtrue substitutions (dotted line; see Methods). Expressing nCas9 fused toPolI3M with an off-target guide yielded only one substitution and atlow-frequency, while an unfused nCas9 and PolI3M did not showsubstitutions at a frequency above 0.04%. c, All four nucleotides weresubstituted by nCas9-PolI3M. d, Description of fluctuation analysisworkflow used to sensitively quantify targeted and global mutationrates. e, The global and targeted mutation rates of wild-type E. coli,nCas9 fused to PolI3M, unfused nCas9 and PolI3M, PolI3M alone, and nCas9alone were determined by fluctuation analysis. On-target gRNA yieldsnicks 11 nucleotides 5′ of the nonsense mutation. Fluctuation analysiswas performed with ten replicates of each group, and error barsrepresent the 95% confidence intervals.

In the initial design, nCas9 (Streptococcus pyogenes Cas9 harboring aD10A mutation) was fused to the N-terminus of a fidelity-reduced variantof E. coli DNA polymerase I (PolI) harboring the mutations D424A, I709N,and A759R (PolI3M)²¹. A plasmid (pEvolvR) expressing the nCas9-PolI3Mand a gRNA in E. coli was tested for its ability to mutate a secondplasmid targeted by the gRNA over 24 hours of propagation.High-throughput targeted amplicon sequencing revealed that the targetplasmid accrued substitutions in a ˜17 nucleotide window 3′ of the nicksite (FIG. 22B), consistent with the established 15-20 nucleotideprocessivity of PolI²². The presence of low-frequency substitutions 5′of the nick site may be due to endogenous 3′ to 5′ exonucleases removinga few nucleotides 5′ of the nick before the polymerase initiatessynthesis. Critically, substitutions of all four nucleotide types wereobserved (FIG. 22C). In addition to substitutions, PolI is known tocreate deletions, which accounted for 25% of the observed variants inthe 17 nucleotide window²³. No insertions were detected. As controls,expressing nCas9-PolI3M with an off-target guide only showed onelow-frequency substitution, while targeting pTarget with an unfusednCas9 and PolI3M, as well as nCas9 alone, did not show substitutions ata frequency greater than 0.04%.

To sensitively quantify the mutation rate and mutagenesis window lengthof EvolvR variants, a fluctuation analysis was designed²⁴. For thisassay, the pEvolvR plasmid was cotransformed into E. coli with a plasmid(pTarget) containing the aadA spectinomycin resistance gene disabled bya nonsense mutation (FIG. 22D). After 16 hours of growth, the cultureswere plated on spectinomycin and the mutation rates were determined fromthe number of resistant colony forming units (CFU). As shown in FIG.22E, fluctuation analysis estimated the mutation rate of wild-type E.coli to be approximately 10⁻¹⁰ mutations per nucleotide per generation,similar to previously reported values²⁵. The global mutation rate (themutation rate of the untargeted genome in cells expressing EvolvR) wasdetermined by measuring the spectinomycin-resistance reversion rate ofcells carrying a gRNA targeting dbpA, a fitness-neutral RNA helicasegene in the E. coli genome²⁶. The targeted mutation rate was determinedwith a gRNA nicking 11 nucleotides 5′ of the nonsense mutation inpTarget. Expressing nCas9 fused to the N-terminus of PolI3M dramaticallyincreased the mutation rate at the targeted locus 24,500-fold over wildtype while increasing the global mutation rate 120-fold over wild type(FIG. 22E), a global mutation rate comparable to that of previous E.coli targeted mutagenesis techniques^(1,27,28). By comparison,expressing nCas9 and PolI3M as separate proteins, PolI3M alone, nCas9alone, or catalytically inactive Cas9 (dCas9) fused to PolI3M, showedsignificantly lower targeted mutation rates (p<0.05 with a simpletwo-sided student's T test), suggesting that both PolI3M and the nickcreated by nCas9 are essential for EvolvR-mediated mutagenesis. Finally,by replacing the D10A nCas9, which nicks the strand complementary to thegRNA, with the H840A nickase, which nicks the strand non-complementaryto the gRNA, it was found that the direction of EvolvR-mediatedmutagenesis relative to the gRNA is dependent on which strand is nicked(FIG. 25 ).

FIG. 23A-23H|EvolvR provides tunable mutation rates and mutagenesiswindow lengths, combinatorial mutations, multiplexed targeting, andcontinuous diversification of genomic loci. a, Introducing mutationsfound to lower non-specific DNA affinity into the fused nCas9 (enCas9)²⁹increased the global mutation rate 223-fold compared to the wild typemutation rate (1.9-fold greater than nCas9-PolI3M), while increasing thetargeted mutation rate 212,038-fold above wild type (8.7-fold greaterthan nCas9-PolI3M). b, Mutagenesis rates were dependent on the fidelityof the polymerase. PolI with a D424A mutation (PolI1M) was lessmutagenic than PolI with both D424A and I709N mutations (PolI2M), whilePolI3M (D424A, I709N, A759R) was the most mutagenic. c, Screeningmutations in PolI3M previously shown to decrease wild type PolI fidelityrevealed that PolI3M with additional mutations F742Y and P796H (PolI5M)had a mutation rate 7,770,000-fold greater than wild type cells onenucleotide from the nick. Introduction of these mutations had no effecton the global mutation rate compared to PolI3M. Off-target mutationrates for the other variants were not measured. d, The editing windowlength was increased by incorporating the thioredoxin binding domain ofbacteriophage T7 DNA polymerase into PolI3M (PolI3M-TBD).enCas9-PolI3M-TBD provided a targeted mutation rate 56 nucleotides fromthe nick that was 555-fold above the global mutation rate, whileenCas9-PolI3M showed no targeted mutagenesis 56 nucleotides from thenick. e, enCas9-PolI3M-TBD targeted to a plasmid containing two nonsensemutations in the spectinomycin resistance gene (pTarget2) showed thatEvolvR is able to generate combinations of multiple mutations. f,enCas9-PolI3M targeted to E. coli's endogenous genomic ribosomal proteinsubunit 5 gene, rpsE, generated 16,000-fold more spectinomycin resistantcolony forming units (SpecR CFU) than when targeted to the dbpA locus.g, enCas9-PolI3M-TBD targeted to rpsL increased the rate of acquiringstreptomycin resistance without increasing the rate of acquiringspectinomycin resistance. Coexpression of both rpsL and rpsE gRNA'sincreased both spectinomycin and streptomycin resistant CFUs. h,Cultures expressing enCas9-PolI3M-TBD and either the rpsL gRNA or bothrpsE and rpsL gRNAs grew in streptomycin-supplemented media whilecultures expressing an off-target gRNA or the rpsE gRNA did not. Afterback-dilution into spectinomycin- and streptomycin-supplemented media,only cultures expressing both rpsE and rpsL gRNAs grew. (For allfigures, on-target gRNA nicked 11 nucleotides 5′ of the nonsensemutation unless labeled otherwise. Ten replicates of each group wereperformed for bar and scatter plots; error bars indicate 95% confidenceintervals for mutation rates and one standard deviation from the meanfor SpecR CFU/viable CFU and OD 600 nm. “*” denotes p<0.05 with a simpletwo-sided student's T test).

It was hypothesized that the targeted mutation rate could be furtherincreased by promoting the dissociation of nCas9 from DNA after nickingthe target locus. Therefore, a set of mutations (K848A, K1003A, R1060A)previously suggested to lower Cas9's non-specific DNA affinity³⁰ wereintroduced into the fused nCas9. The resulting enhanced nicking Cas9(enCas9) fused to PolI3M increased the global mutation rate 223-foldcompared to wild type cells (1.9-fold greater than nCas9-PolI3M), yetelevated the mutation rate at the targeted locus by 212,000-fold(8.7-fold greater than nCas9-PolI3M) (FIG. 23A).

PolI3M was initially chosen because it was the most error-prone variantof PolI previously characterized. However, it was hypothesized that themodularity of EvolvR would enable tuning of the mutation rate by usingpolymerases with different fidelities. First, it was confirmed that thefidelity of the polymerase determines mutation rates by comparing PolIvariants, in decreasing order of fidelity: PolI1M (D424A), PolI2M(D424A, 1709N), and PolI3M (D424A, I709N, A759R) (FIG. 23B). Next, tofurther increase EvolvR's targeted mutation rate, several additionalmutations previously shown to individually decrease wild type PolIfidelity were screened^(21,31,32) (FIG. 24C). PolI3M with the additionalmutations F742Y and P796H (PolI5M) displayed a mutation rate onenucleotide from the nick 7,770,000-fold greater than wild type cells,and 33-fold higher than PolI3M, making it the most error-prone PolImutant ever reported. Surprisingly, PolI5M did not exhibit a higherglobal rate of mutagenesis than PolI3M (FIG. 24B) and did not showhigher mutation rates than PolI3M 11 nucleotides from the nick (FIG. 26).

It was hypothesized that using more processive DNA polymerases couldincrease the editing window length, so PolI5M was exchanged for the moreprocessive bacteriophage Phi29 DNA polymerase (Phi29). Coexpression ofgRNAs targeting different distances from the nonsense mutation, eitherwild type Phi29 or variants with previously reported fidelity-reducingand thermostabilizing mutations, and the Phi29 single-stranded bindingprotein led to targeted mutagenesis both 56 and 347 nucleotides from thenick site (FIG. 27 ). However, the mutation rate at these distances wasnot as high as what was achieved with PolI3M at shorter distances.

It was hypothesized that an alternative method to increase the editingwindow length while retaining high mutation rates would be to increasethe processivity of PolI. Previous work has shown that fusing thethioredoxin binding domain (TBD) of bacteriophage T7 DNA polymeraseincreases PolI's processivity³⁴. FIG. 23D shows that while the originalenCas9-PolI3M did not show a difference between global and targetedmutation rates 56 nucleotides from the nick, incorporation of the TBDinto the PolI3M EvolvR gene (enCas9-PolI3M-TBD) produced a 555-foldincrease over the global mutation rate at this range. To leverage thisincreased editing window length, enCas9-PolI3M-TBD was targeted to aplasmid (pTarget2) containing two nonsense mutations (11 and 37nucleotides from the nick) in the antibiotic resistance gene, andEvolvR's ability to generate combinations of multiple mutations with asingle gRNA was thereby shown (FIG. 23E).

It was hypothesized that unintended translation products consisting offunctional DNA polymerase not fused to a functional CRISPR-guidedprotein contributed to undesirable off-target mutagenesis³⁵. Therefore,the EvolvR coding sequence (enCas9-PolI3M-TBD-CO) was codon-optimized toremove three strong internal RBSs identified with the RBS Calculator³⁶.The off-target mutation rate decreased 4.14-fold when expressingenCas9-PolI3M-TBD-CO compared to enCas9-PolI3M-TBD while the on-targetmutation rate only decreased 1.23-fold (FIG. 28 ).

The ability to couple EvolvR-mediated mutagenesis to a non-selectablegenetic screen would considerably broaden EvolvR's utility. It was foundthat after targeting EvolvR to a plasmid containing a GFP cassette withan early termination codon, 0.06% and 0.07% of the population wasexpressing GFP while no cells were expressing GFP using an off-targetgRNA (FIG. 29 ). Importantly, EvolvR also showed the capacity todiversify chromosomal loci by increasing the fraction of the populationresistant to spectinomycin 16,000-fold after targeting enCas9-PolI3M toE. coli's endogenous ribosomal protein subunit 5 gene, rpsE, which hasmutations known to confer resistance to spectinomycin³⁷ (FIG. 23F).

Next, it was hypothesized that EvolvR avoids the cell-viability andevolutionary escape issues associated with non-targeted mutagenesissystems³⁸. It was found that, unlike two previously developednon-targeted continuous mutagenesis systems, EvolvR does not impede cellviability or growth rate (FIGS. 30A and 30B). Additionally, targetingEvolvR to the rpsE gene evolved more spectinomycin resistant CFU's permL compared to these previous E. coli non-targeted mutagenesis systems,even when normalized by optical density (FIG. 30 ).

It was hypothesized that EvolvR could enable simultaneousdiversification of distant genomic loci through coexpression of multiplegRNAs. First, expression of a gRNA targeting enCas9-PolI3M-TBD to rpsL,a ribosomal protein subunit gene with mutations known to conferstreptomycin resistance³⁹, increased the rate of acquiring streptomycinresistance compared to wildtype cells, without increasing spectinomycinresistant CFUs (FIG. 23G). In comparison, coexpression of the gRNAstargeting rpsE and rpsL generated approximately the same number ofspectinomycin and streptomycin resistant CFUs as expression of the rpsEgRNA or rpsL gRNA alone, respectively. This capacity to simultaneouslydiversify multiple loci will be useful for identifying epistaticinteractions. Expression of two gRNA's that nick separate strands atgenomic loci separated by 100 base-pairs was lethal, while nicking thesame strand at the same distance was not lethal. Therefore, if multiplegRNAs were used to increase the length of the target region, targetingthe same strand is suggested.

To evolve resistance to both spectinomycin and streptomycin, it washypothesized that EvolvR's continuous diversity generation could beutilized for continuous directed evolution, in which mutagenesis,selection, and amplification occur simultaneously, to allow adaptationto modulated selection pressures with minimal researcher intervention.First, cultures expressing enCas9-PolI3M-TBD and either the rpsL gRNA orboth rpsE and rpsL gRNAs grew in liquid media supplemented withstreptomycin, whereas cultures expressing an off-target gRNA or the rpsEgRNA did not (FIG. 23H). After the cultures were diluted 1000-fold intoliquid media supplemented with both spectinomycin and streptomycin, onlycultures expressing both rpsE and rpsL gRNAs grew.

FIG. 24A-24D|EvolvR identified novel mutations to E. coli's RibosomalSubunit 5 gene, rpsE, that confer spectinomycin resistance. a,Spectinomycin inhibits protein synthesis through interactions with the30S ribosome. b, enCas9-PolI3M-TBD targeted to different parts of theendogenous rpsE gene with five gRNAs showed higher rates ofspectinomycin resistance than targeting dbpA (off-target). c, Afterselection, high-throughput sequencing of the resistant cells containinggRNA's A, B, and C revealed that all twelve types of substitutions aswell as deletions (del) were generated. Error bars indicate one standarddeviation from the mean. d, Five mutations not previously described asconferring spectinomycin resistance were regenerated in a new strain ofE. coli (RE1000), and growth curves in varying concentrations ofspectinomycin confirmed the mutations provide spectinomycin resistance.Shaded area represents +/−one standard deviation from the mean of threebiological replicates.

Spectinomycin's clinical utility as a broad-spectrum antibiotic hasmotivated previous efforts to characterize genomic mutations conferringspectinomycin resistance^(40,41). EvolvR's capacity was used todiversify the genomic rpsE gene to identify novel mutations that conferspectinomycin resistance by disrupting the spectinomycin binding pocketof the 30S ribosome (FIG. 24A). First, enCas9-PolI3M-TBD was targeted tofive dispersed loci in the endogenous rpsE gene using gRNA's that nickafter the 119^(th), 187^(th), 320^(th), 403^(rd), or 492^(nd) base pairwithin the 504 base pair rpsE coding sequence (FIG. 31 ). Then, the cellpopulations were challenged for growth on agar plates supplemented withvarying concentrations of spectinomycin and observed that resistance washighest with the gRNAs targeted to the domain of the ribosomal subunitprotein proposed to interact with spectinomycin (FIG. 24 ). Afterselection, high-throughput sequencing of the resistant cells containinggRNA's A, B, and C revealed that all twelve types of substitutions, aswell as deletions, were generated (FIG. 24C). For functional analysis,five of the candidate mutations not previously described as providingspectinomycin resistance were introduced into a different strain of E.coli (RE1000) using oligonucleotide-mediated recombination. Growthcurves in varying concentrations of spectinomycin confirmed that each ofthe five mutations (A17-19; K23N, A24; A24; A26; G27D) provided varyinglevels of spectinomycin resistance, but reduced fitness in the absenceof selection (FIG. 24D). Using these mutations, it was hypothesized thatmutations that move Lys26 relative to the spectinomycin binding pocketconfer resistance to spectinomycin by removing a hydrogen bond thatstabilizes spectinomycin's interaction with the ribosome, which led tothe discovery of more novel spectinomycin resistance-conferringmutations (FIG. 32 ). These mutations were accordingly submitted to theAntibiotic Resistance Genes Database⁴². This rapid method to determinegenotypes conferring antibiotic resistance is generally useful forimproving the effective use of antibiotics.

FIG. 25 |The direction of EvolvR-mediated mutagenesis relative to thegRNA is dependent on which strand is nicked. The previous fluctuationanalysis in FIG. 22E demonstrated that nCas9-PolI3M mutates a window 3′of the nick site. Here the study directly tested whether mutations arebeing generated 5′ of the nick site using a different gRNA. Since DNApolymerases synthesize in the 5′-3′ direction, it was hypothesized thatnCas9-PolI3M would not provide an elevated mutation rate 5′ of the nicksite. The study indeed found that expressing a guide RNA which targetednCas9(D10A)-PolI3M to nick 16 nucleotides 3′ from the nonsense mutation(red “x”) did not show targeted mutagenesis. It was hypothesized thattargeted mutagenesis could be induced using the same gRNA by using aCas9 variant harboring the H840A mutation, which nicks the DNA strandnon-complementary to the gRNA, rather than the D10A mutation, whichnicks the strand complementary to the gRNA. It was found thatnCas9(H840A)-PolI3M increased the mutation rate 16 nucleotides 3′ fromthe nick by 52 fold compared to the global mutation rate of cellsexpressing an off-target gRNA. The D10A nCas9 variant was used for allsubsequent experiments. “*” denotes p<0.05 with a simple two-sidedstudent's T test).

FIG. 26 |PolI5M elevates mutation rate 1 but not 11 nucleotides from thenick compared to PolI3M. PolI3M with F742Y and P796H mutations (PolI5M)elevates the mutation rate 33 fold 1 nucleotide from the nick comparedto PolI3M. PolI5M did not have a higher mutation rate than PolI3M 11nucleotides from the nick. “*” denotes p<0.05 with a simple two-sidedstudent's T test).

FIG. 27 |Fusing a more processive DNA polymerase to enCas9 increases thetarget window length. PolI was exchanged for a more processive andhigher fidelity bacteriophage Phi29 DNA polymerase (Phi29). Due to Phi29not having a flap endonuclease, residues 1-325 of PolI were insertedbetween enCas9 and Phi29. Using gRNA's targeting different distancesfrom the nonsense mutation, it was found that Phi29 with two previouslyreported fidelity-reducing mutations (N62D and L384R) elevated themutation rate 56 nucleotides from the nick compared to the globalmutation rate^(33,48). When Phi29's single-stranded binding protein(ssb), known to improve the activity of Phi29, was expressed, anelevation in targeted mutation rate was seen⁴⁹. Finally, since theactivity of Phi29 is known to decrease at temperatures above 30° C. andthe fluctuation analysis was performed at 37° C., mutations previouslyreported to improve the thermostability of Phi29 (iPhi29) were added anda targeted mutation rate 347 nucleotides from the nick site that wassignificantly greater than the global mutation rate was observed⁵⁰.Unfortunately, mutations decreasing Phi29's fidelity are known todecrease its processivity explaining the inability to identify Phi29variants that retain high processivity while offering as high of amutation rate as PolI3M³³. (Ten replicates of each group; error barsindicate 95% confidence intervals for mutation rates; “*” denotes p<0.05with a simple two-sided student's T test).

FIG. 28 |Removing internal ribosome binding sequences decreasesEvolvR-mediated off-target mutagenesis. enCas9-PolI3M-TBD-CO isenCas9-PolI3M-TBD that was codon optimized to remove strong ribosomebinding sites in the EvolvR coding sequence predicted to produce anuntethered DNA polymerase. The off-target mutation rate decreased4.14-fold when expressing enCas9-PolI3M-TBD-CO compared toenCas9-PolI3M-TBD while the on-target mutation rate only decreased1.23-fold.

FIG. 29A-29B|EvolvR-mediated mutagenesis can be coupled with anon-selectable genetic screen. a, To test the capability forEvolvR-mediated mutagenesis to be coupled with a non-selectable geneticscreen, a target plasmid containing a GFP cassette with an earlytermination codon in the GFP coding sequence (pTarget-GFP*) wasdesigned. After cotransforming pEvolvR with pTarget-GFP* and growing for24 hours, the GFP positive fraction was analyzed and sorted. In the tworeplicates expressing an off-target gRNA, no GFP cells were detected orsorted. In contrast, for the two replicates expressing a gRNA nickingfour nucleotides away from the chain-terminating mutation in GFP'scoding sequence, it was found that 0.06% and 0.07% of the total cellswere GFP positive. These results agree with sequencing outcomes fromFIG. 22B which showed that expressing nCas9-PolI3M for 24 hours producessubstitutions in the target region at frequencies between 0.5% to 1%. b,After culturing the sorted populations, both replicates expressing anoff-target gRNA did not show growth, while both replicates expressingthe on-target gRNA grew bright green.

FIGS. 30A-30C|EvolvR enables targeted genome diversification withoutaffecting viability or growth rate. a, The viability of TG1 E. coliexpressing EvolvR targeted to the essential rpsE gene was significantlyhigher than TG1 E. coli transformed with the MP6 plasmid and inducedwith 25 mM arabinose and 25 mM glucose (as previously described) as wellas XL1-Red E. coli. Viability was measured relative to TG1 E. colitransformed with an empty control plasmid. b, TG1 E. coli transformedwith an empty control plasmid and TG1 E. coli transformed with pEvolvRtargeting the rpsE gene showed similar growth curves while XL1-Red E.coli and TG1 E. coli transformed with MP6 plasmid and induced with 25 mMarabinose and 25 mM glucose grew much slower and saturated at lowerfinal optical densities. c, The spectinomycin resistant CFU per mLsaturated culture normalized by optical density of TG1 targeting EvolvRto the rpsE gene was significantly higher than XL1-Red E. coli and TG1E. coli transformed with MP6 plasmid and induced with 25 mM arabinoseand 25 mM glucose. Asterisks (*) denote p<0.05 in two-tailed t-test.

FIG. 31 |Locations of gRNA targets and novel mutations relative to therpsE gene. enCas9-PolI3M-TBD was targeted to five dispersed loci in theendogenous rpsE gene using gRNA's that nick after the 119^(th),187^(th), 320^(th), 403^(rd), or 492^(rd) base pair of the 504 base pairrpsE coding sequence. The locations of the previously identified rpsEmutations that provide spectinomycin resistance are colored orange andthe region where new spectinomycin resistance mutations were identifiedis highlighted in red.

FIGS. 32A-32B|Deletions in ribosomal protein S5 confer spectinomycinresistance. a, The mutations that were discovered confer spectinomycinresistance would be expected to move Lys26, which is predicted tohydrogen bond with spectinomycin, relative to the spectinomycin bindingpocket. It was hypothesized that mutations that move Lys26 relative tothe spectinomycin binding pocket removes that hydrogen bond anddestabilizes spectinomycin's interaction with the ribosome, therebyconferring spectinomycin resistance. b, Therefore, the study testedwhether deleting any single amino acid between residue 16 and 35 confersspectinomycin resistance. It was found that deleting residue 23, 24, 25,26, 27, or 28 all provide spectinomycin resistance, while deleting anyof the residues between 16 to 22 or 29 to 35 do not. This supports thehypothesis that one mechanism of resistance to spectinomycin isdisruption of the interaction between Lys26 and spectinomycin.

Methods

Plasmid Construction: All plasmids were constructed using a modularGolden Gate strategy⁴³. pEvolvR consisted of EvolvR and gRNA expressioncassettes, a pBR322 origin of replication, and a kanamycin resistancecassette. pTarget consisted of a p15a origin of replication carryingboth a functional trimethoprim resistance cassette for selection and adisabled spectinomycin resistance gene (aadA) harboring a Leu106Ternon-sense mutation. pTarget2 is identical to pTarget with the exceptionthat the aadA gene now carried both Glu98Ter and Leu106Ter mutations.The full plasmid sequences are provided in FIG. 36 .

High-throughput sequencing of pTarget sample preparation: A pTarget andpEvolvR plasmid were cotransformed into 50 uL of chemically competentTG1 E. coli prepared by a TSS/KCM method. Cells were allowed to recoverin the TSS/LB solution for 1 hour, before 4 μL of the transformation mixwas inoculated into 2 mL of LB containing 25 μg/mL kanamycin and 15μg/mL trimethoprim. The cultures were grown for 24 hours at 37° C. whileshaking at 750 rpm. 1.5 mLs of each culture was miniprepped using aZippy Plasmid Prep kit (Zymo Research).

The oligos pTarget-F and pTarget-R were used to amplify the targetregion in a 20 cycle PCR reaction using 100 ng of miniprepped DNA as thetemplate. A second PCR reaction added Illumina sequencing adapters andindices to the previous PCR product over 10 thermocycles. A Qubitfluorimeter was used to quantify the DNA prior to pooling samples. Thesample pool was submitted to the UC Berkeley Vincent J. Coates GenomicsSequencing Laboratory for quality control and sequencing. Qualitycontrol consisted of fragment analysis (Advanced Analytical) andconcentration measurement of the sequenceable fraction by quantitativePCR (Kapa Biosystems). The pooled sample was mixed with Illumina PhiXsequencing control library at 10% molarity, diluted to 14 pM, denatured,and run on an Illumina MiSeq using a 150 bp paired-end read MiSeqReagent Kit v2. Resulting basecall files where converted intodemultiplexed fastq format using Illumina's version 2.17 bcl2fastq.

High-throughput sequencing data analysis: Perfectly complementary pairedreads were filtered and the 5 randomized nucleotides, amplificationprimer sequences, and first and last three nucleotides were trimmedusing a custom python script. Bwa and samtools were used to generatealignment files using the wild type aadA gene sequence as a reference.VarScan2 was used for variant calling with the parameters: min-coverage1; min-reads2 1; variants 1; min-var-freq 0.0005; p-value 0.994. Thelimit of detection was determined by sequencing a culture transformedwith an empty vector as a control. The highest frequency variant was0.04% so all substitutions with a frequency under 0.05% were discarded.

Fluctuation analysis assay: 50 μL of chemically competent TG1 E. coliwere contransformed with pEvolvR and pTarget or pTarget2. After 1 hourof recovery at 37° C., 4 μL was inoculated into a 1.996 mL LB containing25 μg/mL Kanamycin and 15 μg/mL Trimethoprim. After shaking at 37° C.for 16 hours, 1 mL and 1 μL of culture were plated on separate LB agarplates containing 50 μg/mL spectinomycin. Additionally, for viable CFUcounting, 300 μL of 1:50,000,000 diluted culture was plated on LB agarplates. After 24 hours of incubation at 37° C., spectinomycin resistantCFU and viable CFU were counted. Ten replicates were used for eachcondition.

Calculation of mutation rate and statistics: The Ma-Sandri-SarkarMaximum Likelihood Estimator was used to determine mutation rates as itis the most accurate and valid for all mutation rates²⁴. Falcor was usedto calculate the mutation rates by inputing the viable and resistant CFUcounts for the ten replicates⁴⁵. A simple two-tailed students t-test wascarried out to determine p values as previously described⁴⁶.

Fluorescence-activated cell sorting of EvolvR libraries: Sony CellSorter SH800: pEvolvR expressing either an on- or off-target gRNA wascontransformed with pTarget-GFP* and shaken at 37° C. for 24 hours. Foreach sample, the GFP positive fraction of a million events was sortedwith a Cell Sorter SH800 (Sony) using a 488 nm laser and a 525/50 nmemission filter.

Continuous evolution of E. coli resistant to both spectinomycin andstreptomycin: pEvolvR expressing enCas9-PolI3M-TBD and either theoff-target gRNA (targeting dbpA), rpsL gRNA, rpsE gRNA, or both rpsL andrpsE gRNAs was transformed into TG1 E. coli as previously described.After recovering for one hour, 4 μL of transformation mix was inoculatedinto 2 mL of LB supplemented with 25 μg/mL kanamycin and cultures werepropagated over 16 hours at 37° C. 2 μL of culture was inoculated into198 μL of LB supplemented with 50 μg/mL of streptomycin. A Tecan M1000Pro spectrophotometer was used to measure each well's optical densityover 12 hours of growth at 37° C. Each well was then diluted 1000-foldin LB supplemented with 50 μg/mL of streptomycin and 25 μg/mL ofspectinomycin and the optical density of 200 μL of culture was againmeasured with a Tecan M1000 Pro spectrophotometer over 24 hours ofgrowth at 37° C. Three biological replicates of each gRNA wascharacterized.

High-throughput sequencing of spectinomycin resistant E. coli: A pEvolvRplasmid expressing enCas9-PolI3M-TBD with rpsE-gRNA-A, -B, -C, -D, or -Ewere transformed into chemically competent TG1 E. coli and recovered for1 hour before innoculating 4 μl of the transformation mix into 1.996 mLof LB supplemented with 25 μg/mL kanamycin. The cultures were grown for16 hours at 37° C. while shaking. 1 mL and 1 μL of each culture wereplated on separate LB agar plates containing 10, 100, or 1000 μg/mLspectinomycin. Resistant CFUs were counted in the same manner as thefluctuation assays. The colonies of each plate were then scraped intoseparate cultures containing 2 mL of LB supplemented with 50 μg/mLspectinomycin and grown for 16 hours at 37° C. Genomic DNA was purifiedusing the Wizard Genomic DNA Purification Kit (Promega). 100 ng ofpurified genome was then processed and sequenced in the same manner asalready described for the sequencing analysis of pTarget, with the oneexception that oligos rpsE-F and rpsE-R were used in the first round ofPCR.

Oligonucleotide recombination: Re-introduction of rpsE mutations wasperformed using RE1000 E. coli (EcNR1 ilvG+ dam@λTermdualTetO-pTet< >{kil, λ cI} ΔampR pConst::araE pConst::araC lacIQ1recJ_off xonA_off dnaG.Q576A cymR< >SS7) developed for recombineering.Electro-competent cells were prepared fresh from overnight cultures ofbacteria. The saturated culture was back-diluted 1:70 into 5 mL LB with100 ng/μl anhydrous tetracycline and shaken at 37° C. until the ODreached 0.5. Cultures were then transferred to an ice-water bath andswirled for approximately 30 seconds before being chilled on ice for 10minutes. Chilled cultures were centrifuged at 8000 RPM for 1 minute. Thesupernatant was aspirated and the pellet was resuspended in 1 mLice-chilled 10% glycerol. The aspiration and resuspension was repeatedtwice. The final pellet was resuspended in 70 μL chilled 10% glycerolfor each transformation. 1 μg of oligonucleotide was electroporated intothe cells. The cells were recovered for 1 hr at 37° C. in 1 mL LB andstreaked out on LB agar plates containing 50 μg/mL spectinomycin.Successful recombination was verified by Sanger sequencing aPCR-amplification of the genomic rpsE gene.

Spectinomycin resistance characterization: Single colonies ofsequence-verified rpsE mutants were grown overnight in LB media and thenback-diluted 1:200 into LB containing 0, 100, or 1000 μg/mLspectinomycin. A Tecan M1000 Pro spectrophotometer was used to measureeach well's optical density over 8 hours of growth at 37° C. Threebiological replicates of each mutant at each spectinomycin concentrationwere characterized.

Example 3

The EvolvR system was adapted for use in eukaryotic cells. EvolvRprovides for diversification of all nucleotides at user-definedpositions without generating double stranded breaks or relying on HDR.

A HEK293T cell line with a genomically-integrated,constitutively-expressed blue fluorescent protein (BFP) gene(HEK293T-BFP) was used. As depicted in FIG. 39A, a BFP gene (SEQ IDNO:1215) can become a green fluorescent protein (GFP) gene (SEQ IDNO:1217) by undergoing a particular single-nucleotide substitution (SEQID NO:1218) causing an H67Y missense mutation. The frequency of GFPpositive cells in an EvolvR-expressing population was used as a relativeproxy for the cell's targeted mutation rate.

An EvolvR expression plasmid, designated pEvolvR-HT, was constructed.The pEvolvR-HT expression plasmid can be transiently transfected intohuman cells. As depicted in FIG. 39B, the pEvolvR-HT expression plasmidconsists of a gRNA expression cassette driven by the human U6 promoteras well as a CMV promoter-driven enCas9-PolI5M gene tagged with two SV40nuclear localization sequences (NLSs) and an mCherry fluorescentreporter. Two days after transiently transfecting pEvolvR-HT intoHEK293T-BFP cells, transfectants were enriched by sorting mCherrypositive cells using FACS. As depicted in FIG. 39C, the sortedpopulation was allowed to expand for five days; the frequency ofGFP-expressing cells in the expanded population was analyzed using flowcytometry. As shown in FIG. 39D, while a population not expressingEvolvR and a population expressing EvolvR with an off-target gRNAtargeting the aavs1 locus did not produce any GFP-expressing cells, apopulation expressing EvolvR with a gRNA that nicks 15 base-pairs awayfrom the H67Y mutation showed 0.05% GFP-expressing cells. Estimatingthat the population expressed EvolvR for six generations, the observedmutation rate is approximately 2.5×10⁻⁴ mutations per nucleotide pergeneration. This mutation rate is comparable to the mutation rateobserved in E. coli.

Example 4

The base-pair editor (BPE) system was adapted for use in eukaryoticcells. BPEs provide for editing both nucleotides of user-definedbase-pairs by directing the synthesis of a DNA polymerase acrossdeaminated templates without relying on double-stranded breaks, HDR,genome replication, or redirection of endogenous mismatch repairpathways.

A HEK293T-BFP cell line with a genomically-integrated,constitutively-expressed BFP gene was used. As depicted in FIG. 39A, aBFP gene can become a green fluorescent protein (GFP) gene by undergoinga particular single-nucleotide substitution causing an H67Y missensemutation. The frequency of GFP-positive cells in a BPE-expressingpopulation was used as a relative proxy for the BPE's editingefficiency.

A BPE expression plasmid was constructed. The BPE expression plasmid wastransiently transfected into human cells. The plasmid consists of a CMVpromoter-driven fusion cassette, where the cassette encodes the fusionprotein: NLS, rAPOBEC1, enCas9, NLS, E. coli PolI. Three days aftertransiently transfecting this plasmid with a gRNA expression plasmid anda mCherry transfection control plasmid into HEK293T-BFP cells, thefrequency of GFP-expressing cells was analyzed using flow cytometry.

As depicted in FIGS. 40C-40D, the population of cells transfected withthe BPE plasmid showed 22% and 22.31% GFP-positive fractions whenco-transfected with an on-target gRNA (FIG. 40C), and 0.37% and 0.41%GFP-positive fractions when co-transfected with an off-target gRNA (FIG.40D). As shown in FIGS. 40A-40B, a similar plasmid lacking thepolymerase showed 6.51% and 5.83% GFP-positive fractions with anon-target gRNA (FIG. 40A), and 0.40% and 0.41% GFP-positive fractionwith an off-target gRNA (FIG. 40B). These results show that fusing a DNApolymerase to Cas9/deaminase fusions increases editing efficiencies.

REFERENCES

-   1. Camps, M., Naukkarinen, J., Johnson, B. P. & Loeb, L. A. Targeted    gene evolution in Escherichia coli using a highly error-prone DNA    polymerase I. Proc. Natl. Acad. Sci. U.S.A 100, 9727-32 (2003).-   2. Crook, N. et al. In vivo continuous evolution of genes and    pathways in yeast. Nat. Commun. 7, 13051 (2016).-   3. Esvelt, K. M., Carlson, J. C. & Liu, D. R. A system for the    continuous directed evolution of biomolecules. Nature 472, 499-503    (2011).-   4. Ma, Y. et al. Targeted AID-mediated mutagenesis (TAM) enables    efficient genomic diversification in mammalian cells. Nat. Methods    13, 1-9 (2016).-   5. Hess, G. T. et al. Directed evolution using dCas9-targeted    somatic hypermutation in mammalian cells. Nat. Methods 13, 1036-1042    (2016).-   6. BRENNER, S., STRETTON, A. O. W. & KAPLAN, S. Genetic Code: The    ‘Nonsense’ Triplets for Chain Termination and their Suppression.    Nature 206, 994-998 (1965).-   7. Maheshri, N., Koerber, J. T., Kaspar, B. K. & Schaffer, D. V.    Directed evolution of adeno-associated virus yields enhanced gene    delivery vectors. Nat. Biotechnol. 24, 198-204 (2006).-   8. Bryson, D. I. et al. Continuous directed evolution of    aminoacyl-tRNA synthetases. Nat. Chem. Biol. 13, 1253-1260 (2017).-   9. Hubbard, B. P. et al. Continuous directed evolution of    DNA-binding proteins to improve TALEN specificity. Nat. Methods    12:939 (2015).-   10. Costantino, N. & Court, D. L. Enhanced levels of lambda    Red-mediated recombinants in mismatch repair mutants. Proc. Natl.    Acad. Sci. U.S.A 100, 15748-53 (2003).-   11. Wang, H. H. et al. Programming cells by multiplex genome    engineering and accelerated evolution. Nature 460, 894-8 (2009).-   12. Barbieri, E. M., Muir, P., Akhuetie-Oni, B. O., Yellman, C. M. &    Isaacs, F. J. Precise Editing at DNA Replication Forks Enables    Multiplex Genome Engineering in Eukaryotes. Cell 171, 1453-1467.e13    (2017).-   13. DiCarlo, J. E. et al. Yeast Oligo-Mediated Genome Engineering    (YOGE). ACS Synth. Biol. 2, 741-749 (2013).-   14. Ronda, C., Pedersen, L. E., Sommer, M. O. A. & Nielsen, A. T.    CRMAGE: CRISPR Optimized MAGE Recombineering. Sci. Rep. 6, 19452    (2016).-   15. Findlay, G. M., Boyle, E. A., Hause, R. J., Klein, J. C. &    Shendure, J. Saturation editing of genomic regions by multiplex    homology-directed repair. Nature 513, 120-123 (2014).-   16. Mao, Z., Bozzella, M., Seluanov, A. & Gorbunova, V. DNA repair    by nonhomologous end joining and homologous recombination during    cell cycle in human cells. Cell Cycle 7, 2902-2906 (2008).-   17. Aguirre, A. J. et al. Genomic Copy Number Dictates a    Gene-Independent Cell Response to CRISPR/Cas9 Targeting. Cancer    Discov. 6, 914-29 (2016).-   18. Choi, P. S. & Meyerson, M. Targeted genomic rearrangements using    CRISPR/Cas technology. Nat. Commun. 5, 4728 (2014).-   19. Frock, R. L. et al. Genome-wide detection of DNA double-stranded    breaks induced by engineered nucleases. Nat. Biotechnol. 33, 179-186    (2014).-   20. Mao, Z., Bozzella, M., Seluanov, A. & Gorbunova, V. Comparison    of nonhomologous end joining and homologous recombination in human    cells. DNA Repair (Amst). 7, 1765-71 (2008).-   21. Camps, M., Naukkarinen, J., Johnson, B. P. & Loeb, L. A.    Targeted gene evolution in Escherichia coli using a highly    error-prone DNA polymerase I. Proc. Natl. Acad. Sci. U.S.A 100,    9727-32 (2003).-   22. Bambara, R. A. & Choi, T. On the Processive Mechanism of    Escherichia coli DNA Polymerase I Quantitative Assessment of    Processivity. J. Biol. Chem. 253, 413-423 (1973).-   23. de Boer, J. G. & Ripley, L. S. An in vitro assay for frameshift    mutations: hotspots for deletions of 1 bp by Klenow-fragment    polymerase share a consensus DNA sequence. Genetics 118, (1988).-   24. Sarkar, S., Ma, W. T. & Sandri, G. v. H. On fluctuation    analysis: a new, simple and efficient method for computing the    expected number of mutants. Genetica 85, 173-179 (1992).-   25. Drake, J. W. A constant rate of spontaneous mutation in    DNA-based microbes. Proc. Natl. Acad. Sci. U.S.A 88, 7160-4 (1991).-   26. Jagessar, K. L. & Jain, C. Functional and molecular analysis of    Escherichia coli strains lacking multiple DEAD-box helicases. RNA    16, 1386-92 (2010).-   27. Fijalkowska, I. J. & Schaaper, R. M. Mutants in the Exo I motif    of Escherichia coli dnaQ: defective proofreading and inviability due    to error catastrophe. Proc. Natl. Acad. Sci. U.S.A 93, 2856-61    (1996).-   28. Wang, H. H. et al. Programming cells by multiplex genome    engineering and accelerated evolution. Nature 460, 894-8 (2009).-   29. Kleinstiver, B. P. et al. High-fidelity CRISPR-Cas9 nucleases    with no detectable genome-wide off-target effects. Nature 529,    490-495 (2016).-   30. Slaymaker, I. M. et al. Rationally engineered Cas9 nucleases    with improved specificity. Science (80-.). 351, 84-88 (2015).-   31. Minnick, D. T. et al. Side chains that influence fidelity at the    polymerase active site of Escherichia coli DNA polymerase I (Klenow    fragment). J. Biol. Chem. 274, 3067-75 (1999).-   32. Loh, E., Salk, J. J. & Loeb, L. A. Optimization of DNA    polymerase mutation rates during bacterial evolution. Proc. Natl.    Acad. Sci. U.S.A 107, 1154-9 (2010).-   33. Truniger, V., Lazaro, J. M., de Vega, M., Blanco, L. & Salas, M.    phi 29 DNA polymerase residue Leu384, highly conserved in motif B of    eukaryotic type DNA replicases, is involved in nucleotide insertion    fidelity. J. Biol. Chem. 278, 33482-91 (2003).-   34. Wang, Y. et al. A novel strategy to engineer DNA polymerases for    enhanced processivity and improved performance in vitro. Nucleic    Acids Res. 32, 1197-1207 (2004).-   35. Whitaker, W. R., Lee, H., Arkin, A. P. & Dueber, J. E. Avoidance    of Truncated Proteins from Unintended Ribosome Binding Sites within    Heterologous Protein Coding Sequences. ACS Synth. Biol. 4, 249-257    (2015).-   36. Salis, H. M. The Ribosome Binding Site Calculator. in Methods in    enzymology 498, 19-42 (2011).-   37. Funatsu, G., Schiltz, E. & Wittmann, H. G. Ribosomal    proteins. XXVII. Localization of the amino acid exchanges in protein    S5 from two Escherichia coli mutants resistant to spectinomycin.    Mol. Gen. Genet. 114, 106-11 (1972).-   38. Zheng, X., Xing, X.-H. & Zhang, C. Targeted mutagenesis: A    sniper-like diversity generator in microbial engineering. (2017).    doi:10.1016/j.synbio.2017.07.001-   39. Timms, A. R., Steingrimsdottir, H., Lehmann, A. R. &    Bridges, B. A. Mutant sequences in the rpsL gene of Escherichia coli    B/r: Mechanistic implications for spontaneous and ultraviolet light    mutagenesis. MGG Mol. Gen. Genet. 232, 89-96 (1992).-   40. Brocklehurst, P. & Peter. Antibiotics for gonorrhoea in    pregnancy. in Cochrane Database of Systematic Reviews (ed.    Kellie, F. J.) (John Wiley & Sons, Ltd, 2002).    doi:10.1002/14651858.CD000098-   41. Lee, R. E. et al. Spectinamides: a new class of semisynthetic    antituberculosis agents that overcome native drug efflux. Nat. Med.    20, 152-158 (2014).-   42. Liu, B. & Pop, M. ARDB—Antibiotic resistance genes database.    Nucleic Acids Res. 37, 443-447 (2009).-   43. Lee, M. E., DeLoache, W. C., Cervantes, B. & Dueber, J. E. A    Highly-characterized Yeast Toolkit for Modular, Multi-part Assembly.    ACS Synth. Biol. (2015). doi:10.1021/sb500366v-   44. Koboldt, D. C. et al. VarScan 2: somatic mutation and copy    number alteration discovery in cancer by exome sequencing. Genome    Res. 22, 568-76 (2012).-   45. Hall, B. M., Ma, C.-X., Liang, P. & Singh, K. K. Fluctuation    analysis CalculatOR: a web tool for the determination of mutation    rate using Luria-Delbruck fluctuation analysis. Bioinformatics 25,    1564-5 (2009).-   46. Rosche, W. A. & Foster, P. L. Determining Mutation Rates in    Bacterial Populations. Methods 20, 4-17 (2000).-   47. Hess, G. T. et al. Directed evolution using dCas9-targeted    somatic hypermutation in mammalian cells. Nat. Methods 13, 1036-1042    (2016).-   48. de Vega, M., Lazaro, J. M., Salas, M. & Blanco, L.    Primer-terminus stabilization at the 3′-5′ exonuclease active site    of phi29 DNA polymerase. Involvement of two amino acid residues    highly conserved in proofreading DNA polymerases. EMBO J. 15,    1182-92 (1996).-   49. Ducani, C., Bernardinelli, G. & Hogberg, B. Rolling circle    replication requires single-stranded DNA binding protein to avoid    termination and production of double-stranded DNA. Nucleic Acids    Res. 42, 10596-10604 (2014).-   50. Povilaitis, T., Alzbutas, G., Sukackaite, R., Siurkus, J. &    Skirgaila, R. In vitro evolution of phi29 DNA polymerase using    isothermal compartmentalized self replication technique. Protein    Eng. Des. Sel. 29, 617-628 (2016).-   51. Greener, A., Callahan, M. & Jerpseth, B. An efficient random    mutagenesis technique using an E. coli mutator strain. Mol.    Biotechnol. 7, 189-195 (1997).-   52. Badran, A. H. & Liu, D. R. Development of potent in vivo    mutagenesis plasmids with broad mutational spectra. Nat. Commun. 6,    8425 (2015).

While the present invention has been described with reference to thespecific embodiments thereof, it should be understood by those skilledin the art that various changes may be made and equivalents may besubstituted without departing from the true spirit and scope of theinvention. In addition, many modifications may be made to adapt aparticular situation, material, composition of matter, process, processstep or steps, to the objective, spirit and scope of the presentinvention. All such modifications are intended to be within the scope ofthe claims appended hereto.

1-84. (canceled)
 85. An editing system comprising: a) an enzymaticallyactive RNA-guided endonuclease that introduces a break in at least onestrand in a target DNA; b) a DNA polymerase that binds to the target DNA5′ to the break; and c) a guide RNA that binds the endonuclease; d)wherein the endonuclease, DNA polymerase, and guide RNA are exogenouslyintroduced into a cell, or are encoded by one or more exogenouslyintroduced nucleic acids.
 86. The system of claim 85, wherein the guideRNA comprises a protein-binding segment comprising a nucleotide sequencethat binds to the endonuclease, and a target-binding segment comprisinga nucleotide sequence that is complementary to a target nucleotidesequence of the target DNA.
 87. The system of claim 85, wherein theguide RNA comprises one or more of: a) a modified base; b) a modifiedbackbone; c) a modified sugar moiety; d) a non-natural internucleosidelinkage.
 88. The system of claim 85, wherein the guide RNA guides theendonuclease to introduce the break in the target DNA.
 89. The system ofclaim 85, wherein the break in at least one strand is a single-strandedbreak.
 90. The system of claim 85, wherein the DNA polymerasesynthesizes a new strand on the target DNA.
 91. The system of claim 90,wherein the DNA polymerase introduces a mutation in the new strand. 92.The system of claim 91, wherein the DNA polymerase introduces a mutationin the new strand at a distance of from 1 nucleotide to 100 nucleotidesfrom the single-stranded break in the target DNA.
 93. The system ofclaim 85, wherein the endonuclease comprises a class 2 CRISPR/Casendonuclease.
 94. The system of claim 93, wherein the class 2 CRISPR/Casendonuclease comprises a type V or type VI CRISPR/Cas endonuclease. 95.The system of claim 93, wherein the class 2 CRISPR/Cas endonucleasecomprises a Cas9 polypeptide.
 96. The system of claim 93, wherein theclass 2 CRISPR/Cas endonuclease comprises a Streptococcus pyrogenes Cas9polypeptide.
 97. The system of claim 85, wherein the endonuclease andthe DNA polymerase are fused as parts of a fusion polypeptide.
 98. Thesystem of claim 97, wherein the fusion polypeptide, when complexed witha guide RNA, exhibits a target mutation rate of from 10⁻⁸ to 10⁻⁷, 10⁻⁷to 10⁻⁶, 10⁻⁶ to 10⁻⁵, 10⁻⁵ to 10⁻⁴, 10⁻⁴ to 10⁻³, or 10⁻³ to 10⁻²mutations per nucleotide per genome replication event.
 99. The system ofclaim 97, wherein the fusion polypeptide further comprises a linkerconnecting the endonuclease and the DNA polymerase.
 100. The system ofclaim 97, wherein the fusion polypeptide further comprises a nuclearlocalization signal.
 101. The system of claim 97, wherein the fusionpolypeptide comprises, in order from N-terminus to C-terminus: a) theenzymatically active RNA-guided endonuclease; and b) the DNA polymerase.102. The system of claim 97, wherein the fusion polypeptide comprises,in order from N-terminus to C-terminus: a) the enzymatically activeRNA-guided endonuclease; b) a linker; and c) the DNA polymerase. 103.The system of claim 97, wherein the fusion polypeptide comprises, inorder from N-terminus to C-terminus: a) a nuclear localization signal;b) the enzymatically active RNA-guided endonuclease; and c) the DNApolymerase.
 104. The system of claim 97, wherein the fusion polypeptidecomprises, in order from N-terminus to C-terminus: a) a nuclearlocalization signal; b) the enzymatically active RNA-guidedendonuclease; c) a linker; and d) the DNA polymerase.
 105. The system ofclaim 97, wherein the fusion polypeptide comprises, in order fromN-terminus to C-terminus: a) the DNA polymerase; and b) theenzymatically active RNA-guided endonuclease.
 106. The system of claim97, wherein the fusion polypeptide comprises, in order from N-terminusto C-terminus: a) the DNA polymerase; b) a linker; and c) theenzymatically active RNA-guided endonuclease.
 107. The system of claim97, wherein the fusion polypeptide comprises, in order from N-terminusto C-terminus: a) a nuclear localization signal; b) the DNA polymerase;and c) the enzymatically active RNA-guided endonuclease.
 108. The systemof claim 97, wherein the fusion polypeptide comprises, in order fromN-terminus to C-terminus: a) a nuclear localization signal; b) the DNApolymerase; c) a linker; and d) the enzymatically active RNA-guidedendonuclease.